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Type 1 diabetes is characterised by insulin deficiency leading to chronic hyperglycaemia 
causing microvascular and macrovascular complications. Current treatment with glucose 
monitoring and insulin administration can cause recurrent serious hypoglycaemia 
significantly impacting on quality of life. Despite considerable advances towards an 
artificial pancreas, only pancreatic β-cell replacement therapy can restore truly normal 
glucose homeostasis. Existing clinical options for this are whole pancreas and isolated islet 
transplantation. Pancreas transplantation requires major abdominal surgery and can lead 
to dangerous early complications including pancreatitis, as the organ is particularly 
susceptible to post mortem stress prior to reimplantation. When successful, pancreas 
transplantation usually leads to insulin independence. Islet transplantation is a minimally 
invasive procedure, but many islets are also lost through post mortem stress associated 
with isolation and transplantation, negatively impacting on islet microenvironment, 
viability, mass and function. Long term insulin independence is rarely sustained. The 
overall aim of the work comprising this thesis was to explore tissue engineering 
approaches to provide isolated islets with sufficient replacement of the lost niche to 
maintain integrity, mass, viability and function and therefore transplant outcomes. The 
research question hereby was, how the culture of islets in proximity or contact with a 
hydrogel impacts on islet health with the hypothesis that the replacement of lost ECM via 
a hydrogel will improve islet integrity, viability and function after isolation and prior to 
transplant.  
Specific objectives were: 
1. To characterise the islet niche in situ within human donor pancreas and analyse 
acute changes related to ischaemia, tissue processing and islet isolation.  
2. To evaluate biocompatibility and impact on islet integrity, viability and function of 
extracellular matrix (ECM) replacement through a novel collagen-containing 
hydrogel. 
3. To explore bioengineering approaches to reduce the impact of hypoxia on islets 




Islet microenvironment, integrity and morphology in situ was analysed in a pancreas with 
minimal ischaemic damage by immunohistochemistry (IHC), immunofluorescence 
staining (IF) and electron microscopy (EM) analysis revealing peri-islet basement 
membrane (BM), peri-vascular BM, rich vascularisation and endocrine cell-to-cell 
connections. Impact of ischaemia on donor pancreata was analysed by EM analysis 
leading to development of the Newcastle EM Ischaemia Score (NEMIS). Characterisation 
of isolated islets with IHC, IF and EM showed loss of peri-islet BM and reduced integrity 
through the isolation process.  
Biocompatibility of a novel ECM replacement hydrogel comprising collagen I, alginate and 
fibrinogen (CAF) with a pseudoislet model derived from the MIN6 β-cell line and primary 
human islets was confirmed by propidium iodide (PI) viability staining and integrity scoring. 
Maintained metabolic function was confirmed by Seahorse flux analysis.  
Towards islet hypoxia reduction an electrospun nanofiber membrane to provide 
microchannels for oxygen delivery and dynamic culture to prevent islet clumping were 
assessed. Expression of hypoxia-induced gene signature was reduced in dynamic culture 
with maintained viability (PI staining), and improved integrity scores, but decreased ATP 
production (Seahorse flux analysis). As a final step a perifusion system was developed to 
facilitate ECM replacement simultaneously with decreased hypoxia.  
In conclusion, the quality of transplanted pancreatic tissue is negatively impacted through 
organ preservation and islet isolation. A new EM ischaemia score has been developed to 
inform better selection of donor organs. A novel collagen-containing hydrogel has a 
potential in replacement of islet ECM, but hypoxia remains an unresolved challenge to 
successful β-cells tissue engineering. Reducing hypoxia with dynamic culture enables 
maintained islet quality in vitro and an engineered perifusion system may enable 
preparation of novel β-cell microtissue for successful transplantation without the 
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1 Chapter 1. Introduction  
1.1 Human pancreas structure and acinar tissue 
The pancreas is a complex organ located behind the stomach in the upper abdomen with 
length in the adult male ranging from 14-18 cm and a weight of about 100 g (Longnecker, 
2014, Lankisch and Banks, 1998). The organ can be divided into tail, body, head and 
uncinate process, whereby the head is located near the duodenum and the tail near the 
spleen (Wittingen and Frey, 1974, Longnecker, 2014). The pancreas primarily consists of 
two components, the exocrine and the endocrine compartment. 
1.2 The exocrine pancreas  
The exocrine tissue secretes digestive enzymes transported into the gut via the pancreatic 
duct into the duodenum (Figure 1.1). This makes up more than 95% of the pancreas and 
includes acinar cells, duct cells, vessels, nerves and extracellular matrix (ECM)(Longnecker, 
2014, Lankisch and Banks, 1998). The digestive juice is produced by acinar cells which are 
grouped in grape like tubular networks named acini which converge into the duct system 
(Longnecker, 2014, Bardeesy and DePinho, 2002, Lankisch and Banks, 1998). The duct 
system comprises the intralobular ducts, interlobular ducts and main pancreatic duct, 
which transports the digestive enzymes from the pancreas to the small intestine 
(Longnecker, 2014).  
 
Figure 1.1: Pancreas tissue structure.  
a) pancreas and duodenum connected via the duct b) exocrine pancreas macrostructure and c) exocrine pancreas 
microstructure d) endocrine pancreas in between exocrine pancreas (Bardeesy and DePinho, 2002). 
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1.2.1 The endocrine pancreas 
1.2.2 Human islet structure and function 
The second function of the pancreas is tight regulation of blood glucose levels through the 
production and release of hormones into the bloodstream - predominantly insulin and 
glucagon. The endocrine compartment is comprised of islets of Langerhans which are 
distributed throughout the whole pancreas. Islets make up just 1-2% of the pancreatic 
tissue with a size range of 50 µm to 400 µm diameter (Longnecker, 2014, Nam et al., 2010, 
Stendahl et al., 2009).  
 
 
Figure 1.2: Endocrine cell distribution in human islets.  
Human islet in a post mortem pancreas tissue section with immunofluorescence staining for insulin (red), glucagon 
(green) and somatostatin (blue). Picture from (Cabrera et al., 2006). 
 
The distribution of islets through the pancreas is not uniform with estimates that up to 
45% of all islets may be found in the tail (Wittingen and Frey, 1974). Islets contain different 
cell types (Figure 1.2) which synthesize, store and secrete distinct hormones: α-cells 
(glucagon), β-cells (insulin), δ-cells (somatostatin) and PP-cells (pancreatic polypeptide) 
(Bardeesy and DePinho, 2002, Cabrera et al., 2006). It is not finally clarified if the 
composition of different cell types in human islets follows a specific distribution or not, 
compared to rodent islets where β-cells are located in the core and mantled by a thinner 
layer of the other endocrine cells (Steiner et al., 2010, Cabrera et al., 2006, Bosco et al., 
2010). In human islets it has also been reported that islets in the neck of the pancreas 
possess a higher proportion of α-cells (Cabrera et al., 2006). Islets are highly vascularised 
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(Figure 1.3), consequently every single endocrine cell is located near a blood vessel 
(Bonner-Weir and Orci, 1982, Cabrera et al., 2006). Despite representing a small 
proportion of the pancreas (2-3%), islets receive between 15% and 20% of the pancreatic 
blood flow with up to ten-fold higher blood flow compared to the exocrine tissue (Holt et 
al., 2010, Lifson et al., 1989).  
 
 
Figure 1.3: Vascular system around and in the islet of a rat demonstrating the dense vascularisation.  











1.2.3 Insulin biosynthesis and glucose homeostasis 
The different cell types in islets produce different hormones to regulate glucose 
homeostasis. Insulin is produced by β-cells and secreted in response to elevated blood 
glucose levels.  
 
 
Figure 1.4: Structure of proinsulin with the A-chain, B-chain and C-peptide.  
Picture from (Akinlade et al., 2014). 
 
The β-cells have a high metabolic activity due to constant insulin synthesis and secretion 
and therefore also a high mitochondrial activity. Expression of the insulin gene is induced 
in the presence of increased blood glucose level by enhanced activity of transcription 
factors including Pdx-1, NeuroD1/β2 and MafA (Andrali et al., 2008). These transcription 
factors are influenced by changes in glucose concentration though several mechanisms 
including translocation to the nucleus, altered binding activity and interaction with other 
proteins (Andrali et al., 2008). Activation of the transcription factors leads to expression 
of the insulin gene and translation of the polypeptide, preproinsulin, comprising a signal 
peptide, A-chain, B-chain and C-chain (also called C-peptide) (Holt et al., 2010). With the 
cleavage of the signal peptide proinsulin with the A chain and the B chain of insulin and 
the C-peptide is transported into secretory vesicles (Holt et al., 2010, Steiner et al., 2009) 
(Figure 1.4). There, the C-peptide chain is cleaved and stored together with mature insulin 
in secretory granules until exocytosis occurs (Holt et al., 2010, Steiner et al., 2009). 
Through intake of carbohydrates, blood glucose levels rise leading to proportionate insulin 
release as shown in Figure 1.5 (Lemaire and Schuit, 2012). Glucose is transported inside 
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the β-cell through a glucose transporter where it is phosphorylated by glucokinase 
(Ashcroft and Rorsman, 2012, Holt et al., 2010). Subsequently it is metabolised inside the 
mitochondria via aerobic glycolysis and mitochondrial oxidation leading to an increase of 
adenosine triphosphate (ATP)(Lemaire and Schuit, 2012, Holt et al., 2010). High levels of 
ATP in the β-cell leading to closure of K+-channels and, in turn, depolarisation of the cell 
membrane which is followed by opening of Ca2+ channels (Lemaire and Schuit, 2012, Holt 
et al., 2010, Rorsman et al., 2000). Influx of Ca2+ ions leads to exocytosis of insulin granules 
(Ashcroft and Rorsman, 2012, Holt et al., 2010).  
 
 
Figure 1.5: Schematic summary of insulin stimulus secretion coupling (Lemaire and Schuit, 2012).  
 
Secretion of insulin takes place in different ways. First there is a basal secretion which 
controls the blood glucose levels during fasting, constituting approximately 50% of overall 
secretion (Polonsky et al., 1988). Second, insulin is released by the β-cell in response to 
carbohydrate intake in two phases (Grayson et al., 2013)(Figure 1.6). The first phase 
occurs fast after the increase of blood glucose levels and peaks quickly (Ashcroft and 
Rorsman, 2012). This is possible due to membrane bound insulin granules which can be 
released in a time span of a few minutes (Holt et al., 2010). Subsequently the second 
phase occurs which is ATP-dependent, and a more sustained and slower insulin release 





Figure 1.6: Insulin release after food intake with characteristic two phases in response to high blood glucose levels (Holt 
et al., 2010). 
 
1.3 Tissue structure and its role in function 
1.3.1 Extracellular matrix 
ECM is present in two different forms, the basement membrane (BM) and the interstitial 
matrix, distinguishable through their structure (Figure 1.7).   
In general ECM is present in various tissues as BM where the matrix is in close contact to 
cells separating different structures from one another (Theocharis et al., 2016, LeBleu et 
al., 2007). Main components are collagen IV and laminin forming two networks which are 
linked by additional ECM proteins, such as nidogen and perlecan (LeBleu et al., 2007, 
Jayadev and Sherwood, 2017, Pozzi et al., 2017). Furthermore, minor factors specific to 
individual tissue requirements including different proteins, glycoproteins, and 
proteoglycans, including argin, fibulin, hemicentin, collagen XV, collagen XVIII, SPARC and 
BM90 may form part of the network (LeBleu et al., 2007, Jayadev and Sherwood, 2017).  
ECM can also be present as interstitial matrix where it provides a scaffold for cells and 
defines the characteristics of tissues, such as mechanical properties (Theocharis et al., 
2016). Main components include fibrous proteins, polysaccharides and proteoglycans. 
ECM proteins are for example elastins, fibronectins, laminins and collagens, with fibrous 
collagen, especially collagen I, being most abundant forming a three-dimensional mesh 
(Frantz et al., 2010). Additionally proteoglycans, glycoproteins and polysaccharides like 
fibronectin or hyaluronic acid are capable of retaining water thus forming a gel like 
structure (Hynes and Naba, 2012). Further compounds such as growth factors can bind to 
components of the ECM functioning as a reservoir and can be released if required or 




Figure 1.7: Schematic of extracellular matrices and their components when forming BM or interstitial matrix.  
Modified from (Theocharis et al., 2016).  
 
Specifically in the pancreas, ECM is present as BM around the border of the islets and 
around acinar clusters as well as BM around the vessels inside of islets (Wang et al., 1999, 
van Deijnen et al., 1992, Otonkoski et al., 2008). The main components are collagen IV, 
laminin, perlecan and fibronectin and it functions as a three-dimensional barrier structure 
which provides structural support for different cell types and tissues, playing a role also in 
cell signalling (Salvay et al., 2008, Cross et al., 2017). The BM around the vessels in human 
islets has a characteristic appearance of a doubled layered structure and is secreted by 
endothelia cells (Otonkoski et al., 2008, Nikolova et al., 2006, Virtanen et al., 2008). 
Additionally the whole islet is surrounded by a discontinuous BM also called peri-islet 
capsule which separates the endocrine cells from the exocrine cells of the pancreas (van 
Deijnen et al., 1992). The capsule shown in Figure 1.8 consists of two layers of BM with 
ECM components including collagen fibres in between the layers (van Deijnen et al., 1992). 
Analysis of decellularized organs showed the matrisome of complete human pancreas 
matrix composed mostly of different collagens especially fibril forming collagens with 
collagen I the most abundant as well as collagen IV which is part of the BM (Sackett et al., 
2018). Second most abundant in the ECM of human pancreas were glycoproteins like 
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fibrillin and laminin. It was shown that the composition of ECM in islets is impacting on 
their mechanical properties especially stiffness showing the importance of ECM for tissue 
properties (Nagy et al., 2018). Furthermore, it is suggested that mechanical stimuli impact 
on the insulin response in MIN6 pseudoislets (Nyitray et al., 2014). In addition, changes to 
the ECM may promote the activation and infiltration of immune cells in the islet 
microenvironment leading to β-cell destruction and therefore Type 1 diabetes (Bogdani 
et al., 2017).   
 
 
Figure 1.8: Transmission electron microscopy of human pancreas.  
The islet cell is separated from an acinar cell by two layers of BM (arrows) with ECM components including collagen 
fibres (dashed arrow) in between. Figure altered from (van Deijnen et al., 1992). 
 
1.3.2 Islet connectivity 
Signalling through cell-to-cell and cell-to-matrix connections can impact on the viability 
and function of islets and are important for the integrity. Connections between islet cells 
can be formed through adherens junctions, tight junctions or gap junctions and they are 
densely distributed in the islet indicating a tightly packed arrangement (Heileman et al., 
2016) (Figure 1.9). Gap junctions in between β-cells are built up by connexin Cx36, which 
forms a channel between two cells (Peiris et al., 2014). Adherens junctions built up by E-
Cadherin connect the actin cytoskeleton of two cells with each other (Fuchs and Raghavan, 
2002). The last form of cell-to-cell adhesion observed in islets are tight junctions which 
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seal the interstitial space between two single cells (Heileman et al., 2016, Tsukita et al., 
2001). Cell-to-cell connections are important to maintain the integrity of islets, as well as 
for the communication between single islet cells especially the regulation of electrical 
activity and insulin secretion in response to changing blood glucose levels (Benninger et 
al., 2011).  
In addition, islet cells are in contact with the ECM in the peri-islet capsule and in the BM 
around the vessels inside the islet (Figure 1.9). This contact is built up by transmembrane 
receptors called integrins, which can influence β-cell function, survival, proliferation, 
motility, differentiation and insulin secretion  (Kaido et al., 2006). Through the attachment 
of ECM proteins to the integrin receptor on the cell surface of the islet, intracellular signal 
cascades are activated. Different cascades are influenced through this binding and in turn 
influence the proliferation, survival and migration of the cell (Townsend and Gannon, 
2019). Loss of the connection to the matrix can lead to matrix detachment-induced 
apoptosis called anoikis, which shows that the cell-matrix interactions are important for 
islet survival (Irving-Rodgers et al., 2014, Cross et al., 2017). The connection to the BM 
around the vasculature appears to be especially important, since the islet is highly 
vascularised providing cell-to-matrix contact for the majority of the islet cells (Nikolova et 
al., 2006).  
 
 
Figure 1.9: Cell-to-cell connections between single β-cells named gap junctions, tight junctions and adherens junction.  
Cell-to-matrix connections between β-cells and the ECM composed of integrins.  
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1.4 Diabetes mellitus 
Diabetes mellitus encompasses metabolic diseases characterised by high blood glucose 
levels leading to at least relative insulin deficiency, associated with risk of long-term as 
well as short-term complications (American Diabetes Association, 2010, World Health 
Organisation, 1999).  
1.4.1 Type 1 diabetes 
Type 1 diabetes is characterised by insulin deficiency leading to necessity for insulin 
replacement for survival. It is believed to be an autoimmune disease where β-cells are 
attacked and killed by the immune system of the patient (Atkinson et al., 2014). The β-
cells are important for regulation of blood glucose levels and through loss of normal 
function this regulation is lost. The trigger for this autoimmune attack is still not clear, but 
it is suggested that there is a genetic as well as an environmental component which can 
influence the development of Type 1 diabetes (Harjutsalo et al., 2008, Barrett et al., 2009). 
The HLA genotypes DR and DQ, where multiple susceptible gene loci have been identified, 
are associated with an increased risk of Type 1 diabetes (Daneman, 2006, Haller et al., 
2005). However, no single gene is either necessary or sufficient for the development of 
Type 1 diabetes (Haller et al., 2005). Nonetheless, a higher incidence rate has been shown 
in certain populations (Barrett et al., 2009, Harjutsalo et al., 2008). The rapid rise in 
incidence over recent years suggests environmental factors rather than genetic 
components may be the critical factor for development of Type 1 diabetes, since the 
transmission of specific haplotypes would take longer to develop (Gillespie et al., 2004). 
Several environmental factors have been postulated including obesity, vitamin D 
deficiency, viral infection and early exposure to cow’s milk (Harjutsalo et al., 2008, Knip et 
al., 2005, Vaarala et al., 2002).  
Additionally, an analysis of children from Asian populations in the United Kingdom (UK) 
showed that they have a much higher incidence rate of Type 1 diabetes than children in 
Asia (Raymond et al., 2001). Next to factors associated with geographic locations such as 
viruses, environmental toxins or foods are suspected as triggers for Type 1 diabetes 
(Daneman, 2006). Diagnosis occurs most commonly in children with increased diagnosis 
in particular geographic locations and ethnic groups (Figure 1.10) (Haller et al., 2005, Holt 




Figure 1.10: Incidence for Type 1 diabetes worldwide (Katsarou et al., 2017). 
 
Type 1 diabetes is increasingly diagnosed in adults across the full age range (Harjutsalo et 
al., 2008, Haller et al., 2005, Thunander et al., 2008). For the diagnosis of diabetes a fasting 
blood glucose level of more than 7.0 mmol/l is required, although there is no need to 
obtain a fasting test if random unfasted glucose is significantly elevated (>11.1 mmol/l) 
(Atkinson et al., 2014). Additionally HbA1c level is measured, providing an indication of 
the average blood glucose concentration over several months with a level higher than 6.5% 
being diagnostic for diabetes (Nathan, 2009). Additionally characteristic autoantibodies 
to islet cells, insulin or glutamic acid decarboxylase can usually be detected (Atkinson et 
al., 2014). At the point of diagnosis approximately 10-20% of functioning β-cell mass is left 
(Knip et al., 2005) (Figure 1.11). Shortly after diagnosis a transient restoration of function 
with decreased injected insulin requirement can take place (Abdul-Rasoul et al., 2006). 
This so called ‘honeymoon phase’ can last from several weeks to months and the insulin 





Figure 1.11: Progression of Type 1 diabetes presented by presymptomatic stages 1 and 2 followed by symptomatic stage 
3 with changes in functional β-cell mass (Katsarou et al., 2017).  
 
1.4.2 Type 2 diabetes 
The commonest form of diabetes mellitus is Type 2 diabetes, making up around 90-95% 
of all diabetes patients and is characterised by insulin resistance within the target tissues 
(American Diabetes Association, 2010). It is often linked with obesity (associated with 
insulin resistance) which, together with other environmental and genetic factors, 
increases the risk of development of Type 2 diabetes (Kahn et al., 2006, Temneanu et al., 
2016). It is normal that sensitivity to insulin changes during life, but in patients with Type 2 
diabetes the pancreatic β-cell cannot compensate for these changes which leads to 
constantly high blood glucose levels (Kahn et al., 2006). Genetic predisposition can 
increase insulin resistance of the tissue which leads to more stress for the β-cells. Patients 
with Type 2 diabetes also have relative insulin deficiency (American Diabetes Association, 
2010). It can be asymptomatic, or symptoms can develop over several months and years, 
similar to those in Type 1 diabetes including thirst and excessive urine production 
(Temneanu et al., 2016).   
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1.4.3 Gestational diabetes 
Another form of diabetes is gestational diabetes where women develop glucose 
intolerance during the pregnancy (Bottalico, 2007). Through placental hormones, insulin 
resistance is increased, and greater β-cell function is required to maintain normal blood 
glucose (Plows et al., 2018). With a genetic predisposition the cells may not be able to 
cope with this amount of stress and the mother will develop diabetes. Onset can occur at 
any stage of pregnancy, but it is more common during the last third, and for women with 
a family history of diabetes, obesity, advanced maternal age or related to certain 
ethnicities (Bottalico, 2007). The high blood glucose resolves after the birth of the child, 
however, the mother is at high risk of developing Type 2 diabetes later in life (American 
Diabetes Association, 2004).  
1.4.4 Other forms of diabetes 
There are a number of rarer forms of diabetes. One category is maturity onset diabetes 
of youth (MODY). It usually presents in children and teenager and is thought to be caused 
by single gene mutations leading to dysfunction of β-cells (Holt et al., 2010). Identified 
mutations affect either the enzyme glucokinase or transcription factors which are 
important for β-cell development and function (Holt et al., 2010, McDonald and Ellard, 
2013).  
Another category of diabetes is neonatal diabetes. It is diagnosed in children with an age 
of under six months and can be permanent or transient (Holt et al., 2010). It can also be 
associated with neurological abnormalities including mental and physical developmental 
delay (Lemelman et al., 2018). Like MODY it is caused by gene mutations which influence 
β-cell function and development (Lemelman et al., 2018, Støy et al., 2007). The majority 
have mutation affecting the K+-channel and therefore the exocytosis of insulin vesicles 
(Holt et al., 2010).  
Additionally, diabetes can develop through pharmaceutical interactions or secondary to 
pancreatic diseases including pancreatitis. Pharmaceutical interactions may reduce 
synthesis or secretion of insulin or they can reduce insulin sensitivity (Holt et al., 2010, 
American Diabetes Association, 2010). Diseases of the exocrine pancreas including 
pancreatic cancer, pancreatitis or cystic fibrosis are categorised as Type 3c diabetes with 
different mechanisms leading to hyperglycaemia (Hart et al., 2016). Whereas it is believed 
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that in cases of pancreatic cancer hyperglycaemia is caused through paraneoplastic 
effects, it is believed that in the case of pancreatitis inflammatory destruction of the 
pancreas may lead to impaired glucose homeostasis (Sah et al., 2013, Hart et al., 2016).  
1.4.5 Complications 
Diabetes can cause specific microvascular complications including retinopathy, 
nephropathy and neuropathy (Forbes and Cooper, 2013). These are caused by chronic 
high blood glucose levels which can occur with all forms of diabetes (Holt et al., 2010). 
High blood glucose levels influence different mechanisms in the cells, which induce 
complications (Forbes and Cooper, 2013). For example, high blood glucose can lead to an 
increased flux of the polyol pathway creating a redox imbalance of oxidized and reduced 
nicotamine adenine dinucleotide (NADH/NAD+) increasing oxidative stress and therefore 
complications of diabetes (Yan, 2018). Another consequence of high blood glucose levels 
is the increased formation of advanced glycation end products (AGE) which can alter 
tissue properties and causing microvascular complications (Singh et al., 2001). Through 
the glycation of proteins their structure and function is disrupted and for example for ECM 
proteins like collagen and fibrinogen this can impact on organ function or lead to vascular 
dysfunction increasing complications of diabetes (Singh et al., 2014, Strieder-Barboza et 
al., 2019). Different studies showed increased AGE formation in tissues of diabetic 
patients with the possibility of suppression of AGE production through pharmacological 
intervention leading to inhibition of deterioration of diabetic complications including 
neuropathy (Kawai et al., 2010, Strieder-Barboza et al., 2019).  
The Diabetes Control and Complications Trial (DCCT) showed that intensive insulin 
therapy in patients with Type 1 diabetes could reduce complications of high blood glucose 
(The Diabetes Control and Complications Trial Research Group, 1993, Nathan, 2014). The 
UK Prospective Diabetes Study (UKPDS) showed that the intensive treatment with insulin 
or sulphonylureas reduced microvascular complications in Type 2 diabetes (UK 
Prospective Diabetes Study Group, 1998).  
Diabetes is also a risk factor for macrovascular disease in parallel with obesity, high fat 
levels, high blood pressure and smoking (Forbes and Cooper, 2013). Associated 
complications include increased risk of a heart attack (myocardial infarction) or a stroke, 
atheroma and a reduction in life expectancy and may be addressed with a healthy lifestyle 
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including weight control and physical activity, avoidance of smoking, reducing of blood 
pressure and lipid control (Daneman, 2006). 
1.4.6 Management of diabetes 
Currently there is no cure for Type 1 diabetes, however with the discovery of insulin in 
1922 inevitable early mortality was prevented (Banting et al., 1922, Holt et al., 2010). The 
primary treatments for Type 1 diabetes combine careful glucose monitoring with 
exogenous insulin treatment (Atkinson et al., 2014). It is thought that the long-term life 
expectancy of newly diagnosed people with Type 1 diabetes could be increased due to 
improvements in glucose monitoring and insulin administration (Miller et al., 2012), but 
this does not diminish the uninterrupted burden of self-management. Additionally, self-
administration of exogenous insulin by injection or continuous subcutaneous insulin 
infusion (CSII) pumps can lead to dangerously low glucose levels (The Diabetes Control 
and Complications Trial Research Group, 1993). Some patients may lose their 
hypoglycaemia awareness resulting in an increased risk of hypoglycaemic events requiring 
assistance from another person and occasionally death (Martín-Timón and Del Cañizo-
Gómez, 2015). These attacks are one of the greatest fears of people with Type 1 diabetes. 
It was shown that the intensive treatment in the DCCT led to an increased rate of 
hypoglycaemic events (Nathan, 2014). This shows that hypoglycaemia is a major limiting 
factor towards achieving blood glucose control (Daneman, 2006). Reasons for 
hypoglycaemic attacks can vary, but typically result from the administration of an insulin 
dose too high for the requirements affected by food intake and physical activity (Daneman, 
2006). These events can lead to fear and anxiety in patients resulting in an impaired 
glycaemic control (Katsarou et al., 2017). In cases of severely impaired blood glucose 
control β-cell replacement therapy in the form of pancreas or islet transplantation can be 
an option.  
For the treatment of Type 2 diabetes insulin resistance has to be addressed. This can be 
achieved with drugs such as metformin or thiazolidinediones (Bailey, 2005). Insulin or 
sulphonylureas administration may be used for intensive blood glucose control to 
decrease the risk of microvascular complications (UK Prospective Diabetes Study Group, 
1998). The potential for recovery of β-cell function following a marked reduction in insulin 
resistance with, in some cases, diabetes remission has been demonstrated through 
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bariatric surgery or very low calorie diet (Knop and Taylor, 2013, Taylor, 2013). Pancreas 
transplantation in combination with a kidney transplant can be an option in selected cases 
of people with insulin-treated Type 2 diabetes in renal failure (Hudson et al., 2015). With 
avoidance of immunosuppression and engraftment of sufficient β-cell mass through 
improved encapsulation strategies or alternative cell sources such as induced pluripotent 
stem cells (iPSCs), β-cell replacement therapy may become a treatment option for more 
patients with Type 2 diabetes (Sneddon et al., 2018).  
1.5 Current β-cell replacement therapy 
1.5.1 Pancreas transplantation 
Transplantation of a whole pancreas typically leads to insulin independence and can be a 
treatment option for Type 1 diabetes patients with severe recurrent hypoglycaemia and 
complete unawareness as well as patients in need of another donor organ for example 
kidney. The pancreas can either be transplanted alone (PTA), after a kidney 
transplantation (PAK) or simultaneous with a kidney (SPK) with a 1-year pancreas graft 
survival of 87% for SPK compared to 78% for PTA (Flatt et al., 2019) 
In the UK patients are considered for transplantation if they experience severe 
hypoglycaemic events and/or chronic renal failure if they have a body mass index (BMI) 
from under 30 kg/m2 and are fit enough to survive the transplantation (Mittal and Gough, 
2014, White et al., 2009). However, the operation is a major abdominal surgery with 
various complications including thrombosis, bleeding, graft pancreatitis or infection 
leading to a relaparotomy rate of 31% and graft loss of 9% in a single centre study (Kopp 
et al., 2018). Despite constant improvements the mortality rate for pancreas recipients 
are still up to 4% at one year post transplantation and up to 20% five years’ post 
transplantation evidencing the severity of the procedure (Gruessner and Gruessner, 2013). 
For transplantation a deceased organ is required which can be obtained from a donor 
after brain death (DBD) or a carefully selected donor after circulatory death (DCD) with 
both demonstrating comparable short term results (Muthusamy et al., 2012). For DCD 
donors limited cold ischaemia time (CIT) is preferable due to a significant impact of CIT on 
graft survival and may be achieved by prioritising local transplant centres (Hudson et al., 
2015). In the UK pancreas donors with an age of <60 years and a BMI of <30 kg/m2 are 
accepted for transplantation and pancreata are allocated on a national basis according to 
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an allocation scheme considering CIT, HLA sensitization, dialysis status, waiting time, age 
matching, donor BMI and HLA mismatch (Hudson et al., 2015, Flatt et al., 2019).  
An additional advantage of transplantation of the whole organ is that islets remain in their 
natural environment and experience less damage compared to an islet transplantation, 
where they are separated from acinar tissue and transplanted into the portal vein of the 
patient. 
1.5.2 Islet isolation and transplantation 
Another possible treatment of Type 1 diabetes is islet transplantation. It is used for some 
Type 1 diabetes patients who suffer from severe blood glucose lability and is now the 
standard of care treatment for individuals with severe recurrent hypoglycaemia in the UK 
with the goal to eliminate hypoglycaemia (Espes et al., 2016, Brooks et al., 2013). 
Compared to whole pancreas transplantation, islet transplantation is a minimally invasive 
alternative to treat severe hypoglycaemia but does not routinely deliver sustained insulin 
independence (Okere et al., 2016, Shapiro et al., 2000). Islets are isolated from a deceased 
pancreas with nationwide allocation in the UK according to the same allocation scheme 
as whole pancreas transplantation (Hudson et al., 2015). Donors with higher BMI are 
‘weighted’ higher for islet transplantation due to better isolation outcomes with increased 
BMI (Hudson et al., 2015, Johnson et al., 2014). During the isolation procedure endocrine 
tissue is enzymatically and mechanically separated from exocrine tissue using manual or 
automated methods (Ricordi et al., 1988). Briefly, the pancreas is perfused with a 
collagenase solution before being cut and transferred into a Ricordi chamber for digestion 
at 37°C combined with gentle shakes (Qi et al., 2009a). Islets are then purified from 
exocrine tissue with a cell separator (COBE) using density gradients leading to fractions 
with different purities (Qi et al., 2009b). Quality control with assessment of viability, purity 
and islet yield with IEQ counting follows (Brooks et al., 2013). Prediction of function after 
transplant can be achieved with glucose induced insulin secretion analysis, oxygen 
consumption rate (OCR)/DNA measurements, transplantation in a mouse model or 
analysis of gene expression profiles (Papas et al., 2007, Hanson et al., 2010, Kurian et al., 
2017). For islet transplantation as part of the UK integrated islet transplant program, islet 
mass >3000 IEQ/kg, viability of >70% and purity >30% are required for the use of an islet 
preparation for transplantation (Brooks et al., 2013). 
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If islets pass quality control and a suitable recipient is available, they are injected into the 
portal vein in a minimally invasive procedure for the patient (Shapiro et al., 2000) 
(Figure 1.12).  
The required immunosuppression for both pancreas and islets transplants is associated 
with increased risk of infections and malignancy in addition to having side effects which 
may impact on quality of life (Hsu and Katelaris, 2009). Additionally, the types of 
immunosuppressive agents must be carefully considered as corticosteroids are toxic for 
the islet cells (McCall and Shapiro, 2012). This finding among other changes led to the 
landmark development of the Edmonton protocol in 2000. Not only was the 
immunosuppression protocol adapted to better suit islet transplantation, but also several 
sequential transplants were undertaken in each recipient until insulin independence was 
achieved (Shapiro et al., 2000). However, major limitations subsequent to transplantation 
including the instant blood mediated inflammatory reaction (IBMIR), hypoxia, 
inflammatory infiltration or mechanical injury followed by islet cell loss of up to 60% still 
need to be addressed (McCall and Shapiro, 2012, Biarnes et al., 2002, Bennet et al., 2011). 
IBMIR takes place, when platelets bind to the surface of the islets and leukocytes infiltrate 
them leading to inflammatory and thrombotic reactions (McCall and Shapiro, 2012). 
These negative effects impair the outcome of islet transplantation, despite administration 
of heparin or insulin.  
 
 
Figure 1.12: Schematic of islet extraction and delivery process. 
Islets are enzymatically isolated from a donor pancreas and injected into the portal vein of the recipient. Image from 
(Naftanel and Harlan, 2005).  
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1.5.2.1 Impact of isolation and transplantation on islets and their ECM 
For research purposes islet transplantation in rodents is often performed as a readily 
accessible model. It is, however, important to note the differences in islet 
cytoarchitecture. Mouse islets (Figure 1.13) have a core of β-cells mantled by a belt of      
α-cells, δ-cells and PP-cells (Bosco et al., 2010). They also contain proportionally more       
β-cells and fewer α-cells compared to human islets (Cabrera et al., 2006).  
 
 
Figure 1.13: Architecture of mouse islets.  
In the core of the islet β-cells (red) are located surrounded by α-cells (green) and δ-cells (blue). Scale bar 50 µm. Image 
adapted from (Cabrera et al., 2006). 
 
ECM is a complex network including a variety of proteins and glycoproteins as described 
in 1.3. During the isolation process, ECM components are digested with an enzyme 
cocktail consisting mostly of collagenase (Qi et al., 2009a, Ricordi et al., 1988). Collagen, 
especially from the BM, is the main target and every component of the ECM is influenced 
differently during the digestion process (Cross et al., 2017, Irving-Rodgers et al., 2014). 
The composition and integrity of ECM seems to be influenced by a range of factors 
including CIT and BMI leading to differences during digestion and therefore different 
isolation outcomes (Hanley et al., 2008, Kin et al., 2008). For example, organs with higher 
CIT showed increased amount of pan-laminin after isolation compared to organs with 
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shorter CIT, but further studies need to clarify the cause (Cross et al., 2017). After isolation 
the BM around islets is lost, but BM around vasculature inside of islets is still visible with 
declining staining intensity over four days in culture (Cross et al., 2017, Irving-Rodgers et 
al., 2014, Wang et al., 1999). Loss of cell-matrix connection leads to an integrin-mediated 
programmed cell death process called anoikis (Thomas et al., 1999).  
In addition to that, the vascular system is impacted as well with loss of endothelial cells 
over culture time and destruction of some vascular BM proteins negatively impacting on 
survival and function of the islets. It was shown that components of the vascular BM 
including laminin-411 and laminin-511 upregulate insulin expression and proliferation in 
MIN6 β-cells revealing their importance for islet function and survival (Nikolova et al., 
2006). 
Additionally, the whole isolation and transplantation process is stressful for islets and 
leads to increased cytotoxicity after isolation and during subsequent culture (Daoud et al., 
2010a, Cross et al., 2017). Loss of contact with the ECM also changes integrin expression 
on the cell membrane of islet cells influencing cell survival (Wang et al., 1999). In culture 
following isolation recovery of BM was observed by Wang et al. after five days of culture, 
but not by Irving-Rodgers et al. after four or seven days of culture (Wang et al., 1999, 
Irving-Rodgers et al., 2014). 
Through the isolation process islets are also cut off from their blood supply leading to 
hypoxia in the core especially in large islets leading to necrotic cell death (Giuliani et al., 
2005). This can lead to further stress and decrease function and viability of islets during 
culture and in the early stages after transplantation (Dionne et al., 1993, MacGregor et al., 
2006).  
Once transplanted, revascularisation can provide islets with sufficient oxygen and nutrient 
supply, but it can take up to ten days till the glomerular microvascular network is rebuilt 
(Menger et al., 1989). Transplanted islets show revascularisation mainly in the periphery 
of the islets and in the stroma around islets (Mattsson et al., 2002). BM is rebuilt and may 




1.5.2.2 Islet preservation 
Before transplantation islets are preserved for at least 24 h in the UK (British 
Transplantation Society, 2019). Typical protocols in other centres internationally include 
islet culture of up to 72 h with some centres extending up to one week (Kin et al., 2008, 
Scharp et al., 1990). The Edmonton protocol of 2000 tried to avoid culture of islets and 
transplanted them immediately (Shapiro et al., 2000). There is still a controversy regarding 
whether a preservation period improves or decreases outcomes of islet transplantation 
(Shapiro et al., 2006). Nevertheless, there are other advantages of a culture period before 
transplantation. For example it provides more time for the centre to prepare the 
transplantation which also includes more time for the recipient to travel to the transplant 
centre (Shapiro, 2011, Shapiro et al., 2006). Additionally, there is more time to start 
immunosuppressive protocols and for additional quality controls of donor islets (British 
Transplantation Society, 2019, Kin et al., 2008). Culture of islets can also increase purity 
and therefore potentially lower the immune response towards the donor tissue triggered 
by dying acinar tissue (Chun et al., 2008). However, the survival rate of islets in culture is 
decreasing with time and remaining islets are often fragmented with smaller cell clusters 
in comparison to intact islets which complicates proper analysis (Matsushima et al., 2016, 
Lim et al., 2011). Additionally, the lack of oxygen leads to necrotic cores with decreasing 
viability after seven days (or less) in culture (Irving-Rodgers et al., 2014). For future culture 
systems it is important to increase viability and function for a better transplantation 
outcome (Chow et al., 2010).  
1.5.2.3 Transplantation site 
The commonly used transplant site for islet transplantation is the portal vein (Shapiro, 
2012). However, there are several disadvantages including IBMIR, liver inflammation, 
bleeding and thrombosis or toxicity, which can be increased by the intake of 
immunosuppressive drugs (McCall and Shapiro, 2012, Shapiro, 2012). Additionally, 
monitoring of the graft within the liver is difficult (McCall and Shapiro, 2012). Other 
potential transplant sites are subcutaneous, omental, kidney capsule or testis 
(Matsushima et al., 2016). The kidney capsule is used as a transplant model in rodents, 
but due to anatomical differences cannot be used in humans (Blomeier et al., 2006).The 
omentum was chosen recently due to its easy access in animal models and initial human 
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transplants have commenced (Espes et al., 2016, Berman et al., 2016). It was shown that 
adipose tissue leads to an increase in vascular endothelial growth factor A (VEGF-A) and 
therefore a better revascularisation (Espes et al., 2016). Other possible sites for islet 
transplantation can be immune privileged sites including testis or the anterior chamber of 
the eye where it is hoped to decrease the requirement for immunosuppressive drugs 
(McCall and Shapiro, 2012).  
1.5.3 Secondary sources of β-cells 
One of the remaining challenges in β-cell replacement therapy is the source of a sufficient 
supply of islets or β-cells, particularly given the current limitations of immunoreaction 
against transplanted material and damage to the donor organ though warm/cold 
ischaemic time. Alternative cell sources may overcome these challenges, improve 
transplantation outcomes and extend the application of β-cell replacement to more 
patients. Potential sources include porcine islets and differentiated β-cells from human 
embryonic stem cells (hESCs) or human induced pluripotent stem cells (hiPSCs) (Kieffer et 
al., 2017, Sneddon et al., 2018).  
Several studies of xenotransplantation into non-human primates and human patients with 
Type 1 diabetes showed restoration of normoglycaemia but regulatory and ethical 
challenges remain (van der Windt et al., 2012). Furthermore, rejection of porcine material 
has to be prevented through additional immunosuppression or encapsulation techniques 
(Park et al., 2015).  
Differentiated β-cells from hESCs or hiPSCs may represent an alternative cell source for  
β-cells without ischaemic damage and, in the case of hiPSCs, without alloimmune reaction. 
Stem cells possess the ability to renew tissues and to differentiate into the required cell 
types (Moore et al., 2015). It is possible to mature hESCs into cells expressing certain key 
markers of β-cells which not only produce insulin through glucose stimulation, but reverse 
diabetes in a mouse model (Rezania et al., 2014). However, the application of hESCs raises 
potential ethical concerns and concerns regarding teratoma formation (Moore et al., 
2015). Another disadvantage is the alloimmune reaction towards the foreign cells which 
may be overcome using hiPSCs. It was shown that hiPSCs from non-diabetic donors and 
donors with Type 1 diabetes can be matured in vitro into cells expressing β-cell markers, 
respond to a glucose challenge in vitro and in a mouse model (Millman et al., 2016). 
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Further research needs to improve the yields of matured cells with successful scale-up 
and improve maturation protocols, since mature cells generated to date express some 
distinct β-cell markers, but remain different from β-cells in islets (Rezania et al., 2014, 
Millman et al., 2016). 
1.6 Tissue Engineering 
Tissue engineering combines regenerative medicine and material sciences to develop 
tissues or organs to restore function in damaged organs or tissues (Vacanti and Langer, 
1999, Perez-Basterrechea et al., 2018). Tissue engineering approaches can provide three-
dimensional constructs for regeneration of tissues and organs made out of a combination 
of cells, biomaterials and specific factors such as VEGF-A as shown in Figure 1.14 (O'Brien, 
2011). Different materials can be combined to achieve optimal mechanical properties 
including stiffness, and with the addition of ECM components and factors the specific 
niche for cells can be created, playing a vital role in tissue organisation and function. 
Various tissues have been developed for in vitro and in vivo applications including skin, 
cartilage and bone constructs (O'Brien, 2011).  
 
 
Figure 1.14: Principle of tissue engineering with the combination of cells, biomaterials and other factors to achieve a 




1.6.1 Tissue engineering for islet transplantation 
The isolation process separates the endocrine from the exocrine parts of the pancreas in 
preparation for islet transplantation. However, through this process islets lose contact to 
their surrounding BM, which is negatively impacting on their viability and function and 
therefore transplant outcomes (Cross et al., 2017, Irving-Rodgers et al., 2014). 
Additionally, the blood supply is discontinued decreasing nutrient and oxygen transfer 
(Komatsu et al., 2017). Tissue engineering approaches including application of matrices 
and scaffolds aim to replace the lost BM to provide cell-matrix-connections, improve islet 
viability and function and therefore quality after isolation and prior transplantation.  
1.6.1.1 Scaffolds for islet transplantation 
Culture of islets on scaffolds could be an option to provide mechanical support after the 
isolation process (Perez-Basterrechea et al., 2018). Requirements for the scaffold 
materials include: Ability to mimic natural pancreas, providing a three-dimensional 
environment, biocompatibility, degradability, ability to support and protect isolated islets 
as well as implementing sufficient mechanical integrity (Perez-Basterrechea et al., 2018, 
Xu et al., 2019, Kaviani and Azarpira, 2016, Blomeier et al., 2006).  
Scaffolds can be composed of synthetic or natural materials with advantages and 
disadvantages of them both (Table 1.1). Synthetic materials like polyglycolic acid (PGA), 
polylactic acid (PLA), polycaprolactone (PCL) or polylactic-co-glycolic acid (PLGA) can 
provide controllable physical and mechanical properties, but demonstrate limited 
biocompatibility as well as producing acidic by-products during degradation (Chan and 
Leong, 2008, Perez-Basterrechea et al., 2018, Kumar et al., 2018). In contrast, natural 
materials show an enhanced biocompatibility along with improved functionality and are 
either polysaccharides including alginate, chitosan and agarose or polypeptides including 
collagen, fibrin and silk (Perez-Basterrechea et al., 2018, Kumar et al., 2018). Alginate is 
widely used for encapsulation of islets due to its biocompatibility and low cost although it 
can attract immune cells leading to formation of fibrotic capsules (Xu et al., 2019). 
Scaffolds in the form of hydrogels have the advantage of a high surface area to volume 
ratio which is beneficial for an effective oxygen and mass transfer (Daoud et al., 2011, 




Table 1.1: Advantages and disadvantages for synthetic and natural polymers for scaffold manufacturing (Kaviani and 
Azarpira, 2016, Perez-Basterrechea et al., 2018). 




• Specific degradation 
rate/biodegradable 
• Non-immunogenicity 
• Good mechanical strength 
• Controllable characteristics 
• Synthesized on large scale 
• Lack of biological activity 
• Hydrophobic nature  
reduces biocompatibility  





• Higher biocompatibility 
• No inflammatory response 
• Biological activity (cell 
adhesion/growth/ 
differentiation) 
• Biochemical properties can 
limit certain approaches 
• Variation in degradation 
rate 
• Poor mechanical strength 
 
Combination of more than one material with complementary mechanical and biological 
features may provide an optimal construct for improved viability and function of isolated 
islets (Xu et al., 2019, Perez-Basterrechea et al., 2018). Combination of polymers with 
natural ECM components is crucial for cell adhesion and growth inside the construct 
(Daoud et al., 2011, Stendahl et al., 2009). These are also important to promote the 
neovascularisation of islets (Daoud et al., 2011). 
1.6.1.2 Combination of material and isolated islets 
ECM lost through isolation may be replaced through combining isolated islets with 
biomaterials. Ideally biomaterials should provide the surrounding microenvironment with 
cell-to-matrix contacts, mechanical stimulation as well as improving revascularisation in 
addition to delivering immune protection (Stendahl et al., 2009, Daoud et al., 2011). 
Various techniques have been proposed to combine isolated islets with ECM materials.  
Isolated islets can be either seeded onto a construct or incorporated during its 
manufacture (Daoud et al., 2010b, Marchioli et al., 2015). Constructs for seeding can be 
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scaffolds, hydrogels or electrospun nanofiber membranes (Daoud et al., 2010b). 
Incorporation of islets within materials is termed encapsulation and can be divided into 
macroencapsulation, microencapsulation or nanoencapsulation according to islet number 
and volume of material (Figure 1.15) (Song and Roy, 2015).   
For macroencapsulation a number of islets are encapsulated in a gel or device which 
allows a greater control over gel parameters but limits oxygen and nutrient transfer (Song 
and Roy, 2015, Desai and Shea, 2017). Macroencapsulation can either be extravascular of 
intravascular which allows the perfusion of the construct (Song and Roy, 2015). During 
microencapsulation single islets are encapsulated in a gel and a number of these 
microencapsulated islets are transplanted, which increases the surface area to volume 
ratio and improves nutrient exchange (Song and Roy, 2015, Desai and Shea, 2017). 
Limitations are the need for a suitably large transplantation site as well as the need for 
prevascularisation of the site. For nanoencapsulation, islets are coated in a conformal way 
or with a layer-by-layer technique to enhance oxygen and nutrient supply, but protect 
against the immune cells (Vaithilingam et al., 2017).  
 
 
Figure 1.15: Encapsulation strategies for isolated islets with macroencapsulation (extravascular), microencapsulation, 




Culture of islets seeded on three-dimensional PGA scaffolds prolonged the survival and 
increased the function of rat islets over a culture period of up to 14 days (Chun et al., 
2008). The PGA scaffold was modified with poly-L-lysine to provide a better adherence for 
the islet cells (Chun et al., 2008). Transplantation of islets seeded on a scaffold into the 
peritoneal cavity of mice showed improved islet function, functional vessels and 
maintenance of islet morphology (Blomeier et al., 2006). Additionally the amount of 
required islets could be decreased with the use of the scaffold compared to the 
conventional method of islets transplantation under the kidney capsule in this rodent 
model (Blomeier et al., 2006). Addition of the ECM proteins collagen IV, fibronectin or 
laminin to the scaffold improved function of transplanted islets as well as the size of the 
islets at 297 days after transplantation compared to non-coated scaffolds (Salvay et al., 
2008). A higher vascular density was found in islets transplanted on coated scaffolds 
compared to the non-coated control (Salvay et al., 2008). Especially the inclusion of 
collagen IV caused rapid euglycemia and a better performance in a glucose tolerance test 
in mice (Salvay et al., 2008). Summed up, this study showed a significant positive influence 
of ECM proteins on transplantation in mice (Salvay et al., 2008). Combination of a scaffold 
and a hydrogel was even more beneficial, which leads to the conclusion firstly that the 3D 
culture with ECM components is beneficial for function and secondly that the increased 
mechanical and diffusivity features of a scaffold further increase function (Daoud et al., 
2011). 
Encapsulation of islets in a gel composed of collagen I, collagen IV and fibronectin 
improved the insulin release compared to islets in suspension or in a collagen I gel (Daoud 
et al., 2011). Advantage of encapsulation of islets in a hydrogel or scaffold is that the islets 
cannot migrate through the tissue, but stay in the desired site (Blomeier et al., 2006).  
One emerging technique for encapsulation would leverage 3D bioprinting to provide 
three-dimensional organization of cells in a printed scaffold (Marchioli et al., 2015). Many 
different approaches can be conceived of, like printing of isolated islets for a transplant, 
printing different primary cells into an islet-like structure or printing stem cell derived 





Islets are complex micro-organs surrounded by a specific microenvironment impacting on 
endocrine function. A better understanding of how acute stress such as organ 
preservation and the isolation process impacts on the islet niche is required to improve 
islet viability and function. There is also a need to characterise the impact of ECM 
replacement strategies on the health of isolated islets in order to determine optimal 
strategies for improving transplant outcomes. This thesis set out to answer how the 
microenvironment of islets changes through acute stress or the isolation procedure and 
how the impact of stress on the tissue can be quantified with the hypothesis that these 
changes influence islet health and a better quantification method will help towards a 
better understanding of the status of whole pancreata and single islets. This thesis also 
wanted to answer the question how the provision of a three-component hydrogel impacts 
on islet health with the hypothesis that the culture of islets in proximity or contact with 
the hydrogel improves islet integrity, viability and function. Further this thesis set out to 
answer how a nanofiber membrane, different hydrogel designs or dynamic culture 
systems impact on islet health through reduction of hypoxia in combination of ECM 
presence with the hypothesis, that the reduction of hypoxic stress improves islet integrity, 
viability and function.  
This thesis had the following aims and objectives: 
Aim 1: To characterise the islet niche in situ and analyse acute changes related to 
ischaemia, tissue processing and islet isolation. 
Objective 1.1: To characterise islet microenvironment, integrity and morphology 
in situ in a pancreas with minimal ischaemic exposure. 
Objective 1.2: To characterise the impact of ischaemia and tissue processing on 
islet microenvironment, integrity and morphology. 
Objective 1.3: To characterise the impact of islet isolation on islet 
microenvironment, viability, integrity. 
Aim 2: To assess ECM replacement through a novel collagen, alginate, fibrinogen (CAF) 
hydrogel and characterise impact of hydrogel on pseudoislets and human isolated islets.  
Objective 2.1: To establish a reproducible model for human islets from the MIN6 
β-cell line and characterise integrity and function. 
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Objective 2.2: To assess biocompatibility of CAF hydrogel with pseudoislet model 
through assessment of viability, morphology and function.  
Objective 2.3: To assess biocompatibility of CAF hydrogel with human isolated 
islets through assessment of viability, morphology and function. 
Aim 3: To develop bioengineering approaches to reduce hypoxic impact on β-cells and 
restore lost ECM in the islet microenvironment.  
Objective 3.1: To develop a bioengineered construct with CAF hydrogel. 
Objective 3.2: To characterise impact of dynamic culture on pseudoislet viability 
and gene expression with and without the presence of CAF hydrogel.  
Objective 3.3: To characterise the impact of an electrospun nanofiber membrane 
on viability and morphology in mouse islets. 
Objective 3.4: To develop a proof of concept system for hydrogel perifusion.  























































2 Chapter 2. Methods 
All chemicals and general reagents were purchased from Sigma Aldrich (Dorset, UK), 
Thermo Fisher Scientific (Waltham, USA) or Melford (Suffolk, UK) if not otherwise declared.   
2.1 Tissue Culture 
2.1.1 MIN6 β-cell line culture 
MIN6 cells are a mouse insulinoma cell line generated by an in vivo mutation of the SV40 
T antigen leading to β-cell tumours (Miyazaki et al., 1990). MIN6 cells behave similar to 
primary islets with a 6-7 fold increase of insulin secretion through glucose stimulation of 
25 mmol/l as well as characteristic glucose metabolism including phosphorylation via 
glucokinase (Ishihara et al., 1993).  
MIN6 cells used in this thesis were kindly provided by Dr Catherine Arden at Newcastle 
University and used between passages p24 and p29. Cells were cultured in high glucose 
Dulbecco Modified Eagle Medium (DMEM) (D6429 Sigma-Aldrich) containing 4.5 g/l 
glucose, L-glutamine and sodium bicarbonate and supplemented with 1% 100x 
penicillin/streptomycin, 0.0005% β-mercaptoethanol, 15% foetal bovine serum (FBS) and 
2.5% 1M HEPES solution. Cells were cultured at 37˚C and 5% CO2 in 75 cm2 tissue culture 
flasks with the culture medium changed every two till three days.  
2.1.1.1 MIN6 sub culture 
MIN6 cells were split when they reached ~80% confluence. After the cells were washed 
with 5-8 ml of phosphate buffered saline (PBS), they were incubated with 2 ml of 1x 
trypsin for 5 min at 37˚C. The flask was gently tapped against the hand to observe, if cells 
detach from the surface and completely washed off with 10 ml culture media. 
Subsequently the cell suspension was centrifuged for 3 min at 549 g and the supernatant 
discarded. The pellet was then resuspended in 10 ml growth media and split in convenient 
dilutions (1:5 or 1:10 in a 75 cm2 flask).  
For storage MIN6 cells were split as described before. The cell pellet was resuspended in 
1 ml of 10% dimethyl sulfoxide (DMSO) and 90% FBS and transferred into a cryovial. The 
vial was then incubated in a Nalgene® Mr Frosty at -80˚C for ~24 h. Subsequently cells 
were transferred into liquid nitrogen for long-term storage. 
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For recovery, MIN6 cells were thawed in a 37˚C water bath and the 1 ml cell suspension 
was added to 9 ml growth media. This was followed by centrifugation for 3 min at 549 g 
and the supernatant discarded. The pellet was resuspended in 12 ml culture media and 
transferred into a 75 cm2 culture flask. Subsequently the cells were incubated at 37˚C and 
5% CO2 until they reached 80% confluence.  
2.1.1.2 Pseudoislet generation and culture 
‘Pseudoislets’ describe a three-dimensional cell cluster generated from single cells which 
allows the study of β-cell microtissue without the need for primary islets. It has been 
shown that MIN6 pseudoislets function similar to mouse islets and they are a valid model 
for islet research (Hauge-Evans et al., 1999, Persaud et al., 2010). 
Pseudoislets were generated by culturing MIN6 cells in suspension culture after splitting 
as described above. After resuspending the pellet, 1.5 ml MIN6 cell suspension was 
transferred into a non-adherent culture dish with 6.5 ml culture medium. After 2-3 days, 
the forming cell aggregates were transferred from the dish into a 15 ml falcon and spun 
down for 1 min at 44 g. The supernatant was discarded, and the pellet was gently 
resuspended in 8 ml fresh growth medium. The forming cell clusters were then 
transferred back into the cell culture dish. Pseudoislets were used after five days of non-
adherent culture.  
2.1.2 Human islet culture 
Isolated islets were provided from the Transplant Regenerative Medicine Laboratory at 
Newcastle University or isolation centres in Canada (Edmonton) and the United Kingdom 
(Edinburgh, London, Oxford). Deceased donor pancreata were accessed under 
appropriate ethical approval (05/MRE09/48 or 16/NE/0230) and adhering to the Human 
Tissue Act at Newcastle University following informed donor family consent. Isolated islets 
were given an internal number for identification (LDIS).  
Human islets were cultured in Connaught Medical Research Laboratories (CMRL) 1066 
medium (Mediatech Inc., Manassas, USA) supplemented with 1.2% 100x penicillin/ 
streptomycin, 1.2% 1M HEPES solution and 2% human serum albumin (Gemini Bio-
Products, USA) in T175 suspension flasks with a density of 200IEQ/cm2. Culture conditions 
were at 37˚C and 5% CO2 with a medium change every 2-3 days. For that, islets were 
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transferred in a tube, centrifuged at 44 g for 1 min and the supernatant discarded. The 
pellet was then resuspended in fresh medium and the islet suspension was carefully 
transferred back into the culture flask.  
2.1.2.1 Donor information 
Key information regarding the status of donor pancreata included in these studies, prior 



















Table 2.1: Pancreas and islet donor information.   
17 pancreata were used with 10 (47%) being from female donors and 7 (41%) from DBD, with average (range) in age of 50 (25-73) years, BMI of 27 (18-33) kg/m2, CIT of 18.1 (4.0-55.4) h and 
WIT of 27.2 (17-37) min. 
21 islet preparations were used with 10 (48%) being from female donors and 13 (62%) from DBD, with average (range) in age of 48 (24-66) years, BMI of 28 (17-37) kg/m2, CIT of 10.5 (2.8-
26.2) h and WIT of 18.5 (12-25) min. 
Abbreviations: Body mass index (BMI), donor after circulatory death (DCD), donor after brain death (DBD), cold ischaemia time (CIT) – defined from cross clamp till fixation, warm ischaemia time 
























169 pancreas female 64 26 DCD 16.5 32 n/s n/s 9.1 No - - 
172 pancreas male 25 23 DCD 8.0 18 n/s n/s n/s No - - 
173 pancreas male 43 27 DBD 5.1 - n/s n/s n/s No - - 
192 islets male 51 33 DBD 4.0 - n/s n/s 9.4 No 90% 50% 
193 pancreas male 71 31 DCD n/s 31 n/s n/s n/s No - - 
194 islets male 59 27 DCD 7.0 105 n/s n/s 6.6 No 90% 91% 
195 islets male 45 28 DBD n/s - n/s n/s n/s No - - 
196 islets male 51 24 DBD 12.5 - n/s n/s n/s n/s 76% 40% 
204 islets female 56 27 DBD 13.0 - n/s 8.7 9 No 70% 48% 
206 islets female 49 31 DBD 26.2 - n/s 10 6.4 No 85% 58% 
209 islets female 38 36 DBD 26.0 - n/s n/s 7.4 No 65% 70% 
210 islets male 24 31 DBD 12.5 - n/s n/s n/s n/s 5% 70% 
211 islets male 45 31 DCD n/s 13 n/s 5.2 n/s No 95% 70% 
214 pancreas male 49 32 DBD 27.0 - 40 n/s n/s No - - 
215 islets male 28 24 DCD 9.9 25 n/s n/s n/s No 50% 73% 
218 pancreas male 53 23 DCD 8.8 17 n/s n/s 6.4 No - - 
219 pancreas male 39 28 DCD 29.8 29 n/s n/s n/s No - - 
221 pancreas female 57 23 DBD 38.1 - 36 n/s 8.3 No - - 
225 islets male 39 25 DCD 6.9 20 n/s n/s 7.9 No 45% 78% 
226 pancreas female 39 24 DBD 18.0 - 36 8.6 n/s No - - 
229 islets Female 51 16.5 DBD 2.8 - n/s n/s n/s n/s 30% 99% 




















[mmol/L] DH purity viability 
236 islets female 53 37 DBD 11.3 - n/s n/s n/s n/s 43% 97% 
237 pancreas male 69 29 DBD 6.3 - n/s n/s n/s No - - 
239 islets female 66 30 DCD 11.8 n/s n/s n/s n/s n/s n/s n/s 
244 both female 49 27 DCD 13.2 12 31 n/s n/s No 50% 78% 
245 islets female 65 29 DCD 12.3 n/s n/s n/s n/s n/s 30% 82% 
247 islets female 48 33 DBD 7.7 - n/s n/s 9.2 No 60% 77% 
248 islets male 44 30 DBD n/s - 37 22.7 n/s No 95% 71% 
256 islets male 53 26 DBD n/s - 36 9.3 5.8 No 80% 78% 
266 islets female 65 28 DCD n/s 16 46 n/s n/s No 90% 69% 









2.1.3 Mouse islets 
2.1.3.1 Mouse islet isolation 
Rodent islets are established as well studied model for islet isolation and transplantation. 
C57DL/6 mice (between ten and twelve weeks of age) were used for rodent islet isolation 
in these studies. Mice were sacrificed by cervical dislocation and the pancreas and bile 
duct were exposed. Collagenase P solution (Roche, Basel, Switzerland) was injected into 
the ductal system. If the ductal system was difficult to access, the enzyme solution was 
injected directly into the pancreatic tissue and repeated local injections were performed.  
Afterwards the pancreas was dissected out of the abdomen and cut into small pieces. For 
digestion the pancreas was incubated in the enzyme solution for 10 min at 37°C. Following 
that, the tissue was manually swirled for 30 sec to break down as much acinar tissue as 
possible. The enzyme reaction was stopped by adding ME199 media (Corning®, New York, 
USA) containing 0.3% bovine serum albumin (BSA) and the suspension was centrifuged at 
500 g for 2 min at 4°C. The pellet was then resuspended in medium containing BSA and 
transferred through a metal mesh to separate undigested tissue. The filtered solution was 
centrifuged at 500 g for 2 min at 4°C and the resulting pellet was resuspended in 
Histopaque®-1077 and overlaid with medium without BSA. The two-layered suspension 
was centrifuged for 20 min at 2,800 rpm at 4°C in a MSE Sanyo Harrier refrigerated 
centrifuge (MSE Ltd, London, UK). Islets are located in the supernatant and are collected 
in a 100 µm nylon cell strainer followed by transfer into a culture dish with medium 
containing BSA.  
2.1.3.2 Mouse islet culture 
Mouse islets were cultured in RPMI 1640 media containing 2 g/l glucose (Corning, New 
York, USA) supplemented with 10% FBS and 1% 100x penicillin/streptomycin overnight in 
a not adherent culture dish at 37˚C and 5% CO2. The following day mouse islets were 
handpicked for experiments under a dissecting microscope (Leica, Wetzlar, Germany). 
2.1.4 Propidium iodide staining 
Islets or pseudoislets were transferred into a 2 ml Eppendorf tube and allowed to settle 
down for 3 min. Medium was removed carefully from above and human/mouse islets 
were resuspended in 890 µl PBS, 100 µl dithizone and 10 µl propidium iodide (PI) solution 
whereas pseudoislets were resuspended in 990 μl PBS and 10 μl PI solution. The tube was 
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inverted to mix islets with the solution and incubated for 5 min which also allowed the 
islets to settle at the bottom of the Eppendorf tube. As much solution as possible was 
removed and 1 ml PBS was added. Islets were transferred into a 12-well plate and if 
possible 50 islets were assessed by estimation on how much percent of the whole islets 
were viable in 5% intervals. The average value and standard deviation were calculated 
with Microsoft Excel.  
2.1.5 Islet equivalent (IEQ) estimation 
For the estimation of IEQ a sample (50-100 μl) was taken from the islet culture and 
transferred into a 35 mm diameter culture dish. Under the inverted microscope, the 10x 
objective was used to count islets according to the diameter from 50-100 μm, 101-150 μm, 
151-200 μm, 201-250 μm, 251-300 or 301-350 μm. Islet counts were then converted into 
IEQ by multiplication of a factor according to Table 2.2 to normalise them to the standard 
of 1 IEQ which equals 150 µm diameter (Ricordi et al., 1990). With these islet equivalents 
and the dilution factor, the total IEQ count per sample can be calculated.  
 
Table 2.2: Diameter range of islets and conversion factor for IEQ assessment 
Diameter range for a circular islet Multiplier for IE volume conversion 
50-100 μm 0.167 
101-150 μm 0.667 
151-200 μm 1.685 
201-250 μm 3.5 
251-300 µm 6.315 
301-350 μm 10.352 
>400 µm 22.75 
 
2.2 Tissue fixation and processing for paraffin embedding 
Pancreas biopsies were taken by the islet isolation team and fixed in 10% formalin 
overnight, before exchanging the solution to 70% ethanol. Some donors were part of the 
Quality in Organ Donation (QUOD) Expand project, which is a part of a nationwide biobank 
project in the UK to collect samples of pancreas/islets, heart and lungs. QUOD was 
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established by NHS Blood and Transplant (NHSBT) to focus research on improving quality 
for organ donation and transplantation.  
Isolated islet or pseudoislet samples were transferred to a 15 ml tube and allowed to 
settle for 3 min. The culture plate was washed with medium to detach the remaining islets 
from the culture plate. After a centrifugation step at 44 g for 1 min, the medium was 
discarded, and the pellet was resuspended in 4% formalin followed by an incubation 
overnight at 4˚C. The next day the tube was centrifuged for 1 min at 44 g, the formalin 
solution discarded, and the pellet resuspended in PBS. For the embedding islets were 
transferred to a conical shaped plastic container and as much of the PBS as possible was 
removed before they were resuspended in 1% liquid agarose (Helena Biosciences Europe, 
Gateshead, UK) which was allowed to cool to ~37°C which is a suitable temperature for 
cell embedding. The agarose was allowed to harden and after transferred to an 
embedding cassette, there followed another incubation in 10% formalin solution. 
Both tissue samples and embedded islet samples were processed for embedding and 
cutting of sections by the Cellular Pathology service in the Royal Victoria Infirmary 
Newcastle.  
2.3 Tissue fixation and processing for Transmission electron microscopy (TEM) 
The tissue or islet samples were fixed in glutaraldehyde solution for at least 24 h. 
Processing started with rinsing of the samples five times in 0.1 M cacodylate buffer (Agar 
Scientific Ltd, Stansted, UK) for approximately 3 min followed by 1 h incubation in 3% 
potassium ferrocyanide in 2% osmium tetroxide (TAAB, Aldermaston, UK) in buffer at 4°C. 
Subsequently washing steps followed where the samples were first rinsed twice with 
demineralised water (ddH2O) which was added to the samples and removed immediately 
and secondly incubated five times for 3 min in ddH2O. Biopsies were then incubated in 
filtered thiocarbohydroxide for 20 min at room temperature followed by washing steps 
as previously described. After thiocarbohydroxide was washed out the samples were 
treated with 2% osmium tetroxide in ddH2O for 30 min at room temperature. Again, 
washing steps followed and finally biopsies were incubated in 1% uranyl acetate (TAAB, 
Aldermaston, UK) in the refrigerator overnight. The following day the samples were 
washed to remove the uranyl acetate and dehydrated with increasing concentrations of 
acetone. Biopsies were incubated for respectively 30 min in 25%, 50% and 70% acetone 
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in deionised water followed by twice in 100% acetone for 1 h. After dehydration the 
samples were impregnated with resin. TAAB4 epoxy medium resin kit (TAAB, Aldermaston, 
UK) was used and mixed to the specifications of the manufacturer. It was mixed well and 
diluted in acetone. Samples were incubated for 1 h respectively in the 25%, 50% and 75% 
resin followed by 100% resin overnight. The following day biopsies were incubated twice 
for 1 h in 100% resin and another time for at least 3 h before they were embedded in fresh 
100% resin for 24-36 h at 60°C.  
The processed biopsies in the resin blocks were trimmed to a trapezium shape and 1 µm 
or 0.5 µm sections were made with an ultramicrotome (Reichert, Vienna, Austria). These 
sections were stained with toluidine blue (TAAB, Aldermaston, UK) to stain acidic tissue 
components and is used for processed tissue sections to highlight the morphology 
(Sridharan and Shankar, 2012). The distinct morphology helps to characterize the semithin 
section under light microscopy to find a suitable area for ultrathin cuts. Eventually the 
block was trimmed further to reduce the surface area for cutting and as soon as the right 
size and the right area were reached, ultrathin sections of approximately 70 nm were 
made. Ultrathin sections were stretched with chloroform (VWR International, Radnor, 
USA) aerosol and placed carefully on suitable grids (Gilder Grids, Grantham, UK). These 
samples could then be analysed with the TEM.  
2.4 Immunofluorescence staining (IF) 
4 µm sections were cut onto slides and placed in Histo-ClearTM II solution (National 
Diagnostics, Atlanta, USA) for 10 min to remove the paraffin from the sections. For 
rehydration the slides were placed for 3 min in 100% ethanol and 3 min in 90% ethanol 
followed by deionised water. Afterwards the water was replaced with PBS, where the 
slides could be retained until antigen retrieval. 2-Amino-2-(hydroxymethyl)propane-1,3-
diol/Ethylenediaminetetraacetic acid (TRIS/EDTA) pH 9 buffer or citrate pH 6 buffer was 
transferred into a pressure pod with the slides and heated up in the microwave for 20 min. 
Afterwards the solution was cooled down to 40°C, the sections were circled using a 
hydrophobic pen and incubated with blocking solution consisting of 20% FBS in PBS for 
1 h to block non-specific binding. After two washing steps with PBS the primary antibodies 
were pipetted onto the tissue samples and incubated at 4°C overnight. Antibodies were 
diluted in 5% FBS in PBS according to Table 2.4 and, as a negative control, dilution buffer 
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alone without primary antibody was added to the section. The next day, excess antibody 
was washed off with two wash steps in PBS and subsequently all sections were incubated 
with the secondary antibodies for 1 h at room temperature. Antibodies were diluted 
according to Table 2.4 in 5% FBS in PBS solution. Again, the samples were washed twice 
with PBS and sections were incubated with 0.1 µg/ml DAPI solution for 5 min. Finally, 
slides were mounted using mounting medium containing DAPI (Vector Laboratories, 
Burlingame, USA). Nail polish was applied as a seal around the glass plates to prevent 
dehydration of the stained sections. The samples were stored at 4°C in a light-proof box 
to prevent quenching of the fluorescence signal. For image analysis a Leica SP8 STED 
confocal microscope (Leica, Wetzlar, Germany) was used. The control sections with no 
primary antibodies were used to adjust suitable exposure times for the different filters 
and then staining was analysed on the sections containing primary antibodies.  
Table 2.3: Primary antibodies used for staining with company and dilution 
Antibody Host species Company Dilution 
Rabbit polyclonal to CD31 (ab28364) 
(Lot: GR150486-14) Rabbit 
Abcam, 
Cambridge, UK 1:100 
Rabbit polyclonal to Collagen IV 
(ab6586)  
(Lot: GR 248055-3/CR 292187-6) 
Rabbit Abcam, Cambridge, UK 1:500 
Human E-Cadherin Antibody 
(Monoclonal Mouse IgG2B Clone 
#180215) 
(Ref: MAB1838) (Lot: JAT0111031) 
Mouse R&D Systems, Minneapolis, USA 1:1000 
Monoclonal Anti-Glucagon antibody 
produced in mouse [K79bB10] 
(G2654-2ML)  
(Lot: 084M4793) 
Mouse Sigma Aldrich, St. Louis, USA 1:100 
Polyclonal Guinea Pig Anti-Insulin 
(Ref: A0564) (Lot: 10119708) Guinea pig 
Dako, Agilent 
Technologies, 
Santa Clara, USA 
1:200  
Rabbit polyclonal to Laminin 
(ab11575)  
(Lot: GR3180809-1) 
Rabbit Abcam, Cambridge, UK 1:100  
Rabbit monoclonal to pan Cadherin 
[EPR1792Y] (ab51034) (Lot: GR73907-
3) 
Rabbit Abcam, Cambridge, UK 1:100  
Rabbit monoclonal to Vimentin 
[EPR3776] (ab92547)  
(Lot: GR3186827-10) 
Rabbit Abcam, Cambridge, UK 1:100  
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Table 2.4: Secondary antibodies with company and dilution 
Antibody Host species Company Dilution 
Goat anti-Guinea Pig IgG (H+L) Highly 
Cross-Adsorbed Secondary Antibody, 
Alexa Fluor 488 
(Ref: A11073) (Lot: 458631/1637243) 
Goat Thermo Fisher, Waltham, USA 1:500 
Donkey anti-Rabbit IgG (H+L) Highly 
Cross-Adsorbed Secondary Antibody, 
Alexa Fluor 568 
(Ref: A10042) (Lot: 1668655) 
Donkey Thermo Fisher, Waltham, USA 1:500 
Donkey anti-Mouse IgG (H+L) Highly 
Cross-Adsorbed Secondary Antibody, 
Alexa Fluor 568 
(Ref: A10037) (Lot: 1752099) 
Donkey Thermo Fisher, Waltham, USA 1:500 
Donkey anti-Rabbit IgG (H+L) Highly 
Cross-Adsorbed Secondary Antibody, 
Alexa Fluor 647 
(Ref: A31573) (Lot: 1826679) 
Donkey Thermo Fisher, Waltham, USA 1:500 
Donkey anti-Mouse IgG (H+L) Highly 
Cross-Adsorbed Secondary Antibody, 
Alexa Fluor 647 
(Ref: A31571) (Lot: 1069838) 
Donkey Thermo Fisher, Waltham, USA 1:500 
 
2.5 RNA extraction and processing 
2.5.1 RNA extraction 
Samples from human isolated islets or pseudoislets were transferred into a 15 ml falcon 
tube and islets were allowed to settle to the bottom of the tube for 3 min. As much of the 
medium which the islet has been cultured in as possible was used to wash the culture 
plates/dishes to increase islet numbers. Islets were then centrifuged for 1 min at 44 g, the 
culture media was discarded, and the pellet resuspended in 1 ml PBS to wash off residues 
of medium. This washing step was performed an additional time before the pellet was 
resuspended in 250 µl of lysis buffer containing 2.5 µl 2-mercaptoethanol and snap frozen 
in liquid nitrogen. The samples were stored at -80°C until RNA extraction was performed 
with the GenEluteTM total RNA purification kit according to the provided protocol (Sigma-
Aldrich, St. Louis, USA).  
Samples were thawed and the lysate was transferred to a filtration column followed by 
centrifugation for 1 min. All centrifugation steps were run at maximum speed (20,238 g 
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on the centrifuge used). The filtration column was discarded, and 70% ethanol was mixed 
with the flow-through. This was then transferred onto a binding column and centrifuged 
for 30 sec at maximum speed. The flow through was discarded and 250 µl of Wash 
Solution 1 was added. After centrifugation of 30 sec at maximum speed the membrane 
was incubated for 15 min with a mixture of 10 µl DNaseI and 30 µl DNase digestion buffer. 
Subsequently, the DNaseI was washed off with 250 µl of Wash Solution 1 followed by 
centrifugation for 15 sec at maximum speed. The membrane then was washed with 500 µl 
of Wash Solution 2 which was centrifuged for 15 sec over the membrane followed by an 
additional step of 500 µl Wash Solution 2 centrifuged for 2 min at maximum speed. The 
column was then transferred to a new collection tube and the RNA was eluted with 50 µl 
elution solution and centrifugation for 1 min at maximum speed. Extracted RNA was 
stored at -80°C until further experiments were carried out.  
2.5.2 Complementary DNA synthesis 
1 µl of the RNA samples were quantified with a NanoDropTM 2000 (Thermo Fisher, 
Waltham, USA) and all samples were normalised to the lowest measured value. Purity of 
RNA samples with an A260/280 ratio ranged from ~1.2-3.7 and majority of preparations 
had an A260/280 ratio ~2.0. A high capacity complementary DNA (cDNA) reverse 
transcription kit (Applied Biosystems, Foster City, USA) was used to convert the extracted 
RNA into cDNA. A master mix was pipetted consisting of 2 µl 10x RT buffer, 0.8 µl 25x 
dNTP mix, 2 µl 10x RT random primers, 1 µl MultiScribeTM reverse transcriptase and 4.2 µl 
nuclease-free H2O (Roche, Basel, Switzerland) per reaction. 10 µl of normalised RNA and 
10 µl of master mix were combined. For each run, a blank sample without enzyme was 
added to test for contaminations. The cDNA was generated with the TC-512 gradient 
thermal cycler (Techne Inc., Burlington, UK) with the optimised cycling conditions for the 
transcriptase shown in Table 2.5. 
 
Table 2.5: Conditions for the thermal cycler for cDNA synthesis.  
Settings Step 1 Step 2 Step 3 Step 4 
Temperature 25°C 37°C 85°C 4°C 
Time 10 min 120 min 5 min ∞ 
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2.5.3 Quantitative real time PCR 
The cDNA was generated from extracted RNA as described in 2.5.1 and 2.5.2 to allow 
assessment of RNA transcripts using quantitative real time PCR (qRT-PCR). For each DNA 
probe a master mix was created with a volume of 18 µl per reaction consisting of 0.5 µl 
DNA probe (Table 2.6), 0.5 µl TE buffer pH 8.0 (AmbionTM, Thermo Fisher, Waltham, USA), 
10 µl LightCycler® 480 Probes Master (Roche, Basel, Switzerland) and 7 µl H2O. The master 
mix was pipetted into each well of a LightCycler® Multiwell Plate 96 (Starlab, Hamburg, 
Germany) and 2 µl of cDNA sample was added. The plate then was sealed with polyolefin 
film (Starlab, Hamburg, Germany) and spun down for 16 sec.  The qPCR was carried out 
with a LightCycler® 480 (Roche, Basel, Switzerland) starting with a pre-incubation cycle at 
95°C for 10 min followed by 50 cycles with a target of 95°C for 15 sec, 60°C for 1 min and 
40°C for 10 sec. The generated gene expression data were normalised with RPLP0 as 
housekeeping gene and the delta-delta Ct method was used to calculate the fold change 
of the gene expression in different culture conditions compared to static culture on 
normal tissue culture plastic.  
 





Ribosomal protein, large, R0 RPLP0 Mouse Mm00725448_s1 
Insulin 1 Ins 1 Mouse Mm01950294_s1 
Insulin 2 Ins 2 Mouse Mm00731595_gH 
Glucose transporter protein type 1 
(Glut 1) 
Slc2a1 Mouse Mm00441480_m1  
Monocarboxylic acid transporter 4 
(Mct4) 
Slc16a3 Mouse Mm00446102_m1 
Lactate Dehydrogenase A LDHA Mouse Mm01612132_g1 




2.6 Protein extraction and processing 
2.6.1 Protein extraction 
Human isolated islets or pseudoislets were transferred into a 15 ml Falcon tube and 
allowed to settle at the bottom under gravity for 3 min. The medium above was gently 
taken of and used to wash the culture plates/dishes to increase the number of islets. Islets 
were then spun down for 1 min at 44 g and washed with 1 ml of PBS. After an additional 
centrifugation of 1 min at 44 g, PBS was discarded, and islets were resuspended in 200 µl 
protein extraction buffer (Table 2.7) or PBS. The islet suspension was then transferred into 
an Eppendorf tube and sonicated at 14 Hz for 15 s, before the samples were snap frozen 
in liquid nitrogen and stored at -80°C. 
Table 2.7: Composition protein extraction buffer 
100 mM Tris pH 7.4 
100 mM KCl 
1 mM EDTA 
25 mM KF 
0.1% Triton X-100 
0.5 mM sodium orthovanadate 
1% protease inhibitor 
 
2.6.2 Bradford assay 
A standard curve with BSA was generated in a clear 96 well plate for protein 
concentrations of 20-400 µg/ml in a volume of 10 µl. Therefore, an albumin standard with 
2 mg/ml was diluted in protein extraction buffer or PBS with two wells for each 
concentration. Protein samples were centrifuged for 5 min at maximum speed and 10 µl 
of the supernatant was pipetted into each of two wells. 200 µl of 1x Bio-Rad protein assay 
dye reagent concentrate (Bio-Rad, Hercules, USA) was added and the plate was incubated 
for 5 min at room temperature before absorption was measured with a SpectraMax® 190 
plate reader (Molecular Devices, San Jose, USA) at 595 nm. If absorption of undiluted 
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protein samples was higher than the absorption of 400 µg/ml standard, the samples were 
diluted, and absorption was measured after incubation with Bradford solution for 5 min. 
Unknown protein concentrations were calculated from the standard curve.  
2.7 Seahorse flux analysis and normalisation 
2.7.1 Seahorse flux analysis 
The day prior to the experiment the sensor cartridge was hydrated with Seahorse XF 
calibration buffer (Agilent Technologies, Santa Clara, USA) and incubated at 37°C or room 
temperature until the experiment. Human isolated islets or pseudoislets were assessed 
with the IEQ method as previously described (2.1.5) and 200-300 IEQ of islets were 
pipetted per well into an islet capture microplate (Agilent Technologies, Santa Clara, USA) 
in a volume of 25 µl. After an islet capture screen was installed with the help of forceps, 
the well was topped up with 225 µl of culture media. The plate was incubated overnight 
to allow the islets to recover from transfer stress.  
The next day, Seahorse assay media was prepared: 33.2 ml of basic DMEM were mixed 
with 17.5 µl of 1 M glucose, 350 µl of 200 mM solution of L-Glutamate, 1.05 ml of FBS and 
350 µl of 100 mM Pyruvate (Gibco, Thermo Fisher, Waltham, USA). The pH of the media 
was checked and if necessary, adjusted to pH 7.4.  
On the islet capture plate, the islet culture media was washed away from the plate with 
~400 µl of assay medium twice and the wells were finally topped up with 450 µl medium. 
The plate was then incubated at 37°C without CO2 for ~1 h.  
During this time the injection ports of the sensor cartridge (Agilent Technologies, Santa 
Clara, USA) were loaded with the desired solutions. Port A was filled with 50 µl of assay 
medium or 25 µM glucose solution. In port B 55 µl of an oligomycin from Streptomyces 
diastatochro-mogenes solution with a concentration of 50 nM was pipetted. In port C 
60 µl of 3.5 µM of carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP) was 
added and in port D 65 µl of 2.5 µM antimycin A from Streptomyces sp. The cartridge was 
loaded into the XF24 Analyser (Agilent Technologies, Santa Clara, USA) for calibration, 
followed by the cell plate where OCR and extracellular acidification rate (ECAR) were 
analysed over time. The results were normalised to the amount of protein or DNA per well 
and ATP production could be calculated according to Mookerjee (Mookerjee et al., 2017).  
46 
 
2.7.2 DNA extraction 
DNA extraction was performed with the DNeasy® Blood & Tissue Kit (Qiagen, Hilden, 
Germany). Human isolated islets or pseudoislets were washed with PBS and resuspended 
in 180 µl buffer ATL (Qiagen, Hilden, Germany) with 20 µl proteinase K (Qiagen, Hilden, 
Germany). The suspension was mixed by vortexing for ~15 sec and incubated at 56°C for 
15 min. In a next step lysis buffer (buffer AL) (Qiagen, Hilden, Germany) was added, 
samples were mixed by vortexing and incubated for further 10 min at 56°C. Subsequently 
200 µl 100% ethanol was added, samples were mixed and pipetted onto the binding 
column. The column was centrifuged for 1 min at 6010 g and the flow-through was 
discarded. 500 µl of Wash Solution 1 (buffer AW1) (Qiagen, Hilden, Germany) was 
pipetted onto the column and centrifuged for 1 min at 6010 g. Then 500 µl Wash Solution 
2 was added (buffer AW2) (Qiagen, Hilden, Germany) and the column was centrifuged for 
3 min at 18,407 g. In a last step 100 µl of elution buffer (buffer AE) (Qiagen, Hilden, 
Germany) was pipetted onto the membrane, incubated at room temperature for 1 min 
and centrifuged for 1 min at 6,010 g. DNA was stored for short term at 4°C and for long 
term at -20°C. 
2.7.3 PicoGreenTM analysis 
Quantification of DNA was performed with Quant-iTTM PicoGreenTM dsDNA Assay Kit 
(InvitrogenTM, Thermo Fisher, Waltham, USA). With the dilution of a 2 µg/ml DNA stock 
solution in 1x TE buffer DNA concentrations of 1 ng/ml to 1 µg/ml were generated in 
duplicate wells of an opaque 96 well plate with a final volume of 100 µl/well. DNA samples 
were diluted in 1xTE buffer and 100 µl aliquots were pipetted into the plate. For each 
reaction 100 µl of PicoGreenTM working solution was added and incubated for 3 min at 
room temperature protected from light. Fluorescence was measured with an excitation 
of ~480 nm and an emission of ~520 nm. Unknown concentrations of DNA were calculated 




2.8 Tissue engineering 
2.8.1 Electrospun nanofiber membrane 
Mouse islets were seeded on a PCL electrospun nanofiber membrane kindly provided 
from Dr Piergiorgio Gentile (Newcastle University) and cultured for 3-4 days. After that 
culture period islets and the membrane were washed twice with PBS and fixed in 4% 
formalin overnight at 4˚C. The next day formalin was exchanged with PBS with storage at 
4˚C until the staining protocol was started. For staining the islets were incubated with 0.2% 
Triton-X100 for 1 h at room temperature on a shaker at low speed to permeabilise the cell 
membranes, followed by blocking in 20% FBS for 1 h. Primary antibodies (Table 2.3) were 
then incubated overnight at 4˚C on a shaker at low speed. The next day islets were washed 
twice in PBS and incubated with the secondary antibodies (Table 2.4) for 1 h at low shaking 
speed followed by PBS washes. Membrane and islets were then mounted onto a glass 
slide and covered with a coverslip with mounting medium containing DAPI (Vector 
Laboratories, Burlingame, USA). Nail polish was applied as a seal around the glass plates 
to prevent dehydration of the stained sections. Samples were stored at 4°C in a light-proof 
box to prevent quenching of the fluorescence signal. 
2.8.2 Collagen I/alginate/fibrinogen Hydrogel 
2.8.2.1 Hydrogel generation 
A hydrogel consisting of collagen I, alginate and fibrinogen (CAF) was produced according 
to an adjusted protocol after Montalbano et al. (2018). As preparation alginic acid sodium 
salt from brown algae (low viscosity) (Sigma Aldrich, Dorset, UK) was dissolved in PBS to 
reach a concentration of 5% w/v and fibrinogen from bovine plasma type I-S (Sigma 
Aldrich, Dorset, UK) was dissolved in PBS to obtain a concentration of 10% w/v. 6 mg/ml 
collagen solution pepsin soluble in 0.01 M hydrogen chloride (Collagen Solutions, Glasgow, 
United Kingdom) was used in the existing concentration. In a first step fibrinogen solution 
was mixed with alginate solution in a volume to volume ratio of 1:2 (alginate:fibrinogen). 
Then collagen was added with the same volume as fibrinogen leading to a volume to 
volume ratio of 2:1:2 (collagen:alginate:fibrinogen). For the crosslinking of alginate, a 
solution of CaCl2 in a concentration of 2% was prepared by dissolving CaCl2 in H2O. 
Thrombin from bovine plasma was dissolved in DMEM basic media to achieve a 
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concentration of 400 U/ml for the crosslinking of fibrinogen. Both solutions were mixed 
in a 1:1 ratio leading to an end concentration of 1% CaCl2 and 200 U/ml thrombin. 
For the coating of wells of cell culture plates with CAF, 200 µl of precursor solution was 
pipetted into the well and spread as even as possible with the pipette tip. ~100 µl of 
crosslinking solution was added in drops on top and the gel and incubated for 30-60 min 
at room temperature followed by 6-24 h at 37°C. In a following step the crosslinking 
solution was washed off with either PBS or culture medium and islets were incubated for 
72 h in the coated wells before they were analysed. Samples were taken for PI staining, 
embedding and staining as well as Seahorse analysis.  
For the encapsulation of islets into the gel, 100 µl of CAF precursor solution was mixed 
with 500 IEQ of islets and pipetted onto a cell culture plate. The crosslinking solution was 
pipetted on top of the gel and incubated at room temperature for 30 min followed by ~2h 
at 37°C. Subsequently the crosslinking solution was washed off the gel with culture 
medium and the well was topped up with the appropriate amount of culture medium. 
Islets were assessed after 72 h encapsulated in the CAF hydrogel. Samples were taken for 
PI staining, RNA extraction and IF staining.  
2.8.2.2 PI staining 
Media was aspirated and gel was washed with PBS. Gel and islets were incubated in 990 µl 
PBS and 10 µl PI solution for 7 min in the dark. Subsequently the PI solution was removed, 
1 ml PBS was added and if possible 50 islets were assessed for percentage of live cells. The 
average value and standard deviation were calculated with Microsoft Excel.  
2.8.2.3 RNA extraction 
Medium was removed from the well and the hydrogel was washed twice with PBS. Then 
the gels were scraped off the tissue culture well and transferred into a 1.5 ml Eppendorf 
tube. 250 µl of RNA lysis buffer was added and a sterile homogenizer was used to 
completely dissolve the gel. Samples were snap frozen in liquid nitrogen and stored at          
-80°C. Extraction of RNA was performed according to 2.5.1.  
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2.8.2.4 Freeze drying and scanning electron microscopy (SEM) analysis 
Hydrogel samples were freeze dried for 48 h at 0.06 mPa and -50°C with a Christ Alpha1-
2 LD plus freeze dryer (Martin Christ Gefriertrocknungsanlagen GmbH, Osterode am Harz, 
Germany) and analysed with a TM3030 SEM (Hitachi Ltd., Chiyoda, Japan).  
2.8.2.5 Swelling analysis 
Hydrogel samples were freeze dried as described before and incubated for 24 h in water. 
Hydrogels were weight before (Wd) and after (Wh) and swelling was calculated according 
to: 
Swelling (%) = [(Wh - Wd)/Wd] x 100. 
2.8.3 Orbital shaker method 
To reduce hypoxia in islets, dynamic culture through a rotation platform was added to the 
gel system. 6 well plates were coated with CAF as described in 2.8.2. Islets were then 
seeded on top of the hydrogel with 1,000-2,000 IEQ/well and incubated on the orbital 
shaker adjusted to 60 rpm. Islets without presence of CAF and islets with and without CAF 
in static culture were used as comparison. Samples were taken for PI staining and RNA 
analysis.  
2.8.4 Perifusion development 
 
Figure 2.1: Schematic set up for perifusion of hydrogel/β-cell construct. 
A perifusion system was developed to provide oxygenated medium flow through a 
hydrogel/cell construct to decrease hypoxia (Figure 2.1). Perifusion chambers were 
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connected via tubing to a tank containing medium. Two sets of tubing was used for the 
set up: FisherbrandTM Silicon Platinum-cured Tubing with an outer diameter of 4.5 mm 
(product code: 11552563, Fisher Scientific, Loughborough, United Kingdom) and 
Masterflex L/S® Precision Pump Tubing Peroxide-Cured Silicone L/S 16 (product code: WZ-
96400-16, Cole-Parmer®, Eaton Socon, United Kingdom). An off-the-shelf fish tank pump 
provided oxygenation of the medium in the tank. A 302S peristaltic pump (Watson 
Marlow, Falmouth, UK) with a 314 four roller five channel micro pump head (Watson 
Marlow, Falmouth, UK) was used to provide movement of medium through the system. 
Oxygen content of the medium was measured with a Fibox 4 oxygen sensor (PreSens 
Precision Sensing GmbH, Regensburg, Germany). The final system without the oxygen 
sensors is pictured in Figure 2.2. For the development phase sterile PBS (Sigma-Aldrich, 
Dorset, United Kingdom).  
 
Figure 2.2: Perifusion system with chambers, peristaltic pump, fish pump and media tank.  
2.9 Statistical analysis 
Mean values and standard deviations were calculated in Excel. Unpaired Student’s t-tests 
and multiple Student’s t-test were carried out with GraphPad Prism 8 (GraphPad Software 
Inc., California, USA). Spearman’s rho correlation (two-tailed) was performed with SPSS 
Statistics (IBM, New York, USA).  
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3 Chapter 3. Impact of post mortem ischaemia, tissue processing and 
islet isolation on islet microenvironment, integrity, morphology and 
function 
3.1 Introduction 
In pancreas tissue, islet cells are surrounded by a specific microenvironment composed of 
ECM, vasculature and exocrine cells providing a defined niche (Longnecker, 2014).  The 
microenvironment can be altered through disease exposure including pancreatitis and 
cystic fibrosis leading to pancreatic pathologies identifiable with traditional 
histopathology and at an ultrastructural level by TEM analysis (Pickartz et al., 2007). 
Pathological changes can progress over time impacting pancreas morphology (Sheppard 
and Nicholson, 2002). In the case of pancreatitis, histology typically shows development 
of fibrotic tissue especially around ducts accompanied by infiltration of lymphocytes, 
plasma cells and eosinophilic cells (Pickartz et al., 2007). In addition to established 
disease/gross pathology, other factors including donor age and donor BMI have been 
shown to impact on organ morphology. At an ultrastructural level it was observed that 
the amount of lipid droplets in endocrine cells correlated with donor BMI and the amount 
of lipofuscin correlated with age (Cnop et al., 2010, Rosengren et al., 2012).  
During organ retrieval, blood supply to the organ is stopped and the organ is flushed with 
specialised cold-preservation solution for transport (NHSBT, 2018b). During this period 
termed ‘cold ischaemia’, the organ typically has no access to oxygen and increasing 
hypoxic exposure can impact on tissue structure and single cell status (Zhang et al., 2018, 
Nevalainen and Anttinen, 1977). Specialised retrieval and transport protocols have been 
developed in an effort to decrease impact of hypoxia on tissue primarily by cooling the 
organ to approximately 4°C (NHSBT, 2018b). Specialised cold-preservation solutions such 
as University of Wisconsin (UW) solution or histidine-tryptophan-ketoglutarate (HTK) 
solution have been developed to maintain the intracellular milieu during cold storage as 
ion channels stop functioning at low temperatures (Iwanaga et al., 2008). In the UK usually 
UW solution is used for in situ perfusion and organ transport (NHSBT, 2018b). However, 
stress through absence of sufficient oxygen supply can impact on organ function and cell 
status and therefore outcomes of transplantation (Rudolph et al., 2017).  
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Once the organ is connected to the vascular system of the transplant recipient in a whole 
organ transplant, blood flow is re-established to the pancreas and specifically to the islets. 
However, complications after pancreas transplantation can include reperfusion injury or 
graft thrombosis and these can decrease organ function and transplantation outcomes 
(Gruessner and Gruessner, 2016, Humar et al., 2004).  
For isolated islet transplantation, endocrine and exocrine tissue is separated by enzymatic 
and mechanical procedures (Qi et al., 2009a, Qi et al., 2009b). The isolation process 
especially impacts on islet microenvironment with loss of the peri-islet capsule and loss 
of connection to the vasculature system of the organ (Wang et al., 1999, Irving-Rodgers 
et al., 2014, Cross et al., 2017). The loss of BM is not only a loss of the specific 
microenvironment, but also loss of key cell-matrix connections which may lead to anoikis, 
thereby impacting on viability and function of islets (Irving-Rodgers et al., 2014). Loss of 
blood supply means that islets rely on passive diffusion alone from the moment of 
isolation until they revascularize which may take between ten days and one month 
(Menger et al., 1989, Carlsson et al., 2001). This leads to formations of hypoxic gradients 
inside the islets and may lead to core necrosis, particularly in larger islets, which can 
impact on function (Komatsu et al., 2017). Following transplantation, complications 
including IBMIR further impact on viability and function of islets, negatively impacting 
transplantation outcomes (McCall and Shapiro, 2012, Biarnes et al., 2002, Bennet et al., 
2011).  
3.2 Aims 
Achieving optimal and sustained engrafted endocrine cell function is the priority for any 
β-cell replacement therapy. Therefore, it is crucial to understand the impact of acute 
stress on viability and function of endocrine cells to enable future improvements in 
pancreas and islet transplantation procedures and possible interventions for improved 
endocrine function after transplantation.  
Overall aim: To characterise the islet niche in situ and analyse acute changes related to 
ischaemia, tissue processing and islet isolation. 
Objective 1: To characterise islet microenvironment, integrity and morphology in situ in a 
pancreas with minimal ischaemic exposure. 
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Objective 2: To characterise the impact of ischaemia and tissue processing on islet 
microenvironment, integrity and morphology. 
Objective 3: To characterise the impact of islet isolation on islet microenvironment, 
viability, integrity. 
3.3 Results 
3.3.1 Islets in their endogenous niche in situ in human and mouse tissue 
3.3.1.1 Human tissue with short cold ischemia time 
A pancreas from a donor with short CIT off 5 h 3 min allowed analysis of general pancreatic 
features with assessment through histology and at an ultrastructural level. The pancreas 
was obtained from a 43-year-old non-diabetic male DBD donor with a BMI of 26.8 kg/m2 
and no known pancreatic disease before death pathology.  
3.3.1.1.1 Histological assessment with Haematoxylin & Eosin, Sirius red/Fast green and 
immunoperoxidase staining 
A pancreas biopsy stained for Haematoxylin & Eosin (H&E) analysed in lower 
magnification illustrated general features of the organ (Figure 3.1). The majority of the 
section was comprised of acinar tissue appearing darker compared to islets. Islets of 
Langerhans appeared more eosinophilic usually with a round or oval shape and are 
distributed throughout the whole section with some examples indicated by a white arrow. 
Other visible features include ducts (D) and blood vessels (BV). Additionally, pancreatic fat 




Figure 3.1: Analysis of human pancreatic tissue in a donor with short CIT through H&E staining at low magnification. 
Pancreas section from a male donor, DBD, 43 years, CIT 5 h 3 min. Islets appeared more eosinophilic (examples 
indicated with arrows) and were distributed through the whole section. Some ducts (D) and a blood vessel (BV) could 
be identified in addition to pancreatic fat (examples indicated with dashed arrows). Scale bar 100 µm. 
 
Figure 3.2A shows a pancreas section after H&E staining with two islets indicated by white 
dotted lines, appearing more eosinophilic containing larger nuclei compared to acinar 
tissue. Throughout the acinar tissue, some areas stained pinker indicating higher content 
of acinar vesicles whereas other areas appeared bluer indicating higher content of RNA 
and the presence of nuclei (Longnecker, 2014). The general morphology showed how 
acinar cells are grouped together as acini. In panel B the same area was assessed after a 
Sirius red/Fast green (SR/FG) stain with SR binding to all types of collagens, FG binding to 
all non-collagen proteins and a counter stain with haematoxylin staining nuclei blue. Again, 
islets appeared brighter compared to acinar tissue and were surrounded by a BM 
consisting of collagen. Collagen was also present inside islets and throughout the acinar 
tissue. Figure 3.2C shows, in a similar area, staining of the endocrine granule marker, 
chromogranin A, in red indicating the location of islets. Blood vessels were identified 
through staining of CD31 with DAB (brown) and were dispersed throughout the pancreas 





Figure 3.2: Analysis of human pancreatic tissue in a donor with short CIT through different histological stains at higher 
magnification.  
H&E showed a brighter eosin stain in islets, which are indicated by a white dotted line, compared to acinar tissue 
appearing darker (A). Sirius red and Fast green staining (B) stained collagen in red surrounding the islets and vasculature 
inside islets as well as BM throughout acinar tissue. Staining for CD31 in brown and chromogranin A in red (C) indicated 




3.3.1.1.2 Human pancreas assessment through immunofluorescence staining 
 
Figure 3.3: Pancreas tissue stained for pan-cadherin and E-cadherin.  
(A1-A4) Staining for pan-cadherin in red, insulin in green and DAPI in blue. (B1-B4)) No primary antibody control for pan-
cadherin staining. (C1-C4) Staining for E-cadherin in red, insulin in green and DAPI in blue. (D1-D4) No primary antibody 
control for E-cadherin staining. Scale bars 25 µm.  
 
Staining for CD31 in red (Figure 3.4 A1-A4) indicated the distribution of blood vessels in 
pancreatic tissue and specifically within islets (using insulin co-staining). Blood vessels 
could be observed in acinar tissue with potentially higher density in the proximity of and 
inside the islet. Staining for vimentin (Figure 3.4 C1-C4) indicated the distribution of cells 
of mesenchymal origin including endothelial cells which confirmed the presence of blood 




Figure 3.4: Pancreas tissue stained for CD31 and vimentin.  
(A1-A4) Staining for CD31 in red, insulin in green and DAPI in blue. (B1-B4)) No primary antibody control for CD31 staining. 
(C1-C4) Staining for vimentin in red, insulin in green and DAPI in blue. (D1-D4) No primary antibody control for vimentin 




Figure 3.5: Distribution of BM in pancreas tissue with low CIT.  
Analysis of human pancreatic tissue through immunofluorescence staining of collagen IV at low magnification. Sections are shown from two different locations (row A and row B). Staining for 
collagen IV in red indicating BM around islets, vasculature and acini (column 2), insulin in green indicating the position of islets (column 3), glucagon in pink indicating the position of islets 
(column 4) and DAPI in blue showing nuclei (column 5). Column 1 shows a merge of all staining for each location indicating the presence of glucagon and insulin in different islets as well as 





Figure 3.6: Analysis of human pancreatic tissue with low CIT through immunofluorescence staining of laminin and 
collagen IV at higher magnification.  
(A1-A4) Staining for laminin in red, insulin in green and DAPI in blue. (B1-B4) No primary control for laminin staining. 
(C1-C5) Staining for collagen IV in red, insulin in green, glucagon in pink and DAPI in blue. Higher magnification of 
collagen IV distribution in D1-D5 and E1-E5 indicated with the boxes in C1. (F1-F5) No primary control for collagen IV 





Distribution of BM in pancreas tissue was investigated with staining for collagen IV at low 
magnification (Figure 3.5). BM was present in acinar tissue around acini, ducts and blood 
vessels as well as around islets and inside of islets in a vascular distribution (Figure 3.5 A2 
+ B2). At higher magnification, staining for laminin (Figure 3.6 A2) and collagen IV (Figure 
3.6 C2) demonstrated the double layered BM in the peri-islet capsule and the presence of 
BM around the vasculature inside islets. Figure 3.6 D2 and E2 showed the collagen 
network building the scaffold of the BM. Glucagon staining in Figure 3.6 D4 and E4 shows 
the distribution of α-cells adjacent to the BM of the vasculature or the peri-islet capsule.  
3.3.1.2 Human pancreatic tissue with low CIT assessed at ultrastructural level  
To analyse pancreas tissue with CIT as low as possible, a mouse pancreas was removed 
from a recently deceased animal and biopsies were immediately taken for TEM fixation 
and processing. This work was done in compliance with UK law under Schedule 1 protocols. 
Analysis revealed characteristic morphology of exocrine and endocrine parts. Acinar cells 
could be identified by acinar vesicles (AV) and the presence of a high amount of 
endoplasmic reticulum (ER) (Figure 3.7 A) whereas islet cells could be identified through 
the presence of numerous endocrine vesicles (Figure 3.7 A-D). Endocrine vesicles of 
different islet cells possessed distinct characteristics on TEM. Vesicles from δ-cells were 
filled with uniform brighter electron density and in mouse islets could be found at the 
core of the islet in line with prior descriptions from the literature (Figure 3.7 C) (Stendahl 
et al., 2009). The α-cell and β-cell vesicles contained a core with higher electron density 
surrounded by a halo in mature vesicles and with decreasing halo in immature vesicles 
(Figure 3.7 C+D). Furthermore, pre-existing pathology in form of lipofuscin (LF) and lipid 





Figure 3.7: Ultrastructural analysis of mouse pancreas tissue with TEM.  
(A) Interface between exocrine and endocrine tissue (marked by white line). Islets possessed characteristic endocrine 
vesicles (EV) with electron dense core surrounded by light halo whereas acinar vesicles (AV) appear fully filled. (B) 
Endocrine cells inside an islet with one nucleus (N) visible. (C) Two different islets cells could be differentiated by their 
distinct vesicles. (D) Characteristic hormone vesicles (arrows) with electron dense core mantled by light area inside the 








The ultrastructural level examination of short CIT human pancreas tissue displayed the 
same features as mouse pancreas tissue. Acinar cells were grouped together as acini 
(Figure 3.8 A) or around an acinar lumen (Figure 3.8 C+D) and comprised characteristic 
acinar vesicles (AV) as well as a high amount of visible ER (Figure 3.8 A,B,D). Islets could 
be identified through the presence of endocrine vesicles (EV) showing different 
appearance for different islet cell types filling most of the cell (Figure 3.9 A-C). In β-cells, 
vesicles possessed a halo surrounding an electron dense core, sometimes even square-
shaped (Figure 3.9 A-C). Some vesicles possessed a smaller to no halo together with a less 
dense core depending on the maturation status of insulin. Endocrine vesicles of α-cells 
appeared similar to β-cells, which made it difficult to distinguish between them without 
immunogold labelling. Cells solely with filled vesicles possessing light electron density 
were believed to represent δ-cells (Figure 3.9 C). Additionally, ultrastructure analysis 
confirmed presence of BM around islets, indicated by a less electron dense area next to 
the cell membrane followed by an electron dense line revealing the interface of endocrine 
and exocrine tissue (Figure 3.9 D). In some cases, this interface was filled with additional 
ECM components including collagen fibres (Figure 3.9 D+E). Pre-existing pathology in form 
of lipofuscin and lipid droplets could be observed in human tissue as well as mouse tissue 




Figure 3.8: Ultrastructural analysis of human acinar tissue with short CIT.  
(A) Acinar cells characterised by acinar vesicles (AV) with visible nucleus (N), endoplasmic reticulum (ER), mitochondria 
(M) and lipid droplets (LD). (B) Acinar cells grouped together to form acini. (C) Acinar cells forming acinar lumen (AL) 
with white box indicating image part D. (D) Higher magnification of AL with microvilli and adjacent acinar cells. Scale 




Figure 3.9: Ultrastructural analysis of human endocrine tissue with low CIT.  
(A) Group of endocrine cells inside an islet with high amount of characteristic endocrine vesicles (EV) which were 
designated β-cells. No other cell organelles visible except mitochondria (M). Lipofuscin (black arrow) visible in endocrine 
cell. (B) EV (dashed arrows) which were believed to be from β-cells with characteristic halo around an electron dense 
core. (C) Different islets cells could be characterised through their distinct vesicles. The β-cells possessed vesicles with a 
bright mantle around an electron dense core whereas vesicles in δ-cells were completely filled with a medium electron 
density. Intracellular lipid droplet (LD) visible in endocrine cell. (D) Outside of an islet with characteristic basement 
membrane (BM) consisting of a lighter electron density right next to the cell membrane followed by a darker electron 
dense line (arrow). Outside of the islets, ECM components including collagen fibres were visible. (E) ECM components of 
pancreas tissue. Collagen fibres (arrows) displayed as dark electron dense lines (longitudinal section) or circles (cross 
section) depending on the angle of fixation and micro-sectioning. Scale bars: 500 nm.  
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3.3.2 Impact of post mortem ischemia and tissue processing on the islet 
microenvironment, integrity and morphology 
With the retrieval of an organ, the blood supply stops and there is a rapid onset of 
hypoxia/anoxia in cells. Prolonged exposure to these conditions leads to a number of 
changes in cell organelles ultimately substantial damage to whole cell morphology. To 
investigate impact of post mortem ischemia on cell integrity and morphology, four DBD 
(Table 3.1) and eight DCD donors (Table 3.2) were assessed with histological samples 
including H&E and SR/FG and with TEM at an ultrastructural level. CIT of studied donors 
ranged from 6 h 20 min till 38 h 8 min in DBD donors (Table 3.1) and 6 h 26 min till 29 h 
48 min in DCD donors (Table 3.2). 
 
Table 3.1: Information for pancreas DBD donors with ascending CIT. 
With two donors (50%) female, age of (average (±SD)) 53.5 (±12.7) [years] and BMI of 26.9 (±4.1) [kg/m2]. LDIS number 






Type CIT [h] 
WIT 
[min] Gender




1 237 DBD 6.3 - male 69 29.1 
2 226 DBD 18.0 - female 39 24.0 
3 214 DBD 27.0 - male 49 31.5 











Table 3.2: Information for pancreas DCD donors with ascending CIT.  
With four donors (50%) female, age of (average (±SD)) 49.5 (±17.7) [years] and BMI of 24.2 (±3.2) [kg/m2]. LDIS number 






Type CIT [h] 
WIT  
[min] Gender




1 231 DCD 6.4 34 female 65 17.7 
2 172 DCD 8.0 18 male 25 22.8 
3 218 DCD 8.8 17 male 53 22.9 
4 232 DCD 8.9 33 female 73 24.8 
5 215 DCD 9.9 25 male 28 24.0 
6 244 DCD 13.2 12 female 49 26.6 
7 169 DCD 16.5 32 female 64 26.4 
8 219 DCD 29.8 29 male 39 28.3 
 
3.3.2.1 Histological assessment of human pancreata with H&E and SR/FG  
H&E and SR/FG staining revealed different pathological characteristics of pre-existing 
pathology as well as acute changes to tissue morphology with examples shown in Figure 
3.10. Pathology in the pancreas which developed over a period over several weeks till 
years included fibrosis (Figure 3.10 A), microadenoma (Figure 3.10 B), PanIN-1 (Figure 3.10 
C), hyperplasia of islets (Figure 3.10 D) and pancreatitis (Figure 3.10 E). Acute changes 
included inflammation (Figure 3.10 E), oedema (Figure 3.10 D+F), fat necrosis (Figure 3.10 
G), tissue necrosis (Figure 3.10 H) and haemorrhage (Figure 3.10 E,G,H). Acute changes 
may develop during prolonged ischaemia and manifest as changes to cell morphology and 
cell organelles including the nucleus. For a more detailed analysis of ischaemia impact on 




Figure 3.10: Example images for histological analysis of pancreas tissue.  
A:  SR/FG staining indicating distribution of fibrosis in the tissue in red (some areas indicated with black arrows). B: Islet 
(white dotted line) with a diameter of ~1 mm indicating microadenoma. C: Pancreatic intraepithelial neoplasia 1 (PanIN 
1). D: Islet (white dotted line) with a diameter above 250 µm (hyperplasia) with oedema visible inside the islet. E: 
Pancreas tissue with infiltration of mast cells (example indicated with red arrow) and neutrophils (example indicated 
with black arrow) as well as visible red blood cells (indicated with white arrow) showing possible haemorrhage. F: 
Atrophic area of acinar tissue with space in between tissue (black arrows) and little amount of cytoplasm. G: Area of fat 
necrosis indicated with black dotted line as well as possible haemorrhage (black arrow). H: Necrotic area indicated with 
black dotted line with dissolving cells visible. In addition red blood cells (black arrow) indicate possible haemorrhage. 







3.3.2.2 Ultrastructural assessment of human pancreata with TEM 
The TEM enabled assessment of tissue at an ultrastructural level. By investigating 
different donors, recurring features of acute damage through hypoxia could be identified 
(Figure 3.11). Normal nuclei appeared with a dark nuclear membrane and dark chromatin 
inside distributed evenly throughout the nucleus as well as in contact with the nuclear 
membrane (Figure 3.11 A1). Larger chromatin clumps in a fairly round shape located 
inside the nucleus could be identified as a nucleoli. Through prolonged hypoxic exposure, 
chromatin inside the nucleus could clump together and, in some cases, detach from the 
nuclear membrane (Figure 3.11 A2). Normal mitochondria appeared as darker cell 
organelles with oblong shape (Figure 3.11 B1) and in higher magnification single cristae 
inside the mitochondria as well as the doubled layered membrane were visible. Acute 
damage could be identified by a swelling of the mitochondria leading to a brighter 
electron density inside as well as a rounder shape (Figure 3.11 B2). In some cases, the 
cristae could be damaged and/or the shape of the mitochondria was destroyed. 
Furthermore, ER could start to dilate through hypoxic stress impacting on cell morphology 
and integrity leading to difficulties identifying individual cells and even between 
organelles compared to cells with normal appearing ER (Figure 3.11 C1+C2). Another sign 
of damage included development of vacuoles inside of the cell impacting on the overall 
cell morphology and integrity as well as increasing difficulty to identify single cells or cell 






Figure 3.11: Ultrastructural acute damage through hypoxia in exocrine tissue.  
Normal (A1) and changed nuclei (A2), normal (B1) and changed mitochondria (B2) (white arrows), normal ER (C1) (yellow 
arrow) and dilated ER (C2) (dashed yellow arrows) as well as normal cell morphology (D1) and changed morphology 




3.3.2.3 Development of the Newcastle Electron Microscopy Ischaemia Score (NEMIS) for 
analysis of ultrastructural stress induced changes during pancreas preservation 
With these recurrent characteristics the Newcastle Electron Microscopy Ischaemia Score 
(NEMIS) was developed in collaboration with Nicola Dyson from the Transplant 
Regenerative Medicine Laboratory at Newcastle University and helpful feedback from the 
QUOD expand TEM project group. The scoring system was created to investigate if the 
observed damage correlated with increasing CIT in donor pancreata. However, one TEM 
section just represents <1 mm2 of the whole organ and therefore is solely giving an 
indication of the organ status.  
The protocol for imaging was therefore optimized to assess sections from two different 
areas of the pancreas. It was decided to assess 25 cells per section from five different 
areas (Figure 3.12). The first cells in each area were marked with low magnification to 
avoid bias and the four additional cells should all be in contact with each other. Excluded 
were cells which did not possess typical features of acinar cells including ductal cells or 
endothelial cells. Magnification for imaging should exceed 4,000x and if possible, images 
for mitochondria assessment should be taken with a magnification of 6,000x or higher.  
 
 
Figure 3.12: TEM section is divided into five areas to choose five cells in each area with low magnification to reduce bias.  
 
A ‘degradation’ score was developed combining the assessment of nuclei, mitochondria, 
ER and vacuolisation from scores 0 for normal appearance and increasing degradation 
with score 1 to 3 (Table 3.3 and Table 3.4) (Wahba et al., 2016). In more detail a nucleus 
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with normal appearance was scored as 0. Condensation of chromatin from a mild through 
to moderate state was scored as 1 and from a moderate to severe state was scored as 2. 
Severe condensation of chromatin as well as detachment of chromatin from the nuclear 
membrane was scored as 3. Normal appearing sausage shaped condense packed 
mitochondria were scored as 0 and if they had a less condense and more open appearance 
they were scored as 1. If they appeared swollen with a rounder shape and lighter electron 
dense areas in the core the score 2 was given. A score of 3 was chosen if mitochondria 
were swollen and cristae were disrupted or not visible anymore or if mitochondria were 
difficult to identify due to loss of characteristic shape and morphology. If ER in the whole 
cell appeared as electron dense lines representing normality a score of 0 was given. ER 
with mild dilation was scored as 1, with moderate dilation as 2 and with severe dilation as 
3. For the category of vacuolisation, the morphology of the whole cell was assessed. If no 
vacuoles were observed a score of 0 was given. If vacuoles took up to 25% of the whole 
cell it was categorised as mild vacuolisation and scored as 1. Moderate vacuolisation was 
scored as 2 and indicated vacuoles in 25% till 50% of the cell. If vacuoles were taking up 
over 50% of the cell it was categorised as severe vacuolisation and a score of 3 was given.  
 
Table 3.3: Newcastle Electron Microscopy Ischaemia Score (NEMIS) for assessment of pancreatic acinar cells 
Degradation 
score Nucleus Mitochondria ER Vacuolisation 
















































3.3.2.4 Assessment of developmental cohort with NEMIS 
Pre-existing images of the developmental cohort including five DBD and eight DCD donors 
were assessed with the degradation score. Analysis included tissue from male DBD donor 
with very short CIT labelled as DBD-0. Table 3.5 displays DBD donors with increasing CIT, 
followed by DCD donors with increasing CIT. It is important to note that initial sampling 
was done prior to establishment of QUOD protocols and before imaging was optimized. 
3-24 cells were scored for each donor according to availability of images and displayed 
are the averages of all cells scored for the according category.  
 
Table 3.5: Degradation scores for developmental cohort. 
With LDIS identification number, CIT [h], number of cells scored, average nucleus score, average mitochondria score, 


















DBD-0 173 5.1 12 0.83 1.33 0.33 0.92 3.41 
DBD-1 237 6.3 6 0.00 1.61 2.50 2.67 6.51 
DBD-2 226 18.0 5 0.80 2.37 3.00 3.00 9.17 
DBD-3 214 27.0 11 1.00 2.34 0.55 1.36 5.25 
DBD-4 221 38.1 3 0.33 2.00 2.67 3.00 8.00 
DCD-1 231 6.4 6 0.50 1.43 0.50 1.00 3.43 
DCD-2 172 8.0 24 1.04 1.93 0.57 1.83 5.30 
DCD-3 218 8.8 19 0.26 1.77 2.53 2.26 6.82 
DCD-4 232 8.9 5 0.00 2.10 0.60 0.60 3.30 
DCD-5 215 9.9 18 0.22 1.74 0.67 1.61 4.24 
DCD-6 244 13.2 5 0.00 1.54 1.20 1.00 3.74 
DCD-7 169 16.5 11 1.08 0.88 0.10 0.90 2.59 






The quantified scores were correlated with the available donor data. Results for Spearman 
correlation of NEMIS with CIT are shown in Table 3.6. The scores for nuclei had the lowest 
correlation with the CIT of all donors as well as separated analysis for DBD and DCD. NEMIS 
for mitochondria significantly correlated with CIT of all donors, but did not show 
significance in separate analysis of DBD and DCD. NEMIS for ER, vacuolisation and the total 
score did not show a significant correlation and lower correlation coefficients after the 
analysis with CIT from DCD. The correlation graphs in Figure 3.13 show distribution of the 
single scores, indicating that some outliers may impact on the correlation.  
 
Table 3.6: Two-tailed Spearman Correlation and significance of CIT and NEMIS scores for all donors as well as DBD and 
DCD separate. 













Coefficient 0.136 0.577* 0.357 0.226 0.324 
 Sig. (2-tailed) 0.659 0.039 0.231 0.458 0.280 
CITDBD 
Correlation 
Coefficient 0.000 0.600 0.500 0.616 0.500 
 Sig. (2-tailed) 1.000 0.285 0.391 0.269 0.391 
CITDCD 
Correlation 
Coefficient -0.012 0.095 0.238 -0.275 -0.071 







Figure 3.13: Correlation plots between CIT and NEMIS scores. 
For nuclei (A), mitochondria (B), ER (C), vacuolisation (D) and total scores (E). Values for pancreata from DBD donors 
displayed with circles and from DCD donors with squares.  
 
 







































































No significant difference could be observed of the assessed NEMIS between the five DBD 
or eight DCD donors, although the average values for DCD organs seemed to be lower 
indicating less ischaemic damage (Figure 3.14) whereby the average CIT for DBD organs 
was 18.9 (±14.0) h and for DCD organs was 12.7 (±7.6) h.  
 
 
Figure 3.14: NEMIS analysis for five DBD and eight DCD donors.  
Average for donors displayed with standard deviation (SD).  
 
Average scores for acinar and endocrine cells from six different donors showed 
differences in degradation (Figure 3.15). NEMIS for nuclei, mitochondria and ER were 
potentially higher in endocrine cells but with no significant difference. On the other hand, 
scores for vacuolisation were significantly lower in endocrine cells compared to acinar 


















































Figure 3.15: NEMIS analysis for acinar and endocrine cells from six different donors. 
Average displayed with SD. Multiple Student’s t-test revealed significant difference of acinar and endocrine score for 
vacuolisation (p<0.001). 
3.3.3 Impact of islet isolation on islet microenvironment, integrity and morphology 
During the isolation process, islets can be separated from exocrine tissue through 
enzymatically and mechanic breaking of pancreas tissue impacting on islet viability, 
morphology and function. A variety of isolated islets from DBD and DCD donors were 
analysed with histology, immunofluorescence or TEM (Table 3.7 + Table 3.8). 












[kg/m2] Purity  Viability  
1 229 DBD 2.8 - female 51 16.5 30% 99% 
2 237 DBD 6.3 - male 69 29.1 79% 80% 
3 247 DBD 7.7 - female 48 32.5 60% 77% 
4 236 DBD 11.3 - female 53 37.0 42.5% 96.5% 
















[kg/m2] Purity Viability 
1 225 DCD 6.9 20 male 39 24.8 45% 78% 
2 194 DCD 7.0 105 male 59 26.8 90% 91% 
3 215 DCD 9.9 25 male 28 24.0 50% 73% 
4 245 DCD 12.3 n/s female 65 28.8 30% 82% 
5 244 DCD 13.2 12 female 49 26.6 50% 78% 
 
3.3.3.1 Histological assessment of isolated islets 
 
Figure 3.16: Histological assessment of isolated islets with H&E and SR/FG staining.  






H&E staining of isolated islets (Figure 3.16 left column) highlighted the successful removal 
of exocrine tissue as well as impact of isolation on the integrity of islets. Some islets 
possessed a regular circular shape (DCD1 and DCD4) whereas others displayed a higher 
fragmentation with uneven shape (DBD-3). SRFG staining (Figure 3.16 right column) 
confirmed successful purification of endocrine tissue but also revealed absence of peri-
vascular capsule in all islets assessed (DBD-3, DCD-1, DCD-4). In some islets a faint red 
collagen signal inside of islets was visible (DBD-3).  
3.3.3.2 Immunofluorescence assessment of isolated human islets 
IF staining showed localization of specific proteins in human isolated islets. Figure 3.17 
showed an example for islets from donor DBD-3. After isolation islets still stained positive 
for insulin and glucagon (Figure 3.17 A2+A3), with a higher positivity of glucagon 
compared to islets assessed in tissue with short CIT (Figure 3.6 C4, D4, E4). Collagen IV 
and laminin staining confirmed loss of peri-islet capsule and showed presence of BM 
around vasculature inside islets (Figure 3.17 B2, C2, E2). Cell-to-cell contacts were present 
between all insulin positive cells (Figure 3.17 D2). No primary antibody controls confirmed 




Figure 3.17: Immunofluorescence assessment of DBD-3. 
For insulin (column 3), DAPI (column 4), glucagon (A2), collagen IV (B2), laminin (C2), E-cadherin (D2) and vimentin (E2). 





Figure 3.18: No primary antibody control for IF staining of DBD-3.  





3.3.3.3 Ultrastructural assessment of isolated human islets 
At an ultrastructural level, individual isolated islets from two different donors were 
assessed (Figure 3.19). Loss of integrity and increase in fragmentation were observed in 
whole islets (Figure 3.19 A+F) as well as apoptotic/necrotic cells in between normal 
looking islet cells (Figure 3.19 C). Images with the TEM confirmed loss of basement 
membrane shown with the lack of an electron light area followed by an electron dense 
line outside the cell membrane Figure 3.19 B,D,E,G,H). Additionally, damage to the islet 
cell membrane of endocrine cells at the exterior of the islet was characterised as 
discontinuity of the cell membrane (white arrows) (Figure 3.19 B+H). Furthermore, some 
islet cells possessed areas without vesicles indicated with black arrows (Figure 3.19 B,E,G). 
Nevertheless, nearly all observed islet cells still contained vesicles in the majority of the 





Figure 3.19: Ultrastructural assessment of human isolated islets.  
(A) Whole isolated islet. (B) Islet cell identified through endocrine vesicles (EV) with discontinuous membrane (white 
arrow) and area without vesicles in proximity (black arrow). (C) Islet cells next to each other with necrotic cell in the 
middle (dashed line). (D) Islet cell containing mitochondria (M) and high number of endocrine vesicles (EV). (E) Islet cell 
containing lipid droplets (LD) and endocrine vesicles (EV) but area visible with no vesicles (black arrow). (F) Whole 
isolated islet. (G) Islet cell containing lipofuscin (LF) and endocrine vesicles (EV) but area without EV visible (black arrow). 






To investigate the impact of islet isolation at a cellular level, the NEMIS for assessment of 
acute changes in acinar tissue (see 3.3.2.3) was extended to include changes to presence 
of islet vesicles and damage to islet cell membrane (Table 3.9 + Table 3.10). Regarding 
endocrine vesicles, a score of 0 was given if vesicles were present throughout the whole 
of the cell cytoplasm. Areas without vesicles next to the islet cell membrane with at least 
a diameter of a typical endocrine vesicle were assumed as loss of vesicles. This loss next 
to 25% of the whole length of the islet cell membrane was scored with 1, loss of vesicles 
at 25%-50% of the whole length was scored with 2 and loss of vesicles at >50% of the 
whole length was scored with 3. An intact islet cell membrane was scored 0. Presence of 
<25% discontinuous cell membrane was scored with 1, 25%-50% was scored with 2 
and >50% was scored with 3.  
 
Table 3.9: Electron Microscopy Endocrine Damage Score for assessment of acute damage in endocrine cells.  
Assessment includes nuclei, mitochondria, ER, vacuolisation, vesicles and cell membrane. Scores value from 0 indicating 
normal appearance over 1 and 2 till 3 considering increasing damage.  
Score Nucleus Mitochondria ER Vacuolisation Vesicles Cell membrane 















(0-25% of cell) 
Mild vesicle loss 
















(25-50% of cell) 
Moderate 
vesicle loss 



















(>50% of cell) 
Severe vesicle 








Table 3.10: Additional categories to extend NEMIS to Electron Microscopy Endocrine Damage Score for assessment of 
isolated islets.  
White dotted line indicates area next to islet cell membrane without vesicles. Black dotted line indicates length of 




The developed additional scores were applied in combination with the NEMIS to existing 
TEM images of endocrine cells in six tissue samples and two batches of isolated islets 
(Table 3.11). Islets were fixed in the first 24 h after the isolation process and all available 
cells containing endocrine vesicles and displaying viable morphology including intact 
nuclear membrane were assessed. Although only two isolated islet preparations were 
studied, scores for nuclei, mitochondria, ER and vacuolisation appeared higher in 
endocrine cells in pancreatic tissue compared to endocrine cells in isolated islets. 
Especially the degradation in mitochondria seemed to be higher in endocrine cells in situ 
compared to isolated islets. Loss of endocrine vesicles as well as damage to islet cell 
membrane appeared to be higher in isolated islets.  
 

















173 tissue 5.05 0.47 2.02 0.52 0.05 0.80 0.00 
172 tissue 8 2.50 2.22 1.00 0.00 0.86 0.00 
218 tissue 8.78 0.17 2.33 1.71 0.13 2.30 0.10 
232 tissue 8.93 1.75 2.85 2.70 0.00 1.45 0.00 
215 tissue 9.87 1.00 2.00 0.86 0.00 1.35 0.00 
219 tissue 29.8 0.33 2.42 1.73 0.55 2.11 0.08 
215 isolated 9.87 0.20 1.05 0.68 0.08 2.48 1.00 
244 isolated 13.17 0.22 1.16 1.00 0.40 2.90 1.00 
 
Analysis of endocrine damage scores of endocrine cells in pancreas tissue with CIT 
revealed no significant Spearman’s rho correlation in any case (Table 3.12). However, 
together with analysis of scatter plots (Figure 3.20, circles) a trend for a positive 
correlation of CIT with ER-, vesicle- and total score could be observed. No trend could have 
been observed for the nucleus score, whereas mitochondria scores seemed high and 
impact of CIT on cell membrane seemed low in all assessed pancreata. Vacuolisation of 
endocrine cells was challenging to assess due to the high amount of endocrine vesicles, 
which may explain some of the low numbers. Two preparations of isolated islets allowed 
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analysis of the ultrastructural level with the endocrine damage score (Figure 3.20, 
triangles). Impact of CIT on nuclei as well as mitochondria seemed lower compared to 
tissue scoring (although numbers are clearly too low for definitive conclusions), whereas 
no trend was observed for scoring of ER and vacuolisation. Impact on loss of endocrine 
vesicles as well as cell membranes was higher, which may be the results of the isolation 
process.   
 












CIT Correlation Coefficient -0.200 0.314 0.543 0.213 0.600 0.304 0.543 





Figure 3.20: Correlation between CIT and endocrine damage scores. 
For nuclei (A), mitochondria (B), ER (C), vacuolisation (D), vesicles (E), cell membrane (F) and total score (G). Degradation 





This chapter set out to answer how the microenvironment of islets changes through acute 
stress or the isolation process and how this impact can be quantified. It was hypothesised 
that these changes influence islet health and that a better quantification method will 
enable a better understanding of the organ status of the whole pancreas or isolated islets.  
3.4.1 Microenvironment in normal pancreas 
In a first step the analysis of islets and their specific microenvironment was undertaken to 
receive a status of normality through analysis of human tissue with short CIT of 5h.  
Microenvironment was analysed with histology, immunofluorescence and at an 
ultrastructural level and presence of cell-to-cell connections, vasculature, collagen IV and 
laminin could be observed (Figure 3.2-Figure 3.6). This confirmed previous findings about 
islet architecture, microenvironment and vascularisation (Bosco et al., 2010, Cabrera et 
al., 2006, Cross et al., 2017). Staining for CGA, insulin and glucagon revealed islet size and 
distribution (Figure 3.2+Figure 3.6). Interestingly in the male DBD donor with short CIT, α-
cells were predominantly present next to BM (Figure 3.6), mantling β-cells inside and 
increasing α-β-cell contact which may impact on islet physiology (Bosco et al., 2010). 
Contact to α-cells and proximity of glucagon signalling can improve insulin secretion 
significantly (Wojtusciszyn et al., 2008). 
In addition to cell-to-cell contacts, cell-to-matrix contacts seem to be important for 
endocrine function with loss of matrix contact leading to anoikis (Irving-Rodgers et al., 
2014). Staining for pan-cadherin and E-cadherin revealed presence of cell-to-cell 
connections throughout the islet microenvironment (Figure 3.3). Previous studies showed 
that the contact to ECM components impacts on β-cell function via integrin activation in 
mouse islets (Nikolova et al., 2006, Gan et al., 2018). With the observed cytoarchitecture 
it can be hypothesised that contact to ECM components and integrin signalling are 
important for normal α-cell function. In total the specific niche with proximity of α-cells 
as well as ECM components seems to be important for β-cell function (Bosco et al., 2010, 
Cabrera et al., 2006).  
It must be taken into consideration that there are structural and cytoarchitectural 
differences in islets and their microenvironment in different species (Cabrera et al., 2006, 
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van Deijnen et al., 1992, Kim et al., 2009). Additionally, in human pancreata, variability 
has been reported in the islet size, cytoarchitecture and cell composition in each organ 
(Bonner-Weir et al., 2015, Kim et al., 2009). However, it was concluded that all islets 
exhibit a similar pattern of subunits with mantle-core distribution of endocrine cells, also 
seen in Figure 3.6 (Bonner-Weir et al., 2015).  
These differences between different human pancreata could manifest through different 
physiology or development of diseases. Age is one of these factors impacting on islet 
isolation outcomes, with the proposal that differences in ECM may influence islet size and 
composition (Spiers et al., 2018). Islets showed a changed composition through disease-
associated stress with decrease in β-cells proportions through Type 2 diabetes or cystic 
fibrosis (Bogdani et al., 2017, Deng et al., 2004).  
The ultrastructural analysis with TEM provided a more detailed insight into islet 
microenvironment. Analysis of mouse tissue with short CIT and human tissue with short 
CIT showed no differences in appearance of acinar or endocrine cells (Figure 3.7-Figure 
3.9). This confirms that the human tissue sample was adequate to investigate pancreas 
tissue near normality with a low CIT of 5 h.  
3.4.2 Impact of CIT 
Changes to pancreas morphology and structure can impact on function and therefore 
transplant outcomes. Analysis of different pancreata with a range of CIT was performed 
to quantify impact of acute cellular stress towards acinar and islet cells through TEM 
analysis.  
Changes to pancreatic morphology and structure can be related to different donor factors 
such as donor age, BMI or preservation time (Spiers et al., 2018). Studies in different 
centres showed impact of donor BMI, donor age, donor type and CIT on long-term 
outcomes of pancreas transplantation (Gruessner and Gruessner, 2016, Humar et al., 
2004, Rudolph et al., 2017). Organ availability remains a crucial part of pancreas 
transplantation especially in regards to decrease of ideal donors with young age and short 
CIT (Gruessner and Gruessner, 2016). The NHSBT reported 218 patients on the transplant 
list for pancreas transplantation in 2018 with 189 pancreata transplanted (NHSBT, 2018a). 
Eurotransplant reported 276 patients on the waiting list and 207 transplanted pancreata 
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in 2018 (Eurotransplant International Foundation, 2018). Although transplant rates range 
over 50%, this still leaves 13.3% and 25% on the waiting list, increasing diabetes related 
complications and potentially mortality. Utilisation of ‘marginal’ donors may provide the 
needed pancreata to increase transplantation rates, especially keeping in mind increasing 
number of diabetic patients. A single centre study showed that transplantation of  
extended criteria donors is possible, but a slightly higher risk with pancreata from donors 
of age over 45 years and weight over ~90 kg (Krieger et al., 2003). However, it is not fully 
understood why specific donor factors impact on outcomes of transplantation.  
Therefore, a better understanding of organ status is important, especially regarding 
impact of CIT on organs and specifically the pancreas. Impact of acute stress could not be 
detected by histological assessment, but visible changes at an ultrastructural level with 
TEM analysis could be seen (Figure 3.10+Figure 3.11). Changes to cell organelles and cell 
morphology was observed in previous studies investigating hypoxia or induced apoptosis. 
Most observed was clumping of chromatin seen in nuclei of rat cardiomyocytes, human 
placenta, murine macrophage-like cell line, human pancreatic cancer cells, rat pancreas 
and human isolated islets (Dai et al., 2012, Hung et al., 2002, Kang et al., 2000, Liu et al., 
2016, Marselli et al., 2004, Nevalainen and Anttinen, 1977, Wilhelmi et al., 2013, Zhang et 
al., 2018). The second most observed changes through acute stress was development of 
vacuoles in human placenta, human pancreatic cancer cells and rat pancreas (Dai et al., 
2012, Hung et al., 2002, Nevalainen and Anttinen, 1977). Additionally, changes to 
mitochondria morphology and dilation of ER were visible in rat endocrine cells, human 
pancreatic cancer cells or rat pancreas (Dai et al., 2012, Nevalainen and Anttinen, 1977, 
Zhang et al., 2018). These changes were also visible in investigated TEM sections leading 
to development of the NEMIS (Table 3.3+Table 3.4).  
Scores for mitochondria, ER and vacuolisation seem higher compared to the nucleus score 
(Table 3.5) indicating that chromatin clumping may be a better indication for apoptotic 
cells than stress induced damage through hypoxia (Kang et al., 2000). No significant 
correlation with the scores and CIT time of the donors could be observed (Table 3.6). 
However, mitochondria, ER and vacuolisation show a trend to increase with increasing CIT, 
leading to the assumption that these features are impacted by hypoxia. According to the 
presented data, mitochondria show the biggest trend with higher mitochondrial damage 
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with increasing CIT (Figure 3.13); perhaps related to build up of succinate associated with 
prolonged ischaemia and ischaemia reperfusion injury (Chouchani et al., 2014). This may 
indicate that mitochondria are very sensitive cell organelles towards hypoxia showing 
changes even with short CIT (Nevalainen and Anttinen, 1977). Furthermore, scores for 
DBD donors were higher with no significant difference compared to the scores of DCD 
donors (Figure 3.14). This may be due to a slightly higher average in CIT in the used DBD 
donors (18.9 h) versus DCD (12.7 h) which may confirm the trends of higher damage 
scores with increasing CIT.  
Another possibility may be impact of inflammatory reaction induced through brain death 
where cytokines get released similar to observations during sepsis (Schwarz et al., 2018). 
It was shown previously that pancreas samples of brain dead donors had increased 
concentrations of tumour necrosis factor which may impact status of donor pancreata in 
the days following brain death, but before organ procurement (Rech et al., 2014). The 
NEMIS may provide a tool to better understand the factors critical to pancreas wellbeing 
in the peri-transplant period and may lead to development of target therapeutic 
interventions or further refine transplant acceptance criteria without exposing patients to 
unnecessary risk.  
Additionally, presence of endocrine cells in some of the assessed donors enabled 
comparison of acinar and endocrine cells with NEMIS revealing different impact of CIT on 
these cells. Scores for nuclei, mitochondria and ER appeared to be possibly higher in islet 
cells, whereas scores for vacuolisation were significantly lower. Islet cells seem to have a 
very high oxygen demand with a high vascularisation and receipt of 15% and 20% of the 
pancreatic blood flow (Bonner-Weir and Orci, 1982, Holt et al., 2010, Lifson et al., 1989). 
Through the insufficient oxygen supply during organ preservation impact on endocrine 
cells may be higher compared to acinar cells (Olsson and Carlsson, 2011). Significantly 
lower vacuolisation score in islet cells may be due to the fact that endocrine cells usually 
possess a high amount of vesicles making it harder to assess the status of the cytoplasm.  
The NEMIS in this thesis showed that CIT can impact on some cell organelles, but no 
significant correlation was observed. Throughout the development of NEMIS the imaging 
process was optimised to guarantee unbiased, high quality and standardised scoring. In 
addition to that biopsy sampling follows standardized procedures through QUOD 
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protocols, minimizing differences of tissue handling. Images of additional donors with the 
standardized sampling and imaging are being analysed for future investigation of impact 
of CIT on tissue quality. Hereby the EM analysis can provide a helpful tool for a better 
understanding of acute stress towards organs during the retrieval and transportation 
period with the limitation that it will not be suitable for pre-transplant assessment.  
3.4.3 Impact of isolation 
Islet isolation adds further stress onto the endocrine cells, especially through their loss of 
the BM and the connection to the vasculature (Cross et al., 2017, Irving-Rodgers et al., 
2014, Giuliani et al., 2005). The impact of the isolation process onto islets was analysed 
via histopathological staining, IF staining as well as TEM analysis. It could be demonstrated 
that islet isolation successfully removes acinar tissue and leaves a majority of islets for 
transplantation (Figure 3.16). IF staining after isolation showed remaining endocrine cells 
positive for insulin and glucagon (Figure 3.17 A1-A4). No particular pattern according to 
their cytoarchitecture was observed and in some islets the signal for glucagon seemed 
higher compared to staining in tissue. It was shown that culture of isolated islets 
influences the organization of endocrine cells (Bosco et al., 2010). This study revealed that 
the peri-islet capsule is lost through isolation, but that the peri-vascular BM is present 
inside of some islets shown with presence of collagen IV and laminin inside of islets (Figure 
3.17 B1-C4) in keeping with previous findings (Wang et al., 1999, Irving-Rodgers et al., 
2014, Cross et al., 2017). Cell-to-cell connections were present in the whole islet (Figure 
3.17 D1-D4) indicating cohesion of the endocrine cell cluster. Vimentin was used to 
indicate vascular distribution inside of islets because CD31 displayed weak staining 
increasing the difficulty to assess. This may be due to lower expression of CD31 due to 
fenestration of capillaries inside of islets (Bonner-Weir et al., 2015). Vascular distribution 
was still present in some islets after the isolation process (Figure 3.17 E1-E4) which could 
contribute to revascularisation after transplantation (Nyqvist et al., 2011).  
At an ultrastructural level further impact of the isolation process on endocrine cells was 
revealed. Loss of endocrine vesicles and damage to the cell membrane of islet cells at the 
border of the islet was observed (Figure 3.19 A-H). Loss of membrane integrity as well as 
loss of insulin through the isolation process was observed previously (do Amaral et al., 
2013, Brandhorst et al., 1998). These observations at TEM level were added as additional 
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categories to the NEMIS (Table 3.10). Two preparations of isolated islets could be 
compared to endocrine cell assessment in pancreatic tissue of six different donors (Table 
3.11). A Spearman’s rho correlation revealed a trend of impact of the isolation process on 
endocrine vesicle loss and membrane damage (Table 3.12). Interestingly mitochondria 
seemed less damaged in isolated islets, which could be due to the small sample size and 
further islet preparations may clarify. In the endocrine cells the correlation from the 
vacuolisation score with CIT was observed as relatively low compared to vacuolisation 
observed in acinar tissue. This again could be due to the fact that the cytoplasm is harder 
to assess because of the high amount of endocrine vesicles. Another possibility may be 
that endocrine cells are less susceptible towards vacuolisation. Assessment of increasing 
number of donors with the improved imaging protocol will clarify the observed results.  
In summary, the microenvironment of islets is impacted through various factors. NEMIS 
provides a potential tool for a better understanding of the impact of organ preservation 
and limited oxygen supply on pancreata especially endocrine cells, but it will be 
unpractical for pre-transplantation analysis. Further impact on islets was observed 
through the isolation procedure, where islets lose their specific niche. Overall remaining 
challenges were the low number of investigated tissues in addition the lack of a thorough 
understanding of the impact of stress at a molecular level of the cells, leaving room for 
further investigations. In the following part of this project the focus lies on the 
replacement of ECM after isolation to improve islet health and function towards improved 










4 Chapter 4. Providing extracellular matrix replacement to islets through 
a collagen/alginate/fibrinogen hydrogel 
4.1 Introduction 
During the isolation process, islets may lose their specific microenvironment (Cross et al., 
2017, Irving-Rodgers et al., 2014). Replacement of this niche and especially the ECM is 
hypothesised to improve islet heath prior to transplantation (Daoud et al., 2011). Various 
projects have set out to investigate possibilities for ECM replacement and improvement 
of islets during preservation and transplantation (Daoud et al., 2011, Marchioli et al., 2015, 
Najjar et al., 2015). Various techniques have been used to assess islet mass, viability and 
function. Function is most usually assessed by glucose induced insulin secretion, but 
Seahorse flux analysis is gaining increasing popularity due to insight into mechanistic 
understanding of underlying metabolic pathways (Daoud et al., 2011, Marchioli et al., 
2015, Skrzypek et al., 2017, Wikstrom et al., 2012). During a Seahorse experiment, OCR 
and ECAR are measured and specific drugs are injected which affect different parts of the 
electron transport chain and therefore influence OCR and ECAR (Mookerjee et al., 2015, 
Wikstrom et al., 2012). With this information, cellular ATP production can be calculated 
indicating metabolic function which is tightly linked with insulin release (Wiederkehr and 
Wollheim, 2006, Mookerjee et al., 2017, Mookerjee et al., 2015). OCR measurements have 
been investigated as an indicator of islet quality and transplantation outcomes in rodent 
models and more recently and in auto- and allo-transplantation (Papas et al., 2007, Sweet 
et al., 2008, Papas et al., 2015, Kitzmann et al., 2014). Additionally, mitochondria play a 
vital role in the insulin secretion pathway via a complex network of metabolic reactions 
demonstrating the function of β-cells (Mookerjee et al., 2017). In short (Figure 4.1): 
Glucose is transported into β-cells where it is passed through glycolysis, producing ATP 
and converted to pyruvate (Kaufman et al., 2015). Pyruvate can either be reduced to 
lactate or oxidized by mitochondria (Mookerjee et al., 2017). If pyruvate is reduced to 
lactate, protons are produced influencing the extracellular acidification (Mookerjee et al., 
2015). However, low levels of lactate dehydrogenase in β-cells increase pyruvate 
utilisation in mitochondria (Kaufman et al., 2015). If pyruvate is oxidized, it is transported 
into mitochondria where it enters the Krebs cycle to be completely oxidized into CO2 and 
H2O; loading electron carriers needed for the electron transport chain (Mookerjee et al., 
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2017). The electron transport chain is composed of mitochondrial complexes I-IV, which 
are pumping protons over the mitochondrial membrane to create a gradient for ATP 
synthase, which converts ADP into ATP (Wiederkehr and Wollheim, 2006).  
 
Figure 4.1: Glucose metabolism with glycolysis and oxidative phosphorylation.  
Picture adapted from (Mookerjee et al., 2017).  
 
The molecules used during the Seahorse experiment impact on function of these 
complexes (Figure 4.2), and allow calculation of ATP production (Mookerjee et al., 2017, 
Mookerjee et al., 2015). Oligomycin inhibits mitochondrial ATP synthase leading to a 
decrease in OCR due to inhibition of oxidative phosphorylation and increase of ECAR 
because of an increased requirement of glycolytic ATP (Mookerjee et al., 2017, Rose et al., 
2014). FCCP acts as uncoupling agent causing the inner membrane to become permeable 
to protons leading to increase in electron transport chain (ETC) and therefore maximal 
OCR (Mookerjee et al., 2015, Mookerjee et al., 2017). Antimycin A blocks complex III in 
the ETC and therefore fully inhibits mitochondrial respiration, leaving non-mitochondrial 
OCR (Rose et al., 2014). This method delivers a fast investigation of β-cell function and 
may predict outcomes of islet transplantation, but also help analyse strategies for 




Figure 4.2: Mitochondrial electron transport chain with complex I, II, II, IV, and ATP synthase and impact of oligomycin, 
FCCP and antimycin A.  
Oligomycin inhibits ATP synthase, FCCP uncouples H+ transport from ATP synthase, antimycin A inhibits complex III and 
therefore non-mitochondrial OCR.  
 
In this chapter, improvement of isolated islets via ECM replacement is investigated with 
utilization of a novel hydrogel composing of collagen I, alginate and fibrinogen (CAF) 
(Montalbano et al., 2018). Each of these components have been used as replacement for 
ECM for islets before. As first CAF component with collagen, a structural protein forming 
fibrillose structures, was chosen because it is the most abundant protein in pancreata 
(Sackett et al., 2018). Additionally, collagen provides RGD sequences required for 
triggering integrin mediated cell pathways involved into cell proliferation, viability and 
function (Kaido et al., 2006). Collagen I as ECM replacement of islets was shown to 
improve islet viability, adhesion, insulin expression, and insulin release (Daoud et al., 
2010a, Daoud et al., 2011, Stephens et al., 2018). Secondly, alginate, a structural 
polysaccharide, was chosen due to its nontoxic properties and low immunogenic profile 
after purification (Lim and Sun, 1980, Mallett and Korbutt, 2008). Furthermore, alginate 
hydrogels are able to absorb a large amounts of fluid, improving nutrient supply of 
encapsulated cells (Montalbano et al., 2018). It has been shown that alginate 
encapsulated islets remain viable and maintain their function over culture in vitro or in 
vivo (Lim and Sun, 1980, Mallett and Korbutt, 2008, Dufrane et al., 2006). The last 
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component chosen for the CAF was fibrinogen, which is a glycoprotein important during 
blood coagulation where it gets converted to fibrin by thrombin (Chernysh et al., 2012). 
Fibrin gels possess viscoelastic properties, can stimulate wound healing responses and are 
used widely in clinical application as glue making it an ideal candidate for a transplantable 
hydrogel (Janmey Paul et al., 2009). Combinations of fibrin gels and islets showed 
improved revascularisation and long-term function as well as protection against apoptotic 
stimuli (Najjar et al., 2015, Kuehn et al., 2013). 
Combination of stated ECM components may unite several advantages of single 
components which is why a combination of collagen I, alginate and fibrinogen was 
investigated. Encapsulation of islets in a collagen-alginate gels showed improved viability 
over culture, reduced hypoxia, improved function and protection from immune attack 
(Lee et al., 2012). Combination of fibrinogen with alginate or collagen has been 
investigated for cartilage and bone tissue engineering, but not previously for islets (Ma et 
al., 2012, Linsley et al., 2016, Montalbano et al., 2018). Furthermore, the combination of 
all three components showed biocompatibility, proliferation and metabolic activity of 
MIN6 cells, but was not analysed with pseudoislets or human isolated islets (Montalbano 
et al., 2018). 
4.2 Aims 
Loss of the specific islet niche through the isolation process is associated with decreased 
islet viability, mass and function impacting on transplant outcomes. Various strategies for 
ECM replacement therapy have shown some improvements but demonstrated limited 
success. A combination of three hydrogel components and its impact on a pseudoislet 
model as well as human isolated islets was investigated during this project with the 
following aim and specific objectives: 
Overall aim: To assess ECM replacement through a novel (CAF) hydrogel and characterise 
impact of hydrogel on pseudoislets and human isolated islets.  
Objective 1: To establish a reproducible model for human islets from the MIN6 β-cell line 
and characterise integrity and function. 
Objective 2: To assess biocompatibility of CAF hydrogel with pseudoislet model through 
assessment of viability, morphology and function.  
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Objective 3: To assess biocompatibility of CAF hydrogel with human isolated islets 
through assessment of viability, morphology and function. 
4.3 Results 
4.3.1 Establishment of a MIN6 pseudoislet model and characterization of integrity and 
function 
4.3.1.1 Viability of pseudoislet model Day 5 and Day 6 after generation 
Viability of pseudoislets was assessed on Day 5 and Day 6 after generation. A range of 
different sized cell clusters had formed and examples for a smaller and a larger 
pseudoislet on Day 5 are shown in Figure 4.3 A+C. PI staining for smaller pseudoislets 
usually showed a few single dead cells (Figure 4.3 B) whereas core necrosis was observed 
in larger islets (Figure 4.3 D).  The average viability of pseudoislets on Day 5 was 75±11% 
(n=4) with a decline to 64±3% (n=3) on Day 6. On Day 5 >90% of pseudoislets displayed a 
diameter between 50-100 µm Pseudoislets assessed were generated from MIN6 at 
passages p23, p24, p25, and p27.  
 
 
Figure 4.3:  Examples for viability assessment of pseudoislets (p27) on Day 5 after generation. 




Figure 4.4: Viability of MIN6 pseudoislets (p23-p27) on Day 5 and Day 6 after generation.  
Average of n=4 (Day 5) and n=3 (Day 6) repeated studies displayed with SD. 
 
4.3.1.2 Immunofluorescence staining of MIN6 pseudoislets 
A pseudoislet model was generated by culture of MIN6 cells in non-adherent dishes for 
five days. IF staining (Figure 4.5) revealed presence of insulin (A2) in majority of cells in 
addition to strong cell-to-cell connections via E-cadherin especially in the middle of the 
pseudoislet (A3).  
 
 
Figure 4.5: Immunofluorescence staining of MIN6 pseudoislets five days after generation.  
A1-A4: MIN6 pseudoislet (ø ~170 µm) stained for insulin (green), E-cadherin (red) and DAPI (blue). B1-B4: No primary 
control. Scale bars: 25 µm.   
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4.3.1.3 TEM analysis of MIN6 pseudoislets 
TEM allowed analysis of pseudoislets at an ultrastructural level (Figure 4.6). An overview 
in lower magnification (Figure 4.6 A) showed disruption of cell-to-cell connections 
between some cell areas. A higher magnification allowed more detailed analysis of MIN6 
cells inside the pseudoislet (Figure 4.6 B-D) revealing nuclei (N), ER (white arrow), 
mitochondria (M) and insulin vesicles (IV). ER and mitochondria are visible throughout the 
cells comparable to endocrine cells in mouse and human biopsies. Insulin vesicles are 
present, but in a lower quantity compared to (human) tissue samples.  
 
 
Figure 4.6: TEM analysis of MIN6 pseudoislets at Day 5.  
A: Overview of an area within the pseudoislet with single MIN6 cells visible. Scale bar 10 µm. B+C: Higher magnification 
showing MIN6 cells with nuclei (N), ER (arrows), mitochondria (M) and insulin vesicles (IV). Scale bars 2 µm. D: Highest 
magnification revealing membranes of cells and organelles. Scale bar 500 nm.  
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4.3.1.4 Analysis of metabolic function of MIN6 pseudoislets 
Seahorse flux analysis was used to investigate metabolic function of MIN6 pseudoislets. 
To achieve this, pseudoislets were transferred into islet capture microplates and islet 
capture screens were placed on top of the islets to prevent them from moving during 
injection and mixing events. Capture screens and pseudoislets were visible before and 
after the experiment (Figure 4.7 A+B) showing that neither islet transfer into the capture 
plate nor the Seahorse experiment was significantly disrupting pseudoislet integrity 
indicating measurements originated from pseudoislets and not from MIN6 single cells.  
OCR and ECAR were measured over the duration of the Seahorse experiment with 
examples of two wells shown in Figure 4.7 C+D. Both rates are influenced by the injections 
of glucose, oligomycin, FCCP and antimycin. The first injection was either Seahorse 
medium (low glucose, red curve) or 25 µM glucose (high glucose, green curve). Injection 
of medium did not change OCR or ECAR, but injection of glucose led to an increase in both 
measurements. The second injection was oligomycin leading to a decrease of OCR in both 
conditions and decrease of ECAR in high glucose conditions. The injection of FCCP (3) 
caused an increase in OCR in both conditions whereas ECAR was only slightly increased in 
high glucose conditions. The last injection (4) with antimycin A further decreased OCR and 
did not impact on ECAR in both conditions. Based on the changes in OCR and ECAR, ATP 
production could be calculated. To achieve this, values were obtained for: OCRbasal (OCR 
values corresponding to time points of highest ECAR values before oligomycin injection), 
OCRAA (lowest OCR value after antimycin injection), OCRoligo (lowest OCR value after 
oligomycin injection), and ECARbasal (highest ECAR value before oligomycin injection). With 
these values OCRmito and OCROXPHOS could be calculated according to Equation (1) and (2).  
 
(1)   𝑂𝑂𝑂𝑂𝑂𝑂𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 = 𝑂𝑂𝑂𝑂𝑂𝑂𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 − 𝑂𝑂𝑂𝑂𝑂𝑂𝐴𝐴𝐴𝐴  






In the case of the example measurements for low and high glucose conditions this was: 
 
Low glucose:         𝑂𝑂𝑂𝑂𝑂𝑂𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 = 45.330 − 4.360 = 40.971 (𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 𝑂𝑂𝑂𝑂𝑂𝑂/𝑝𝑝𝑚𝑚𝑚𝑚/µ𝑔𝑔 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑚𝑚𝑚𝑚) 
𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂 = 45.330 − 19.272 = 26.058 (𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 𝑂𝑂𝑂𝑂𝑂𝑂/𝑝𝑝𝑚𝑚𝑚𝑚/µ𝑔𝑔 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑚𝑚𝑚𝑚) 
 
High glucose:          𝑂𝑂𝑂𝑂𝑂𝑂𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 = 44.429 − 8.042 = 36.387 (𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 𝑂𝑂𝑂𝑂𝑂𝑂/𝑝𝑝𝑚𝑚𝑚𝑚/µ𝑔𝑔 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑚𝑚𝑚𝑚) 
               𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂 = 44.429 − 18.492 = 25.937 (𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 𝑂𝑂𝑂𝑂𝑂𝑂/𝑝𝑝𝑚𝑚𝑚𝑚/µ𝑔𝑔 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑚𝑚𝑚𝑚) 
 
Basal ECAR for low glucose conditions was 0.220 pmol OCR/min/µg protein and for high 
glucose conditions it was 8.664 pmol OCR/min/µg protein (Figure 4.7 E).  
Produced ATP via glycolysis could be estimated with produced PPR via glycolysis 
calculated with Equation (1)-(3). 
 




(4)   𝑃𝑃𝑃𝑃𝑂𝑂𝑟𝑟𝑟𝑟𝑏𝑏𝑟𝑟 = (10(𝑟𝑟𝑂𝑂−𝑟𝑟𝐾𝐾1) 1 + 10(𝑟𝑟𝑂𝑂−𝑟𝑟𝐾𝐾1)⁄ )(max𝐻𝐻+/𝑂𝑂2) (𝑂𝑂𝑂𝑂𝑂𝑂𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚) 
(5)   𝑃𝑃𝑃𝑃𝑂𝑂𝑜𝑜𝑏𝑏𝑔𝑔𝑔𝑔 = 𝑃𝑃𝑃𝑃𝑂𝑂𝑚𝑚𝑚𝑚𝑚𝑚𝑏𝑏𝑏𝑏 − 𝑃𝑃𝑃𝑃𝑂𝑂𝑟𝑟𝑟𝑟𝑏𝑏𝑟𝑟 
 
The buffer capacity (BP) of Seahorse medium is 0.049 mpH/pmol H+, pk1 (equilibrium 
constant of CO2 hydration and H2CO3 dissociation) at 37°C of 6.093 and maximal H+/O2 of 







For the two example wells ATP produced via glycolysis could be calculated as follows: 
Low glucose: 
𝐸𝐸𝐴𝐴𝑃𝑃𝑜𝑜𝑏𝑏𝑔𝑔𝑔𝑔 = 𝑃𝑃𝑃𝑃𝑂𝑂𝑜𝑜𝑏𝑏𝑔𝑔𝑔𝑔 
                = (0.220/0.049) −
((10(7−6.093) 1 + 10(7−6.093)⁄ )(1)(40.971) 
                = −31.98  (𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 𝐸𝐸𝐴𝐴𝑃𝑃/𝑝𝑝𝑚𝑚𝑚𝑚/µ𝑔𝑔 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑚𝑚𝑚𝑚) 
Negative ATP production via glycolysis means no detectable ATP production.  
High glucose: 
𝐸𝐸𝐴𝐴𝑃𝑃𝑜𝑜𝑏𝑏𝑔𝑔𝑔𝑔 = 𝑃𝑃𝑃𝑃𝑂𝑂𝑜𝑜𝑏𝑏𝑔𝑔𝑔𝑔 
                = (8.664/0.049) −
((10(7−6.093) 1 + 10(7−6.093)⁄ )(1)(36.387) 
                = 143.37  (𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 𝐸𝐸𝐴𝐴𝑃𝑃/𝑝𝑝𝑚𝑚𝑚𝑚/µ𝑔𝑔 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑚𝑚𝑚𝑚) 
 
ATP produced via oxidative phosphorylation could be estimated with OCR of oxidative 
phosphorylation times 2*2.63. For the example wells ATP produced via oxidative 
phosphorylation was calculated as follows: 
Low glucose: 
𝐸𝐸𝐴𝐴𝑃𝑃𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂 = 𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂 ∗ 2 ∗ 2.63 
                       = 26.058 ∗ 2 ∗ 2.63 
                       = 137.07 (𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 𝐸𝐸𝐴𝐴𝑃𝑃/𝑝𝑝𝑚𝑚𝑚𝑚/µ𝑔𝑔 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑚𝑚𝑚𝑚) 
 
High glucose: 
𝐸𝐸𝐴𝐴𝑃𝑃𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂 = 𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂 ∗ 2 ∗ 2.63 
                       = 25.937 ∗ 2 ∗ 2.63 
                       = 136.43 (𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 𝐸𝐸𝐴𝐴𝑃𝑃/𝑝𝑝𝑚𝑚𝑚𝑚/µ𝑔𝑔 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑚𝑚𝑚𝑚) 
105 
 
The total ATP production was estimated by summarizing ATPGlyc and ATPOXPHOS and was 
calculated for the two example wells as follows: 
Low glucose: 
𝐸𝐸𝐴𝐴𝑃𝑃𝑚𝑚𝑚𝑚𝑚𝑚𝑏𝑏𝑏𝑏 = 𝐸𝐸𝐴𝐴𝑃𝑃𝐺𝐺𝑏𝑏𝑔𝑔𝑔𝑔 + 𝐸𝐸𝐴𝐴𝑃𝑃𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂 
                 =  −31.98 + 137.07 
                 = 105.08 (𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 𝐸𝐸𝐴𝐴𝑃𝑃/𝑝𝑝𝑚𝑚𝑚𝑚/µ𝑔𝑔 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑚𝑚𝑚𝑚) 
 
High glucose: 
𝐸𝐸𝐴𝐴𝑃𝑃𝑚𝑚𝑚𝑚𝑚𝑚𝑏𝑏𝑏𝑏 = 𝐸𝐸𝐴𝐴𝑃𝑃𝐺𝐺𝑏𝑏𝑔𝑔𝑔𝑔 + 𝐸𝐸𝐴𝐴𝑃𝑃𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂 
                 =  143.37 + 136.43 
                 = 279.80 (𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 𝐸𝐸𝐴𝐴𝑃𝑃/𝑝𝑝𝑚𝑚𝑚𝑚/µ𝑔𝑔 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑚𝑚𝑚𝑚) 
 
These examples showed the impact of glucose injection on increase of ATP production via 




Figure 4.7: Seahorse flux analysis for metabolic characterisation of pseudoislets.  
Pseudoislets in islet capture plate before (A) and after (B) Seahorse flux analysis (Scale bars 100 µm). Example of one 
well of OCR (C) and ECAR (D) measurements for pseudoislets with low and high glucose conditions during one experiment. 
Injections: (1) Seahorse medium or 25 µM glucose, (2) 50 µM oligomycin, (3) 3.5 µM FCCP and (4) 2.5 µM antimycin A. 
(E) Measurements of OCR and ECAR for shown example wells needed for ATP calculation. (F) ATP production via 
glycolysis and oxidative phosphorylation for shown example wells with low glucose and high glucose injection. (G) Graph 
illustrating ATP production via glycolysis and oxidative phosphorylation for calculated examples.  
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4.3.2 Providing ECM components via coating of tissue culture wells with CAF hydrogel 
and impact on pseudoislet model 
To assess the impact of presence of ECM components, tissue culture wells were coated 
with CAF hydrogel and pseudoislets or human isolated islets were incubated in suspension 
culture for 72 h on top of the hydrogel. Following culture, islets were analysed for viability, 
protein expression and metabolic function.  
4.3.2.1 Hydrogel components dissolved in media 
The different hydrogel components collagen I, alginate and fibrinogen were dissolved in 
culture media and pseudoislets were cultured in respective media or control medium for 
72 h. Bright field images showed pseudoislets after culture in control media (Figure 4.8 A), 
in media with supplemented collagen I (Figure 4.8 B), in medium with supplemented 
alginate (Figure 4.8 C), and in medium with supplemented fibrinogen (Figure 4.8 D). Over 
culture time pseudoislets adhered to non-adherent tissue culture plastic if cultured in 
control medium or medium supplemented with collagen I or fibrinogen, leading to loss of 
integrity and pseudocapsule with single cells growing out from the islet. Culture in 
medium with dissolved alginate prevented strong attachment and therefore preserved 
pseudocapsule and integrity of islets.  
 
 
Figure 4.8: Pseudoislets (p25) after 72 h culture in control wells (A), medium suspended with collagen I (B), alginate (C) 
or fibrinogen (D).  
Scale bars 100 µm. 
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Viability was assessed in two different experiments showing average viability of 72±5% 
after culture in control medium, 70±1% after culture in medium with collagen I, 75±2% 
after culture in medium with alginate and 74±5% after culture in medium with fibrinogen 
(Figure 4.9). This showed none of the CAF components is toxic for MIN6 cells, but the 
components impact on the adherence of pseudoislets to the plastic surface. In addition, 
loss of integrity in not impacting on islet cell viability.   
 
 
Figure 4.9: Viability of pseudoislets (p25+p26) after culture in control media or media with dissolved collagen I, alginate 
or fibrinogen.  











4.3.2.2 CAF analysis 
Analysis of freeze-dried hydrogels reveals porous structure of the gel indicating the 
possibility for media and nutrient transfer through the gel (Figure 4.10). A measurement 
with ImageJ revealed an average pore size of ~11 µm with a range of 2-36 µm with an 
evenly distribution throughout the whole assessed gel surfaces. Energy dispersive X-ray 
spectroscopy (EDS) revealed distribution of nitrogen, carbon, calcium, sodium and 
chlorine throughout the gel (Figure 4.11). After carbon (64%), sodium (12%), chlorine (12%) 
and nitrogen (11%) were the most abundant elements. Chlorine was with 2% the least 
abundant from the elements measured. The high salt content can be explained with the 
preparation of the gel components. 5% alginate solution as well as 10% fibrinogen 
solution are prepared with PBS which is containing a high salt content. Further 
experiments of freeze-dried CAF hydrogels revealed swelling of 686% after 24 h in water.  
 
 
Figure 4.10: SEM analysis of freeze-dried CAF hydrogel.  
A: A view from the surface showed various pores in the gel. B: View from the side showed thin thickness of the freeze-
dried hydrogel but reveals porous structure inside the gel. Scale bars: 50 µm. Freeze drying and SEM analysis with support 




Figure 4.11: Energy dispersive X-ray spectroscopy (EDS) of CAF hydrogel (2:1:2). 
EDS reveals location of elements of nitrogen in blue (A), carbon in white (B), calcium in orange (C), sodium in purple (D) 
and chlorine in pink (E). A combination of all elements combined is shown in (F) and the original image in (G). (H) Shows 
the EDS analysis. EDS analysis with support from Dr Marina Ferreira-Duarte.  
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4.3.2.3 Viability assessment in the presence of CAF 
Pseudoislets were generated over five days followed by incubation for 72 h on CAF-coated 
wells. Viability of up to 50 pseudoislets was assessed with PI staining. Representative 
pseudoislets are shown in Figure 4.12. The bright field images showed fragmentation of 
pseudoislets cultured on control plates (Figure 4.12 A) visible through roughened irregular 
appearing borders, whereas pseudoislets cultured on CAF-coating maintained their 
integrity with pseudocapsule evident through smooth borders (Figure 4.12 B). PI staining 
showed dead cells and core necrosis present in islets after both culture conditions (Figure 
4.12 C+D). Assessment of size distribution with IEQ estimation was performed for four 
different experiments. Majority of pseudoislets had a diameter of 50-100 µm after culture 
in control wells (43±18%) and after culture in CAF coated wells (54±17%). A decreasing 
number of islets showed increasing diameter after both culture conditions with 28±11% 
with 101-150 µm, 19±7% with 151-200 µm, 8±7% with 201-250 µm, 3±3% with 251-
300 µm and 0% with 301-350 µm for control and 29±11% with 101-150 µm, 11±10% with 
151-200 µm, 2±3% with 201-250 µm, 3±5% with 251-300 µm and 1±2% with 301-350 µm 





Figure 4.12: Viability assessment of pseudoislets cultured on control wells (A+C) and CAF-coated wells (B+D).  
Bright field images (A+B) showed size and integrity of pseudoislet. Red immunofluorescent PI staining (C+D) showed 
number of dead cells. Scale bars 50 µm.  
 
Viability of 50 islets was assessed in seven different experiments for control conditions 
and six for CAF conditions which were summarised in Figure 4.13. Viability of 76±6% after 
control and 78±6% after CAF culture conditions was established. An unpaired, two-tailed 






Figure 4.13: Viability of pseudoislets assessed after 72 h of culture on tissue culture plastic (control) or CAF-coated wells 
(CAF).  
N=7 (control) and n=6 (CAF) with standard deviation with 50 islets assessed per experiment and culture condition. No 
significant difference of culture conditions on viability (P > 0.05).   
 
A more detailed viability assessment was performed for two experiments (pseudoislets at 
p27 and p29) where viability was assessed of pseudoislets cultured in control wells (dark 
green/red) or in CAF-coated wells (bright green/red) per size group (Figure 4.14). In both 
experiments and conditions viability was the highest in the smallest islets (50-100 µm) 
with 88-94% and decreased with increasing islet size to 53-69%. No significant difference 
between culture conditions could be observed.  
 
 
Figure 4.14: Viability of pseudoislets cultured for 72 h on tissue culture plastic (control) or CAF-coated wells (CAF) 
assessed per IEQ group.  
Average with standard deviation displayed for each size group with 2-50 single islets assessed. Control conditions shown 
















4.3.2.4 Protein expression of key marker in pseudoislets via IF after ECM presence 
Protein expression in pseudoislets after 72 h culture in control and CAF-coated wells was 
assessed by IF staining with example islets shown in Figure 4.15. Insulin in green (Figure 
4.15 A2+C2) which could be observed in all cells and was maintained through both culture 
conditions. Additionally, expression of pan-cadherin was maintained (red, Figure 4.15 
A3+C3) as observed between all cells showing strong cell-to-cell connections. The pictured 
pseudoislet after control culture displayed a diameter of <50 µm whereas the pseudoislet 
after CAF culture displayed a diameter of >100 µm impacting on the brightness of the 
different staining.  
 
Figure 4.15: Immunofluorescence staining of pseudoislets after 72 h culture on tissue culture plastic (row A and B) or 
CAF-coated wells (row C and D).  
Pseudoislets are stained for insulin (green), pan-cadherin (red) and DAPI (blue). Row B and row D show no primary 
antibody control stains. Scale bars 25 µm. 
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4.3.2.5 Metabolic activity of pseudoislets in the presence of CAF 
ATP production could be estimated through OCR and ECAR measurements during the 
Seahorse flux analysis. Three experiments are illustrated in Figure 4.16 with a high 
variability in and in between experiments. ATP production via glycolysis seemed to be 
higher after culture in control conditions compared to CAF-coated wells for experiment 1, 
whereas ATP production via oxidative phosphorylation (OXPHOS) showed a higher spread 
after control than CAF conditions. ATP production in experiment two and three seemed 
to be similar after both culture conditions.  
 
Figure 4.16: ATP production in pseudoislets after 72 h of culture on tissue culture plastic (control) or CAF-coated wells 
(CAF).  
Single values for ATP production via glycolysis, oxidative phosphorylation and total ATP production for three independent 
experiments are displayed.  
 
4.3.2.6 Integrity index of pseudoislets after CAF presence 
Pseudoislets were assessed for islet shape, border, integrity and diameter based on the 
12-point scoring system previously described by Matsumoto (Matsumoto et al., 2004). 
Scores ranged from 0 till 2 with 0 showing islets with flat shape, irregular border, 
fragmented integrity and a diameter less than 100 µm (Table 4.1). A score of 2 was given 
for pseudoislets with a spherical shape, well-rounded border, compact integrity and a 








































Table 4.1: Scores for pseudoislet integrity index after Matsumoto (Matsumoto et al., 2004) 
Score Shape Border Integrity Diameter 
0 Flat Irregular Fragmented <100 µm 
1 Characteristics of score 0 and 2 100-200 µm 
2 Spherical Well-rounded Compact >200 µm 
 
Images of pseudoislets were assessed and scores given for each pseudoislet pictured. 
Diameter was measured with ImageJ software and transferred manually into the scores. 
Scores of all categories were combined to an average of different experiments per culture 
condition (n=4 for control and n=3 for CAF-coated wells) which described impact of CAF 
presence on integrity of pseudoislets (Figure 4.17). Average integrity score after culture 
in control wells was 2.5±0.6 and after culture in CAF-coated wells 5.6±0.6 showing a 
significant improvement (p<0.001).  
 
 
Figure 4.17: Integrity index of pseudoislets after culture in control and CAF-coated wells.  
Scores from 0 till 2 were given for pseudoislet shape, border, integrity and diameter (Table 4.1). Pictured were combined 
scores from all assessed islets from n=4 experiments for control conditions and n=3 experiments of CAF-coated wells 




4.3.3 Analysis of human isolated islets 
Impact of prolonged culture as well as presence of CAF hydrogel was assessed in primary 
human isolated islets. Available donor data of the eight studied islet preparations is 
summarised in Table 4.2 and quality as well as purity during islet quality control was 
determined from dithizone-stained images in Figure 4.18. Of the total eight preparations 
used for experiments, three were from female donors and four from male donors with 
five organs originating from DBD and two from DCD donors. Age ranged from 24-65 
[years], BMI from 25-36 [kg/m2] and CIT from ~3.5 h to ~26 h. Islet preparations had a 
purity between 5% and 95% and a viability between 58% and 81%.  
 
Table 4.2: Donor data of human isolated islets with donor number, LDIS number, gender, BMI, donor type, cold ischaemia 












[h] Purity Viability 
HI-1 206 female 49 36.1 DBD 26.2 85% 58% 
HI-2 210 male 24 30.5 DBD 12.5 5% 70% 
HI-3 211 male 45 31.1 DCD n/s 95% 81% 
HI-4 247 female 48 32.5 DBD 7.7 60% 77% 
HI-5 248 male 44 29.5 DBD 3.6 95% 71% 
HI-6 256 male 53 25.0 DBD 6.6 80% 78% 
HI-7 266 female 65 28.2 DCD 6.1 90% 69% 






Figure 4.18: Dithizone staining of human isolated islets during islet quality control.  
Number of red cell clusters versus unstained clusters indicates purity. Islets were analysed after a culture period up to 
24 h. Pictures were provided by Minna Honkanen-Scott. Scale bars: 200 µm. 
 
4.3.3.1 Viability of human isolated islets over time of culture 
Viability of human isolated islets was assessed at the start (t = 0 h) and at time points up 
to five days of static culture in non-adherent tissue culture plates with n=2-3 islet 
preparations per time point (Figure 4.19). Average viability of all assessments per time 
point was 76.7±6% at the beginning of the culture period, 78±5% after 24 h, 74±5% after 
48 h of culture, 74±6% after 72 h of culture, and 60±7% after five days of culture. This 





Figure 4.19: Viability of human islets over time in static culture in non-adherent tissue culture plates up to five days.  
Islets from five different donors (HI-1-HI-5) were assessed at different culture time points. Pictured is the average of all 
assessed islets at each time point for each islet preparation.  
 
4.3.3.2 Metabolic function of human isolated islets after isolation 
For metabolic assessment of human isolated islets Seahorse flux analysis was performed 
at Day 1 (HI-6), Day 2 (HI-7) and Day 3 (HI-5) after isolation to gain OCR and ECAR for 
calculation of ATP production (Paragraph 4.3.1.4). Figure 4.20 A+B showed increase in 
total ATP production through glucose stimulation was due to increase in ATP production 
via glycolysis in all three performed experiments with different variabilities of 
measurements in high and low glucose conditions. ATP production via OXPHOS did not 




Figure 4.20: ATP production per well of human isolated islets.  
ATP production via glycolysis displayed with black dots, ATP production via OXPHOS displayed with white squares and 
total ATP production displayed with grey triangles. A: Islets of HI-5 on the third day after isolation. ATP production was 
displayed per µg protein. B: Islets of HI-6 and HI-7 on Day 1 and two after isolation with ATP displayed per ng DNA. 
 
4.3.4 Impact of hydrogel presence on human isolated islets 
4.3.4.1 Viability assessment of human isolated islets after culture on CAF-coated wells 
Dithizone staining in combination with PI staining was used to assess viability of human 
isolated islets. Under bright field illumination, red stained cell clusters could be identified 
as islets with similar appearance after culture in control conditions (Figure 4.21 A) and 
CAF-coated wells (Figure 4.21 B). PI staining with IF analysis showed dead cells in red 
fluorescent staining are present in human isolated islets after both culture conditions 




Figure 4.21: Viability assessment of human isolated islets cultured on control wells (A+C) and CAF-coated wells (B+D).  
Bright field images (A+B) showed size and integrity of islets as well as positivity for insulin with red dithizone stain. Red 
immunofluorescent PI staining (C+D) showed number of dead cells. Scale bars 25 µm. 
 
Viability of islets from HI-6 and HI-8 was assessed after 72 h of culture and summarised in 
Figure 4.22. Viability of human islets after culture on control tissue culture plastic was 
estimated as 63±1% with 34 and 50 islets assessed per experiment. After culture on CAF-




Figure 4.22: Viability of human isolated islets (HI-6 and HI-8) after 72 h culture on tissue culture plastic or CAF-coating.  
Average value with standard deviation of n=2 with 12-50 islets assessed per experiment and condition.  
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4.3.4.2 Protein expression of human isolated islets after CAF presence 
Examples of IF staining are pictured in Figure 4.23 with no primary antibody controls in 
Figure 4.24 of two batches of human isolated islets (HI-5 and HI-6) after culture in control 
(Figure 4.23 A1-A5, C1-C5) and CAF-coated wells (Figure 4.23 B1-B5, D1-D5). All islets 
showed maintained insulin expression in green (Figure 4.23 A2, B2, C2, D2) and glucagon 
expression in purple (Figure 4.23 A3, B3, C3, D3). Collagen IV expression was visualized in 
red (Figure 4.23 A4, B4, C4, D4) and was observed in all pictured islets with lower 
expression in HI-6 after culture in control wells.  
 
 
Figure 4.23: IF staining of human isolated islets after 72 h of culture in control or CAF-coated wells. 
Colum 1 showing merge of all four channels, column 2 showing insulin in green, column 3 showing glucagon in purple, 
column 4 showing collagen IV in red and column 5 showing DAPI in blue. A1-A5: islet of HI-5 after culture in control wells, 
B1-B5: islet of HI-5 after culture on CAF-coated wells, C1-C5: islet of HI-6 after culture in control wells, and D1-D5: Islet 





Figure 4.24. No primary antibody control of Figure 4.23.  
IF staining of human isolated islets after 72 h of culture in control or CAF-coated wells. Colum 1 showing merge of all 
four channels, column 2 showing insulin in green, column 3 showing glucagon in purple, column 4 showing collagen IV 
in red and column 5 is showing DAPI in blue. A1-A5: islet of HI-5 after culture in control wells, B1-B5: islet of HI-5 after 
culture on CAF-coated wells, C1-C5: islet of HI-6 after culture in control wells, and D1-D5: Islet of HI-6 after culture on 
CAF-coated wells. Scale bars 25 µm. 
 
4.3.4.3 Metabolic analysis of human isolated islets in the presence of CAF 
After culture of islets in control and CAF-coated wells ATP production was analysed in 
glucose stimulated conditions with Seahorse flux analysis indicating ATP production of 
islets with no observed significant impact of CAF-coating (Figure 4.25 C). In more detail, 
total ATP production for HI-6 after culture in CAF-coated wells seemed lower, especially 
without consideration of one outlier of ATP produced via glycolysis. For HI-7 ATP 
production was lower in both conditions compared to HI-6. ATP production via glycolysis 
after culture in CAF-coated wells was higher in one well leading to a higher total ATP 




Figure 4.25: ATP production per well of human isolated islets (IL-6 and IL-7) after 72 h of culture on control or CAF-coated 
wells (on Day 6 after isolation).  
ATP production via glycolysis displayed with black dots, ATP production via OXPHOS displayed with white squares and 
total ATP production displayed with grey triangles. ATP is displayed per ng DNA.  
 
4.4 Discussion 
In this chapter it was analysed how a provision of a three-component hydrogel impacts 
on islet health. It was hypothesised that the culture of islets in proximity or in contact with 
the CAF hydrogel improves islet integrity, viability and function.  
4.4.1 Pseudoislet model 
In a first step a readily available pseudoislet model was established out of a MIN6 β-cell-
line to eliminate high variable results through differences in isolated islet preparations. 
Pseudoislets have been widely used as a model for islet research and are established from 
rodent or human cell lines including MIN6, INS1E, αTC1.6, βTC3 or EndoC-βH1 (Hauge-
Evans et al., 1999, Kojima et al., 2014, Merglen et al., 2004, Persaud et al., 2010, Spelios 
et al., 2018, Spelios et al., 2013). Through culture of MIN6 cells in a Petri dish, different 
sized cell clusters (pseudoislets) were generated mimicking primary isolated islets. 
Viability of pseudoislets five days after generation (~75%) (Figure 4.4) was comparable 
with viability of human isolated islets over up to 72 h of culture (~77-74%) (Figure 4.19). 
IF analysis of pseudoislets (Figure 4.5) showed comparable morphology and insulin 
distribution to human isolated islets (Chapter 3 Figure 17). Additionally, TEM analysis 
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revealed characteristic similarities of pseudoislets (Figure 4.6) with human isolated islets 
(Chapter 3 Figure 19) including presence of mitochondria, ER and insulin vesicles (Persaud 
et al., 2010, Riopel et al., 2014). However, due to their tumour origin MIN6 cells have a 
higher proliferation rate compared to primary β-cells leading to continuous growth and 
therefore hypoxia in the islet core (Reers et al., 2011, Komatsu et al., 2017). Additionally, 
less insulin vesicles were observed in pseudoislets compared to primary islets in situ and 
after isolation confirming previously observed differences in insulin content (Persaud et 
al., 2010). Presence of E-cadherin evidenced strong cell-to-cell connection between MIN6 
cells similar to primary islets (Figure 4.5). This has previously been reported in association 
with improved function compared to monolayers (Hauge-Evans et al., 1999). Presence of 
insulin (Figure 4.5+Figure 4.6) as well as ability to generate ATP in response to a glucose 
challenge (Figure 4.7) indicated glucose-responsivity.  
The mitochondria stress test with Seahorse flux analysis for pseudoislets was optimised 
in cooperation with Deborah Cornell and Dr Satomi Miwa who optimised seeding density 
to 200-300 IEQ/well and observed better response if islets were seeded into the plates on 
the day before the experiment. Contrary to this 50-80 islets per well were seeded on the 
day of the experiment in the literature (Wikstrom et al., 2012, Taddeo et al., 2018). Figure 
4.7 A showed pseudoislets are present in the well of the islet capture plate and their shape 
is still intact after plating and fitting of the capture screen, visible under the microscope. 
Even after the Seahorse experiment, pseudoislets remain in the cell cluster (Figure 4.7B) 
showing the obtained data can be assumed to originate from pseudoislets rather than 
single MIN6 cells. Cell-to-cell contacts influenced function of MIN6 cells with insulin 
expression more similar to isolated islets if assembled in a three-dimensional culture 
(Hauge-Evans et al., 1999). For pseudoislets the concentration of oligomycin was 
increased to 50 mM and time after oligomycin injection was increased to 51-71 min which 
led to decrease of OCR till a plateau was observed (Figure 4.7 C). During the mitochondria 
stress test, OCR of pseudoislets (Figure 4.7) changed through injection of the drugs 
oligomycin, FCCP and antimycin A, similar to human isolated islets and mouse islets in the 
literature with decrease after oligomycin, increase after FCCP and decrease after 
antimycin (Taddeo et al., 2018, Wikstrom et al., 2012). Total ATP production was 
increasing with glucose stimulation with rising of ATP production via glycolysis whereas 
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ATP production via OXPHOS was similar in both conditions for the example wells (Figure 
4.7 F+G). This trend could be observed in all experiments with pseudoislets as well as 
human isolated islets with and without glucose stimulation indicating utilization of 
increased available glucose via glycolysis. This may indicate that increased levels of 
pyruvate, produced by glycolysis, are not completely passing through the Krebs cycle, but 
may accumulate as malate and citrate (Schuit et al., 1997).  
Similarities of pseudoislet model with human isolated islets regarding morphology, cell-
to-cell connections, viability, protein expression and metabolic function led to the 
conclusion that MIN6 pseudoislets provide a reproducible and readily available model for 
islet research.  
4.4.2 Cytocompatibility of CAF with pseudoislet model 
Cytocompatibility was assessed with the impact of CAF on viability, integrity, protein 
expression and function. Single components of CAF hydrogel dissolved in medium did not 
negatively impact on viability of pseudoislets (Figure 4.8). Furthermore, a hydrogel 
composed of all components in a ratio of 2:1:2 was compatible with pseudoislets with 
maintained overall viability (Figure 4.13) as well as maintained viability in the different 
size groups (Figure 4.14). In addition to that, cell-to-cell connections are strongly 
expressed after both culture conditions with pan-cadherin staining (Figure 4.15 A3+C3). 
Despite a variability between wells and experiments, metabolic activity seemed 
maintained through presence of CAF compared to pseudoislets cultured in control wells 
(Figure 4.16) and insulin was expressed after culture on CAF-coated wells (Figure 4.15 
A2+C2). However, no improvement of viability, key protein marker expression or function 
was observed. This may indicate that the presence of ECM components is not sufficient 
for improving islet viability and function, but that contact to ECM components via integrin 
receptors is necessary (Kaido et al., 2006). Isolated canine islets lost integrin expression 
over time in culture, with decreasing insulin expression and increasing apoptosis (Wang 
and Rosenberg, 1999). Rat insulinoma cells possessed a higher expression of integrin beta-
1 subunit during pseudoislets formation compared to monolayers, but this expression was 
decreased during prolonged culture without ECM components present (Maillard et al., 
2009). However, an improvement was observed with integrity of pseudoislets assessed 
through scoring. This confirmed previous observations with bright field microscopy 
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(Figure 4.12 A+B), with a general trend of pseudoislets appearing to possess a better 
integrity, pseudocapsule and shape after culture on CAF-coating compared to tissue 
culture wells. Often an attachment of pseudoislets after prolonged culture on non-
adherent tissue culture plastic was observed which was reduced through the CAF-coating. 
One explanation may be that cells including pseudoislets lack receptors for alginate, which 
is typically circumvented by adding RGD sequences to the alginate for better recognition 
(Andersen et al., 2015). Through the application of untreated alginate, the adherence of 
the CAF hydrogel may have decreased maybe through masking of the present RGD 
sequences of collagen I and fibrinogen by alginate (Daoud et al., 2010a, Janmey Paul et 
al., 2009). But in the case of the CAF hydrogel the decreased possibility to attach may be 
an advantage for improved integrity of islets.   
4.4.3 Cytocompatibility of CAF with human isolated islets 
Prolonged culture decreased viability of human isolated islets (Figure 4.21) previously 
associated with reduction in function (MacGregor et al., 2006). Presence of ECM 
components through CAF hydrogel improved viability with culture over 72 h (Figure 4.22), 
together with maintained protein expression of insulin and glucagon (Figure 4.23) 
demonstrating basic biocompatibility of the CAF hydrogel with human isolated islets. 
Assessment of metabolic function revealed variability in between-donors (HI-6 and HI-7) 
with no significant differences observed with and without CAF-coating (Figure 4.25). 
These two examples confirmed previous observations of variability in between 
preparations of human isolated islets (Persaud et al., 2010, Taddeo et al., 2018). The high 
variability between wells and experiments was also observed closer to the isolation before 
prolonged culture and exposure to CAF  (Figure 4.20) with analysis on the first (HI-6), 
second (HI-7) and third (HI-5) day after isolation. In all three experiments glucose 
stimulation did increase ATP production via increase of ATP production via glycolysis 
confirming observed results with pseudoislets (Figure 4.7), whereas ATP production via 
OXPHOS remained on the same level with exception of one outlier I low glucose conditions 
of HI-6. HI-7 had a relatively low ATP production via OXPHOS in both culture conditions 
indicating stressed islets, which could be due to age or circulatory death of the donor 
(Leemkuil et al., 2019). Additionally, the variability fluctuated between donors and 
stimulated/unstimulated conditions. ATP values of HI-5 were less variable in unstimulated 
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wells, ATP values of HI-6 were less variable in stimulated wells, and ATP values of HI-7 
were less variable in unstimulated wells. As high variability between OCR measurements 
with Seahorse flux analysis of different human islet batches has not been reported in the 
literature (Wikstrom et al., 2012, Taddeo et al., 2018). However cell clusters and especially 
islets can be very heterogeneous in their function which may explain varying ATP 
generation rates (Taddeo et al., 2018).  
In summary, it has been shown that MIN6 pseudoislets show comparable viability, 
integrity and ATP production to human isolated islets. The seahorse flux analysis was 
optimised for the analysis of ATP production in pseudoislets and isolated islets, but further 
optimisation seems necessary to reduce variability between wells and experiments. The 
CAF hydrogel was cytocompatible with pseudoislets and human isolated islets whereby 
integrity of pseudoislets and viability of human isolated islets were improved after culture 
on CAF-coated wells. However, a higher benefit was hypothesised through presence of 
ECM components which may indirectly influence intracellular signalling cascades, but the 
direct contact to ECM components seems necessary (Jung et al., 2011). Additionally, the 
CAF hydrogel could be improved by adding pancreas specific proteins like collagen IV, 
laminin or fibronectin (Daoud et al., 2010a). Furthermore, pseudoislets and human 
isolated islets may develop increasing hypoxia especially in the core, impacting on viability 
and function and therefore diminishing any advantageous effects of ECM exposure 
(MacGregor et al., 2006, Dionne et al., 1993). Additionally, a different delivery of ECM 
components towards islets enabling cell-to-matrix contact may improve outcomes of 
short-term culture. The combination of providing ECM components in a more refined 
system as well as reducing hypoxia was thus proposed to further investigate the impact 








5 Chapter 5. Development of bioengineering approaches to reduce 
hypoxia in β-cell/hydrogel products 
5.1 Introduction 
Through the isolation process islets are cut off from their blood supply leading to 
increasing hypoxia over culture time especially in the core (Komatsu et al., 2017). 
Insufficient supply of oxygen and nutrients impacts on cellular processes leading to 
changes in glucose uptake and ATP generation (Cantley et al., 2010). Hypoxia also affects 
islet morphology through loss of integrity and increasing fragmentation (Giuliani et al., 
2005). Additionally, reduced oxygen is associated with increased cell death through both 
apoptosis and necrosis (Giuliani et al., 2005, Olsson et al., 2011). Islet size impacts on the 
degree of hypoxia in islets which can be reduced through increased oxygen tension in the 
medium, whereas potential toxicity of oxygen must also be considered (Komatsu et al., 
2017, Olsson et al., 2011). Typical marker which show an increased mRNA expression in 
hypoxic β-cells are Ldha, Glut-1 and Mct-4 (Cantley et al., 2010). These genes encode 
proteins leading to a shift in ATP production from aerobic OXPHOS to anaerobic glycolysis 
(Cantley et al., 2013, Cantley et al., 2010). Increase in lactate dehydrogenase (LDHA) 
converts pyruvate to lactate and monocarboxylate transporter 4 (Mct4) transports lactate 
out of the cell to prevent acidification (Cantley et al., 2013, Mookerjee et al., 2017). Glut1 
is a glucose transporter used to transfer glucose into the cell through the cell membrane 
for intracellular energy generation (Cantley et al., 2013, Cantley et al., 2010). Interest in 
analysing impact of oxygen deprivation is driven by the relationship between hypoxia and 
transplant outcomes with impaired insulin release and glucose homoeostasis as well as 
glucose sensing (Cantley et al., 2013). Hypoxia is not only a problem after isolation and 
during culture, but also after transplantation with the revascularisation taking up to ten 
days during which time islets are dependent on oxygen supply via diffusion (Menger et al., 
1989). Furthermore it was shown by a study of Olsson et al., that revascularisation is still 
increasing up to at least three months after transplantation (Olsson et al., 2011). It was 
shown that the oxygen tension in transplanted islets was dramatically reduced at 5-10 
mmHg even 9-12 weeks after transplantation, compared to islets in situ with 40 mmHg 
(Carlsson et al., 2001). In addition to the loss of oxygen supply, decreased supply of 
nutrients due to loss of connection to the capillary network may lead to increasing cell 
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death in the islet core (Giuliani et al., 2005). Various approaches have been studied to 
date to reduce hypoxia in islets during culture as well as after transplantation towards 
improved transplant outcomes. For improvement of oxygenation during islet preservation, 
different culture systems including a rotating platform or a microgravity bioreactor have 
been used (Murray et al., 2005, Rutzky et al., 2002, Daoud et al., 2010b). The rotating 
system improved morphology and insulin secretion over a prolonged preservation time 
(Murray et al., 2005). Culture in a microgravity system introduced hollow channels into 
isolated mouse islets potentially improving oxygenation leading to maintained 
ultrastructure of endocrine cells (Rutzky et al., 2002). These techniques improved islets in 
vitro, but as soon as islets were transplanted, they were exposed to low oxygen conditions 
again. One strategy to improve islets even after transplantation is to provide oxygen 
through encapsulation in oxygen generating materials or external through bioartificial 
devices including β-Air (Pedraza et al., 2012, Barkai et al., 2013). With oxygen generating 
CaO2 islet cell death ex vivo could be decreased in addition to improved in vivo function 
of islets in an encapsulated mouse model (Pedraza et al., 2012, Coronel et al., 2019). 
Bioartificial pancreata have shown a beneficial effect of oxygen supply on islets in a mouse 
model, but could not improve metabolic control in a phase I study (Barkai et al., 2013, 
Carlsson et al., 2018).  
5.2 Aims 
Islets lose their specific microenvironment through the isolation process increasing stress 
and hypoxia leading to impaired function and loss of mass. ECM replacement therapies 
provide islets with crucial cell matrix contacts but can increase existent hypoxia even 
further. This chapter examined different strategies to provide islets with ECM components 
simultaneously with reducing hypoxia for improved islet viability and function. The 
specific aims and objectives were: 
Overall aim: To develop bioengineering approaches to reduce hypoxic impact on β-cells 
and restore lost ECM in the islet microenvironment.  
Objective 1: To develop a bioengineered construct with CAF hydrogel. 
Objective 2: To characterise impact of dynamic culture on pseudoislet viability and gene 
expression with and without the presence of CAF hydrogel.  
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Objective 3: To characterise the impact of an electrospun nanofiber membrane on 
viability and morphology in mouse islets. 
Objective 4: To develop a proof of concept system for hydrogel perifusion.  
Objective 5: To characterise CAF hydrogel in a perifusion system.  
5.3 Results 
5.3.1 Microwells in hydrogel as ECM replacement 
To overcome the problem of increasing hypoxia with ECM replacement during prolonged 
islet culture a model with microwells was developed similar to that by (Skrzypek et al., 
2017). This model allows contact to ECM components while through an open top access 
to nutrients and oxygen. Therefore, a synthetic polymer stamp, generated by a 3D laser 
bioprinting method, was provided by the mechanical engineering group with 200 µm 
barrels at an interval of 500 µm (Figure 5.1 A). In a first step the stamp was used to 
generate a hydrogel composed of 2% agarose with microwells (Figure 5.1 B), which was 
chosen due to its stiffness, making the generated microwell hydrogel easy to handle. 
Microwells appeared with even shape and distribution correlating with the stamp. After 
freeze drying of the hydrogel (Figure 5.1 C), some of the microwells were visible (arrows), 
but it was more difficult to spot them compared to the hydrated hydrogel under the 
microscope. Pseudoislets were able to fit within microwells (Figure 5.1 D) with 1-3 
pseudoislets in a single microwell. Some microwells were observed to be empty and 




Figure 5.1: Microwells in 2% agarose hydrogel.  
A: SEM analysis of stamp with 200 µm diameter barrels at an interval of 500 µm. B: Agarose hydrogel with microwells 
visible. C: Freeze dried agarose hydrogel with microwells (arrow) visible. D: Agarose hydrogel with microwells and 
pseudoislets. Scale bars 200 µm.  
 
Exchanging agarose with the CAF hydrogel led to difficulties in removing the hydrogel 
from the stamp, due to the different mechanical properties and resulting softness of the 
CAF hydrogel leading to breaks in the gel. The photograph in Figure 5.2 shows fragments 
of CAF hydrogel after removal from the stamp in PBS in a 12-well plate.  
 
 
Figure 5.2: CAF hydrogels after removal from the stamp in PBS in a 12-well plate.  
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5.3.2 Coated wells in dynamic culture for reduction of hypoxia 
5.3.2.1 Morphology and integrity assessment 
Another approach to reduce hypoxia during islet culture and provide ECM components at 
the same time was to add a dynamic platform to the coated well system. Pseudoislets 
were either added onto wells with or without CAF and were then incubated in static 
culture or on a rotating platform (63 rpm). Figure 5.3 showed pseudoislets after 72 h of 
static culture in control (A) and CAF-coated (B) wells and rotation culture in control (C) 
and CAF-coated wells (D). Pseudoislets possessed smaller diameter after static compared 
to rotation culture with loss of pseudocapsule being observed after static culture in 
control wells. Integrity and shape of pseudoislets was improved through CAF-coating in 
static culture and through rotation culture in control wells. Rotation culture in CAF-coated 
wells often led to clumping of pseudoislets. 
 
 
Figure 5.3: Pseudoislets after 72 h of static (A+B) or rotation (C+D) culture in control wells (A+C) or CAF-coated wells (D).  




These observations could be confirmed with a qualitative scoring described in 4.3.2.6 
(Matsumoto et al., 2004). Integrity was scored the lowest after static culture in control 
wells at 2.5±0.6 (n=4) and was increased after static culture on CAF-coated wells 5.6±0.6 
(n=3), as well as rotation culture in control 5.1±1.0 (n=2) and CAF-coated wells 5.2±1.3 
(n=3) (Figure 5.4). Statistical analysis with an unpaired t-test showed significant 
improvement of integrity score after static culture in CAF-coated wells (p<0.001), rotation 
culture in control wells (p<0.05), and rotation culture in CAF-coated wells (p<0.05) 
compared to static culture in control wells.  
 
Figure 5.4: Integrity score of pseudoislets after static and rotation culture in control and CAF-coated wells (n≥2).  
Unpaired Student’s t-tests revealed significant differences between static culture in control wells with static culture in 
CAF-coated wells (p<0.001), rotation culture in control wells (p<0.05), and rotation culture in CAF-coated wells (p<0.05). 
 
5.3.2.2 Viability assessment 
Viability was assessed by PI staining after 72 h culture in the different culture systems 
(Figure 5.5). With viability of 76±6% (n=7) after static culture in control wells, 78±6% (n=6) 
after static culture in CAF-coated wells, 69±5% (n=3) after rotation culture in control wells, 
73±4% (n=3) after rotation culture in CAF-coated wells. The minor decrease of viability 
after rotation culture in control wells can be explained with the higher diameter in these 
islets (Figure 5.3). However, overall viability appeared to be maintained in all conditions 







































Figure 5.5: Viability assessment of pseudoislets (p27-p29) in different culture systems including static control, static CAF, 
rotation control and rotation CAF.  
For control conditions pseudoislets were cultured in tissue culture suspension wells and for CAF conditions wells were 
coated with CAF hydrogel and pseudoislets were cultured on top of the hydrogel. Static culture was implemented by 
incubation at 37˚C with 20% O2 and 5% CO2. For rotation culture the plates were incubated on a rotating platform with 
a speed of 63 rpm. N≥3 independent experiments. 
 
5.3.2.3 Hypoxia assessment with pimonidazole staining and gene expression 
Staining with pimonidazole (PIM) revealed the presence of hypoxia in pseudoislet cores 
after static culture in control wells (Figure 5.6 A1-A3) as well as CAF-coated wells (Figure 
5.6 C1-C3), whereas islets with comparable size did not show PIM present inside the islet 




































Figure 5.6: Immunofluorescence staining of pseudoislets after different culture conditions with pimonidazole (PIM) in 
green (A2, B2, C2, D2) and DAPI in blue (A3, B3, C3, D3).  
Merge of both channels in A1, B1, C1, D1. Pseudoislets after static (A1-A3) and rotation (B1-B3) culture in control wells, 




Figure 5.7: No primary antibody control of pseudoislets after different culture conditions with pimonidazole (PIM) in 
green (A2, B2, C2, D2) and DAPI in blue (A3, B3, C3, D3).  
Merge of both channels in A1, B1, C1, and D1. Pseudoislets after static (A1-A3) and rotation (B1-B3) culture in control 




Gene expression was analysed with qRT-PCR for insulin (Ins 1 and Ins 2), hypoxia induced 
genes LDHA, Mct4 and Glut1, and the β-cell dedifferentiation marker urocortin 3 (U3) 
(Figure 5.8). After static culture in CAF-coated wells insulin gene expression was similar to 
control culture, whereas hypoxia induced genes showed a slight reduction, and U3 an 
increased expression. After rotation culture in control wells Ins 1 was expressed at a 
similar level compared to static control conditions whereas Ins 2 showed an increased 
expression. Hypoxia induced gene expression was reduced, and U3 expression increased. 
Rotation culture on CAF-coated wells led to a small reduction in Ins 1 expression, whereas 
Ins 2 was expressed at a similar level to static control conditions. Hypoxia induced genes 
showed further reduced expression compared rotation control conditions. Expression of 
U3 was at a similar level compared to static control conditions.  
 
Figure 5.8: Expression of insulin genes (Ins 1 and Ins 2), hypoxia induced genes (LDHA, Mct4, Glut1) and urocortin 3 (U3) 
in pseudoislets (p26 and p27) after 72 h of culture in static control, static CAF, rotation control, and rotation CAF 
conditions.  
Displayed are averages with SD from two independent experiments composed of three wells. Expression was normalised 
to static control culture conditions.  
 
5.3.2.4 Metabolic assessment of static and rotation culture in CAF-coated wells 
Seahorse flux analysis revealed ATP production rate of pseudoislets after culture on CAF-
coated wells in static and rotation conditions (Figure 5.9). Due to the limited number of 
wells on the islet capture plate, just two different conditions could be analysed per one 
experiment. Pseudoislets in CAF-coated wells and static culture (S1+S2) showed a higher 


















ATP production rate via OXPHOS leading to a higher total ATP production rate compared 
to rotation culture (R1+R2). ATP production via glycolysis was similar in CAF S1 and CAF 
R1 excluding one higher value in CAF S1. ATP production via glycolysis in CAF S2 and CAF 
R2 was very low compared to CAF S1 and CAF R1. ATP production via OXPHOS seemed 
more variable after static culture compared to rotation culture excluding one very high 
value in CAF R2.  
 
Figure 5.9: Analysis of metabolic activity of pseudoislets (p27 and p28) cultured on CAF-coated wells in static (S1+S2) or 
rotation (R1+R2) condition.  
ATP production rate via glycolysis (white circles), OXPHOS (grey squares) and total (black triangles) is shown for each 
well for two independent experiments.  
 
5.3.3 Electrospun nanofiber membrane for improved revascularisation of isolated 
islets 
5.3.3.1 Fibre analysis and mouse islet seeding 
An additional idea to reduce hypoxia during islet culture was to use electrospun nanofiber 
membranes for the possible delivery of angiogenesis markers including VEGF-A. 
Electrospun PCL nanofibers were kindly provided by Dr Piergiorgio Gentile from the School 
of Engineering at Newcastle University. Mouse islets were isolated and seeded on top of 
the membrane and interaction of islets and membrane was analysed after 1-4 days of 
culture. Obtained fibre membranes were analysed with SEM showing fibre mesh/network 
at low (Figure 5.10 A) and higher magnification (Figure 5.10 B). Analysis with Image J 





















revealed a fibre diameter between ~0.17 µm and ~1.39 µm. Mouse islets were visible after 
three days of culture in control wells (Figure 5.10 C) and seeded on top of the membrane 




Figure 5.10: Electrospun nanofibers with mouse islets.  
Nanofibers were analysed with the SEM in low (A) and higher (B) magnification. Mouse islets were analysed after culture 
in control wells (C) and on top of the membrane (D) after 72 h of culture. Scale bars 10 µm (A+B) and 100 µm (C+D).  
 
5.3.3.2 Viability assessment of mouse islets over culture time  
Viability of mouse islets was assessed with PI staining after culture in control wells. Due 
to low numbers of isolated islets per isolation different batches were analysed at different 
time points of culture in control conditions, but not of islets cultured on the membrane 
(Figure 5.11). Viability was assessed as followed: On Day 1 of culture it was 89±14% (10 
mouse islets), on Day 2 of culture it was 89±10% (58 mouse islets), on Day 3 of culture it 
was 85±18% (18 mouse islets), and on Day 4 of culture it was 87±10% (13 mouse islets). 
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This shows maintenance of viability of mouse islets over at least four days of culture in 
control wells.  
 
Figure 5.11: Viability of different batches of mouse islets at Day 1-4 of culture in control wells.  
Average viability displayed with SD of 10-58 islets assessed.  
 
5.3.3.3 Immunofluorescent staining of mouse islets after culture on membrane 
Mouse islets cultured on top of the membrane were fixed and stained for insulin, 
collagen IV and DAPI (Figure 5.12). Due to low mouse islet numbers no control without 
primary antibody was used. Insulin staining in green (Figure 5.12 A2+B2) as well as DAPI 
staining in blue (Figure 5.12 A4+B4) showed islet location in addition to indicating viability 
and function. Analysis of an islet at lower magnification (Figure 5.12 A1-A4) suggested 
out-growth of single cells from the islet, which could be confirmed with the analysis of an 
islet at higher magnification (Figure 5.12 B1-B4). Collagen IV staining in red (Figure 5.12 
A3+B3) seemed to non-specific.  













Figure 5.12: Immunofluorescence staining of mouse islets after culture on electrospun nanofiber membrane for three 
days.  
A whole islet (A1-A4) as well as an islet boarder (B1-B4) were stained for insulin in green (A2+B2), collagen IV in red 
(A3+B3) and DAPI in blue (A4+B4). Merge were shown in A1 and B1. Scale bars: 25 µm.  
 
5.3.4 Hydrogel perfusion for reduction of hypoxia in encapsulated pseudoislets 
5.3.4.1 Morphology of encapsulated pseudoislets in static culture 
Pseudoislets were encapsulated in CAF hydrogel and cultured for 72 h in static conditions. 
Most pseudoislets in control wells were attached to the plastic after 72 h of culture, 
showing loss of integrity and shape with single cells growing out of the cell cluster (Figure 
5.13 A). Encapsulated pseudoislets on the other hand contained their pseudocapsule and 
integrity with no single cell out-growth from the cell cluster observed (Figure 5.13 B+C). It 
was possible to observe encapsulated pseudoislets if the CAF hydrogel was thin enough 
for the light to penetrate the gel whereas this was increasingly challenging with thickening 
of gel where the light could no longer penetrate, seen in the bottom right corner of Figure 





Figure 5.13: Pseudoislets after culture of 72 h in control wells (A) and encapsulated (B+C).  
Scale bars 100 µm. 
 
Integrity was assessed with the previously employed scoring method (4.3.2.6) and 
compared to static culture in control wells (Figure 5.14). Integrity of encapsulated 
pseudoislets after 72 h of static culture was assessed with mean score 6.0±0.5 (n=5) 
compared to static culture in control wells with a score of 2.5±0.6 (n=4) (Figure 5.1). A 
significant positive impact of encapsulation on the integrity score was evaluated with the 
statistical assessment through an unpaired Student’s t-test, compared to static culture in 
control wells with p<0.0001.  
 
























Figure 5.14: Integrity score of pseudoislets after static culture encapsulated in CAF hydrogel compared to islets in static 
control conditions.  
Average score displayed of n≥4 experiments with SD. Unpaired t-test showed significant impact of encapsulation on 




5.3.4.2 Viability of encapsulated islets 
 
Figure 5.15: Viability assessment with PI staining with two examples of encapsulated pseudoislets shown after 72 h of 
static culture.  
A bigger islet (A+B) and a smaller islet (C+D) were assessed with phase contrast (A+C) and with red fluorescent PI staining 
(B+D). Scale bars 50 µm. 
 
Viability of pseudoislets was assessed using PI staining after 72 h of culture (Figure 
5.15+Figure 5.16). PI staining was possible if hydrogel was thin enough for assessment of 
pseudoislets under the microscope (Figure 5.15 A+C). PI stain was able penetrate the 
hydrogel and differences between bigger and smaller sized islets could be assessed in the 
red fluorescent channel (Figure 5.15 B+D). After static culture in control wells pseudoislets 
had an average viability of 76±6 (n=7) and after encapsulation 83±5% (n=4), showing a 




Figure 5.16: Viability of pseudoislets after 72 h of static culture in control wells and encapsulated in hydrogel.  
Average of n≥4 displayed with SD.  
 
5.3.4.3 Gene expression of encapsulated pseudoislets 
Expression of insulin genes Ins 1 and Ins 2, hypoxia-induced genes LDHA, Mct-4 and Glut-
1 and the end-differentiated β-cell marker U3 was assessed. Static culture of pseudoislets 
encapsulated in CAF hydrogel was associated with increased hypoxia-induced gene 
expression whereas expression of insulin genes and U3 was comparable to control culture. 
The addition of dynamic culture to encapsulated pseudoislets decreased the expression 
of hypoxia induced genes whereas Ins1, Ins2 and U3 expression were similar to static 




























































Figure 5.17: Hypoxia induced gene expression of encapsulated pseudoislets after 72 h of static versus rotation culture.  
Average of two independent experiments displayed with SD.  
 
5.3.4.4 Protein expression of encapsulated islets with and without hypoxia reduction 
Encapsulated pseudoislets still express insulin after static (Figure 5.18 1B) as well as 
rotation culture (Figure 5.18 2B). Additionally, MIN6 cells showed cell-to-cell contacts via 
E-cadherin protein expression after both culture conditions (Figure 5.18 1C+2C). This 
indicated that the encapsulated pseudoislets are still functional cell clusters.  
 
 
Figure 5.18: Immunofluorescence staining of encapsulated islets after static (1A-AD) and rotation culture (2A-2D).  
Insulin stained in green (1B, 2B), E-cadherin stained in red (1C, 2C) and DAPI stained in blue (1D, 2D). Merge showed 




Figure 5.19: No primary antibody control of immunofluorescence staining of encapsulated islets after static (1A-AD) and 
rotation culture (2A-2D). 
Insulin stained in green (1B, 2B), E-cadherin stained in red (1C, 2C) and DAPI stained in blue (1D, 2D). Merge showed 
combination of all channels (1A, 2A). Scale bars: 25 µm. 
 
5.3.4.5 Perifusion of CAF hydrogel 
For primary investigations of the perifusion system, 20 µl CAF hydrogel without 
pseudoislets was cross-linked on top of a nylon membrane to enable transfer of the gel in 
and out of the chambers (Figure 5.20 A). The system was filled with PBS and was adjusted 
to the lowest possible flow rate of 6.5 ml/min and was allowed to run for ~7 h with no 
observed leaks especially at the chambers (Figure 5.20 B). The CAF hydrogel was still 
present after the perifusion period (Figure 5.21) which was encouraging for future 
experiments of perifusion with encapsulated pseudoislets.  
 
 
Figure 5.20: Photographs of the perifusion set up with hydrogel. 
A: Membrane with hydrogel crosslinked on top was placed inside the chamber. B: Three chambers after ~ 7 h of perifusion 




Figure 5.21: Three membranes with CAF hydrogel before and after ~7 h of perifusion.  
5.4 Discussion 
The present chapter investigated different strategies to provide ECM components to islets 
while decreasing hypoxia to analyse how a nanofiber-membrane, different hydrogel 
designs or dynamic culture systems impact on islet health through reduction of hypoxia 
in combination with ECM presence. It was hypothesised that the reduction of hypoxic 
stress improves islet integrity, viability and function.  
5.4.1 Microwells 
Microwells were fabricated to provide ECM contact, but enable oxygen and nutrient 
supply through an open top. 200 µm was chosen as optimal well, based on an average 
islet diameter of 100-150 µm to enable as much contact between islet and hydrogel 
(Longnecker, 2014). However, it has to be noted that microwells in the literature have 
often had a diameter of 500 µm and therefore larger compared to the microwells in the 
current experiments, but in previous publications the wells were primarily used to prevent 
agglutination of islets (Skrzypek et al., 2017, Darling et al., 2018). Microwells in the current 
study were present in agarose gels generated via a stamp and they were large enough to 
fit pseudoislets (Figure 5.1). Nevertheless, distribution of pseudoislets inside the wells 
remained challenging with a lot of them located in between the holes, which has been 
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observed previously (Darling et al., 2018). One potential for improvement would be to 
change the design of the gel leaving less space in between single wells similar to designs 
in the literature with inter-well spaces of 100-200 µm (Darling et al., 2018, Skrzypek et al., 
2017). Closer proximity may be beneficial for paracrine effects and communication 
between islets, which has been shown to be important between single islet cells and 
therefore could be critical for inter-islet communication (Cabrera et al., 2006, Benninger 
et al., 2011). Furthermore, the high vascularisation of islets is in keeping with signalling 
via the vascular network to attain inter-islet communication (Bonner-Weir and Orci, 1982, 
Cabrera et al., 2006). 
Another way of improvement of the hydrogel construct could be a more precise 
distribution of islets with a bioprinter positioning one islet per well preventing them from 
sticking together and providing them with a higher gel surface inside the microwells. 
Previous studies showed that islet cell lines as well as primary islets are still viable after a 
bioplotting process (Marchioli et al., 2015). Different printing techniques are available for 
manufacturing of cell containing hydrogels with different resolution, cost and compatible 
viscosities (Blaeser et al., 2017, Mandrycky et al., 2016).  
Preparation of a microwell construct out of CAF hydrogel was not successful due to the 
mechanical properties leading to a very soft gel which fragmented when the mould was 
removed (Figure 5.2). Changing gel components could improve mechanical properties 
towards a stiffer gel, however it must be taken into consideration that the pancreas is a 
soft tissue and change of mechanical properties may negatively impact islets. It was 
shown previously that stiffness of cell substrates can impact proliferation, migration, 
spreading and adhesion of cells (Yang et al., 2017). Analysis of 22 pancreata with magnetic 
resonance elastography revealed a mean pancreatic stiffness of 1.42 kPa which is 
comparable to a formulation of the CAF hydrogel with quantities of 2:1:1 and 0.5% 
collagen (Kolipaka et al., 2017, Montalbano et al., 2018). Furthermore, the preparation of 
the microwell CAF construct with a stamp may not be the ideal method. The construct 
could be printed for example with a reactive jet impingement bioprinter which was able 
to print a CAF hydrogel with the composition of 1:2:8 (da Conceicao Ribeiro et al., 2018). 
Within an improved microwell construct hypoxia of islets could be assessed after the 
culture period with PIM staining or analysis of gene expression.  
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5.4.2 CAF-coating in combination with dynamic culture 
An additional approach of providing ECM replacement with simultaneous hypoxia 
reduction was introduction of dynamic culture for CAF-coated wells. It was shown 
previously that constant movement in culture systems with rotating vessels or 
microgravity cultures can be beneficial towards islet viability, integrity and function 
(Rutzky et al., 2002, Murray et al., 2005, Daoud et al., 2010b).  
This combination of CAF-coating and rotating culture in the current project showed 
improvement of pseudoislet integrity (Figure 5.4), maintenance of viability (Figure 5.5) 
and reduction of hypoxia-induced gene expression (Figure 5.8). Improvement in integrity 
and morphology may be due to the lowered adherence properties through alginate 
containing coating or the continuous movement or a combination of both (Kaido et al., 
2006).  
Rotation culture of pseudoislets in CAF-coated wells led to clumping (Figure 5.3 D). The 
seeding density in the current project ranged from 104-208 IEQ/cm2 and was therefore in 
a range were viability and function has been presumed (Brandhorst et al., 2016). However, 
Papas proposed that at a seeding density of 110-150 IE/cm2 anoxia will already impact on 
islets (Papas et al., 2005). Clumping of islets was also observed by Smink after culture on 
hydrophilic compared to hydrophobic biomaterials and, with the hydrogel being 
hydrophilic, aggregation of pseudoislets may be enhanced (Smink et al., 2017). 
Additionally, the hydrogel may change the dynamics of the medium during the rotation 
culture due to changes in the liquid volume or the rougher surface (Figure 4.10) compared 
to the tissue culture plastic. Therefore, a lower rotation speed or seeding density may 
decrease formation of aggregates. Yet the beneficial effects of the CAF-coating and the 
rotation culture still positively impacted on pseudoislet viability (Figure 5.5) and 
morphology (Figure 5.4) compared to static culture in control wells. The decrease in 
metabolic function after rotation culture in CAF-coated wells (Figure 5.9) in addition to 
lack of improvement of insulin gene expression with reduced hypoxia (Figure 5.8) may 
indicate ongoing β-cell stress. This stress could either be due to the hydrophilic properties 
or components of the hydrogel, but also the increased handling of pseudoislets during the 
preparation of the Seahorse experiment (Smink et al., 2016, Lim et al., 2011). Changes to 
the protocols to reduce transfer and washing steps as well as adjustment of hydrogel 
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components to better match native islet ECM may reduce stress and therefore improve 
islet function. 
5.4.3 Nanofiber membrane 
Hypoxia is not only a problem during islet preservation, but also after transplantation until 
full revascularisation has taken place (Olsson et al., 2011). To approach this problem, it 
was hoped that islets may incorporate electrospun nanofibers which could have been 
used to deliver angiogenetic factors into the centre of the islet to attract endothelial cells. 
Nanofibers built up porous scaffolds with a high surface-to-volume area due the high 
amount of nanofibers building up the membrane (Ramakrishna et al., 2006). The idea for 
reducing hypoxia was to improve revascularisation by providing angiogenetic factors 
including VEGF-A inside of the islets which may stimulate blood vessel formation through 
attraction of endothelial cells towards the islet core where hypoxia is highest (Komatsu et 
al., 2017). Delivery of VEGF-A linked to PCL scaffolds was shown to increase 
revascularisation in a chicken chorioallantoic membrane assay and human islets 
embedded inside the construct showed maintained response to glucose challenge after 
seven days’ culture (Marchioli et al., 2016). Phase contrast microscopy as well as confocal 
microscopy confirmed that mouse islets attached to the membrane with single cells 
growing out of the islets (Figure 5.10 and Figure 5.12) impacting on integrity and possible 
differentiation status (Weinberg et al., 2007). Minimal outgrowth of single cells was 
observed with rat islets cultured on laminin coated nanofibers after seven days’ culture, 
but not to as high degree as observed in the current experiments (Sojoodi et al., 2013). 
Suitable coating of the nanofibers may prevent the attachment of islets and therefore 
outgrowth of single cells with maintained islet integrity. However, due to the undesired 
impact on islet integrity the electrospun nanofiber membrane was not further 
investigated.  
5.4.4 Perifusion of encapsulated pseudoislets 
A widely used method to provide ECM components is encapsulation of islets, where 
various techniques have been developed including macro-, micro-, or nano-encapsulation 
(Desai and Shea, 2017, Song and Roy, 2015, Vaithilingam et al., 2017). ECM contacts have 
been shown to be beneficial for islets in different models with improved viability, 
morphology and function (Chun et al., 2008, Blomeier et al., 2006, Daoud et al., 2011). 
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Encapsulation of pseudoislets in CAF hydrogel improved morphology (Figure 5.14) and 
maintained viability (Figure 5.16). Furthermore, it was confirmed that viability assessment 
with PI staining was possible for encapsulated pseudoislets if the CAF hydrogel was thin 
enough for microscopic assessment (Figure 5.15). However, with the encapsulation 
process existing hypoxia in islets was increased through decreased nutrient and oxygen 
transfer (Figure 5.17). It has been shown previously that increasing hypoxia impacts 
negatively on islet viability and function whereas increased oxygen supply can improve 
islets (Pedraza et al., 2012, Komatsu et al., 2017). To take advantage of improved 
morphology and maintained viability of encapsulated pseudoislets, but address the 
challenge of increasing hypoxia, movement of medium was introduced through a rotating 
platform. It was shown that through dynamic culture, via a rotating platform, hypoxia in 
encapsulated pseudoislets could be decreased (Figure 5.17). However, expression of 
insulin genes was not increased suggesting that the construct needed further 
improvement. Therefore, a perifusion system was developed to accommodate the 
hydrogel/β-cell construct and provide improved oxygen and nutrient supply to the 
encapsulated islets (2.8.4). Perifusion of islets has been used previously for analysis of 
function, but not to provide oxygenated media for encapsulated islets. Existing examples 
of perifusion systems for islet analysis include microfluidic devices, where 1-100 islets are 
trapped locally in chambers and dynamically perfused for up to 1 h (Shackman et al., 2005, 
Mohammed et al., 2009). The concept of medium flow around the islets was used in 
combination with encapsulation to develop the perifusion set up. Preliminary 
experiments with the perifusion system of the CAF-hydrogel without islets for ~7 h 
showed promising results for future experiments with encapsulated pseudoislets and 
human islets.  
In summary this thesis showed that the fabrication of microwells in a CAF hydrogel as well 
as the electrospun nanofiber membrane need further optimisation for their application 
with β-cells. It was shown that a contact of β-cells to ECM components is necessary for 
improved islet health with no improved function through dynamic culture on CAF-coated 
wells. However, encapsulation is increasing hypoxia inside islets and needs to be 




6 Chapter 6. General discussion and future experiments 
6.1 General discussion 
Continuous refinements including in organ procurement, isolation processes, islet culture 
or immunosuppression protocols successfully enhanced outcomes of clinical islet 
transplantation with improved glycaemic control and insulin independence in 44% of 
recipients three years after transplantation (Shapiro et al., 2000, Barton et al., 2012). 
However, insulin independence still requires up to three islet transplants indicating that 
islet mass and function is compromised through the isolation and transplantation process 
(Figure 6.1) (Shapiro et al., 2006). Through the isolation process ~50% of the original islet 
mass can be lost (Ichii et al., 2005). The following culture can further decrease this mass 
depending on the duration by up to 35% (Noguchi et al., 2012). Approximately 70% can 
be lost through transplantation and engraftment coupled with stressors including IBMIR 
or low oxygen tension (Emamaullee and Shapiro, 2007).  
 
Figure 6.1: Loss of islet mass through the isolation and transplantation process.  
Maintenance of islet mass, viability and function during the steps of islet transplantation 
may lead to better transplant outcomes. Therefore, further investigation regarding organ 
preservation, islet isolation, islet preservation and islet transplantation are needed. The 
first part of this thesis set out to achieve a better understanding of the impact of pancreas 
preservation time and the isolation process on exocrine and endocrine cells at the cellular 
level. In the second part, approaches to replace the lost ECM with a novel hydrogel 
composed of the three different components collagen I, alginate and fibrinogen were 
explored (Montalbano et al., 2018, da Conceicao Ribeiro et al., 2018). In the course of the 
project the three different islet models, MIN6 pseudoislets, mouse isolated islets and 
human isolated islets, were used to investigate the impact of biomaterials on β-cells. All 
of these have their advantages and disadvantages (Table 6.1). MIN6 pseudoislets are 
generated of an insulinoma cell line, which leads to unchecked proliferation of 
monolayers, in contrast to the low proliferation rate of primary β-cells (Miyazaki et al., 
1990, Hauge-Evans et al., 1999). However, they are readily available and can circumvent 
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ethical concerns of use of animal tissue (Kaur and Dufour, 2012, Persaud et al., 2010). 
Additionally, they should provide higher repeatability due to their uniform nature and 
background (Persaud et al., 2010). However, in the current studies, some variability was 
observed in between different batches of MIN6 cells which may be due to different 
passage number as well as freezing/thawing techniques. The second used model utilised 
was isolated mouse islets. These are primary islets which are composed of the different 
endocrine cell types enabling full in vitro evaluation of islet function (Bosco et al., 2010). 
However, it has to be taken into consideration that the architecture of mouse islets differs 
to human islets (Cabrera et al., 2006). During this project mouse islets were successfully 
isolated, but the numbers of isolated islets was too low for the planned experiments which 
is why MIN6 pseudoislets were mainly used for preliminary biomaterial/cell experiments. 
Third, human isolated islets were available for a number of experiments. The advantage 
is that they are composed of all islet cell types and the goal is clearly to improve human 
isolated islets for transplantation (Bosco et al., 2010, Cabrera et al., 2006). The 
disadvantage is the availability of islets in addition to a considerable variability in between 
isolations, but also donor centres et cetera. (Persaud et al., 2010, Bonner-Weir et al., 
2015). Together, these models provided complementary source of β-cells for the different 
experiments investigating the impact of the microenvironment on islets.  
Table 6.1: Advantages and disadvantages of different islet models used in this thesis.  
 Advantages Disadvantages 
MIN6 pseudoislets • Readily available 
• Higher repeatability 
• Tumour origin 
• Solely β-cells 
Isolated mouse islets 
• Composed of different islet 
cell types 
• Readily available 
• Different islet architecture to 
human 
• Low islet numbers for 
inexperienced isolator 
Isolated human islets • Composed of different islet 
cell types 
• Availability 
• Variations in donor criteria 




6.1.1 Microenvironment of islets 
Islets are highly specialised micro-organs composed of different cell types and tight cell-
to-cell connections surrounded by a highly specified niche including an ECM scaffold, a 
vascular network and acinar tissue (Benninger et al., 2011, Cross et al., 2017, Bosco et al., 
2010, Longnecker, 2014). The present study investigated the islet microenvironment at a 
histological and ultrastructural level and confirmed presence of BM proteins collagen IV 
and laminin, vasculature and cell-to-cell connections (Figure 3.2, Figure 3.3, Figure 3.6, 
Figure 3.8, Figure 3.9). All these components are important for optimal function of β-cells. 
The connection of islet cells to ECM components is important for intracellular signalling 
pathways via integrin receptors also impacting (Bosco et al., 2000). The vasculature does 
not solely provide oxygen, but also contact to ECM components through peri-vascular 
capsule, itself impacting on islet function (Nikolova et al., 2006). Cell-to-cell connection 
are also important for communication between islet cells. Knock down experiments of 
connexin 36 led to decreased function revealing a role in insulin secretion  (Calabrese et 
al., 2003). Additionally, E-cadherin has been shown to impact insulin response in a knock 
out mouse model as well as in human β-cells adhered to cadherin proteins (Wakae-Takada 
et al., 2013, Parnaud et al., 2015).  
Stress during organ preservation and islet isolation impacts on the microenvironment of 
islets potentially impairing function post-transplant. DBD as well as DCD pancreata with a 
range of CIT were analysed in this thesis revealing that a histopathological analysis does 
not reliable show impact of acute stress on pancreas tissue, but TEM analysis with NEMIS 
revealed impact on some cell organelles (3.3.2). Variation in scores revealed complexity 
of cellular stress due to hypoxia (Figure 3.13). Previous studies revealed that increasing 
hypoxia can have a negative affect pancreas transplant outcomes (Rudolph et al., 2017). 
Extended CIT of 18 h decreased islet yield and in vivo function in a mouse model, but 
Kühltreiber was able to show that islet yields from pancreata with CIT ~13 h were 
acceptable in addition to in vitro assessment of function (Pileggi et al., 2009, Kühtreiber 
et al., 2010). However, it was shown that ischaemia affected metabolic pathways of cells 
leading to accumulation of succinate which generating increased reactive oxygen species 
after reperfusion of the organ (Chouchani et al., 2014). Furthermore, the lack of oxygen 
and nutrients leads to damage of cells through apoptosis and necrosis (Giuliani et al., 
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2005). In this thesis, the NEMIS score was developed as a new tool to investigate the status 
of donor pancreata in order to better understand impact of ischaemia on cell morphology. 
Cell death, especially via necrosis, may have a higher impact on the pancreas due to the 
digestive enzymes within the acinar cells causing inflammation in the surrounding tissue 
(Logsdon and Ji, 2013). Pancreatic islets may be more sensitive to ischaemia due to their 
naturally high oxygen demand (Lifson et al., 1989, Jansson et al., 2016). Improved 
preservation methods including perfusion or persufflation may decrease organ damage 
and therefore improve transplant outcomes (Scott et al., 2010, Iwanaga et al., 2008).  
Through islet isolation, a large proportion of damaged acinar cells are removed, but the 
process puts further stress on islets through the mechanical and enzymatic separation of 
endocrine and exocrine tissue (Rosenberg et al., 1999). Through the ultrastructural 
analysis of isolated islets, the impact of CIT of the pancreas in addition to the isolation 
process may be more meaningfully assessed. The severity of the damage may indicate the 
level of potential reversibility to restore function of islets after transplantation. NEMIS 
analysis showed differences in degradation of some organelles, but further tissue samples 
should be analysed for a statistic analysis.  
Overall acute stress at a cellular level could be observed through ischaemia as well as islet 
isolation. NEMIS provides a reliable tool for quantification, but further studies are needed 
with a standardised imaging and cell number to verify these preliminary findings.  
6.1.2 ECM replacement 
Islet isolation is leading to loss of the peri-islet capsule impacting on islet health and mass 
and therefore transplant outcomes. Replacement of this ECM appears to be critical to 
improve islet viability, morphology and function as shown by previous publications (Chun 
et al., 2008, Blomeier et al., 2006, Salvay et al., 2008, Daoud et al., 2011). The novel CAF 
hydrogel has been proposed for use as ECM replacement for isolated islets (Montalbano 
et al., 2018, da Conceicao Ribeiro et al., 2018). Analysis of the individual components 
showed no impact on the viability of pseudoislets, demonstrating their biocompatibility 
(Figure 4.9). The current work showed that presence of ECM components through CAF-
coating of tissue culture wells did not impair viability and expression of key protein 
markers in the pseudoislet model or human isolated islets (Figure 4.13-Figure 4.15). This 
confirmed basic biocompatibility of CAF hydrogel with both MIN6 pseudoislets and 
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isolated human islets over 72 h in culture. However, in vivo biocompatibility testing 
remains outstanding to reveal adverse or beneficial effects. Biocompatibility of collagen I, 
alginate and fibrinogen in vivo has been demonstrated previously in rodent and primate 
models for cartilage, islet and bone research (Dufrane et al., 2006, Liao et al., 2007, Kneser 
et al., 2005). Nevertheless, the possibility for alginate to cause fibrous capsule formation 
must be fully investigated as it has been shown previously that alginate encapsulated 
islets can be surrounded by fibrotic tissue in human trials (Tuch et al., 2009, Jacobs-
Tulleneers-Thevissen et al., 2013). In the present study, metabolic activity was maintained 
in the pseudoislet model after culture on CAF-coated wells compared to control wells, but 
mixed results were observed for human islets (Figure 4.16). This may indicate better 
reproducibility of the Seahorse experiment with the pseudoislet model compared to 
primary islets (Persaud et al., 2010, Hart and Powers, 2019). However, the numbers of 
experiments was relatively low (as methodology for Seahorse studies in islets had not 
previously been established in our group) and more repeats may better demonstrate any 
underlying trend. Providing ECM components via a coating may not be sufficient for β-cell 
improvement, indicating that a direct contact is required. It was shown previously that rat 
islets had improved morphology, viability and function if they were in direct contact to 
ECM producing mesenchymal stem cells compared to co-culture through separated by a 
semi-permeable insert (Jung et al., 2011). Nevertheless, the integrity score was improved 
through CAF-coating in the pseudoislet model showing a beneficial effect of the presence 
of ECM components on morphology. Metabolic analysis revealed increased glycolysis with 
glucose stimulation potentially as an adaptation to the hypoxic status of the pseudoislets 
and the isolated human islets with a shift from oxidative phosphorylation to anaerobic 
glycolysis (Giuliani et al., 2005). Overall, cytocompatibility of CAF with MIN6 pseudoislets 
as well as human isolated islets could be demonstrated, but hypoxia may decrease 
positive impact of ECM presence. Approaches to reduce hypoxic exposure were further 
analysed in the last part of the thesis.  
6.1.3 Hypoxia reduction 
Presence of ECM components was able to maintain certain aspects of islet health, but did 
not improve it indicating that hypoxia in the islets may decrease any benefits of the 
hydrogel (Figure 4.13, Figure 4.16, Figure 4.17). To date, the common method for ECM 
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replacement has been encapsulation of islets which increases the problem of hypoxia 
(Pedraza et al., 2012, Smink and de Vos, 2018). Hence, different strategies to reduce 
hypoxia, but provide ECM components at the same time were assessed.  
One approach was the culture of islets in microwells (5.3.1). Therefore, microwells were 
fabricated with a stamp into a hydrogel, which worked with a stiff gel such as agarose, but 
remained challenging with the CAF hydrogel (Figure 5.1, Figure 5.2). For better generation 
of microwells in CAF hydrogel the properties of the hydrogel could be changed towards a 
stiffer gel, but that may negatively impact on islets. It was shown previously that rat islets 
as well as MIN6 pseudoislets had a lower insulin gene expression on stiffer scaffolds 
(Nyitray et al., 2014). Another approach would be to generate microwells without a stamp 
for example through printing. A previous study showed the potential for bioprinting CAF 
with a reactive jet impingement, but the different proportion of CAF components to this 
study needs to be noted (da Conceicao Ribeiro et al., 2018). Additionally, the distribution 
of islets into the wells remained difficult showing the need for an improvement. 
Positioning of one islet per well could be achieved with a bioprinter, but the additional 
stress of handling or printing may impact on islet health (Sankar et al., 2011, Lim et al., 
2011). If these challenges could be solved the microwells may be a promising tool to 
provide ECM components with improved oxygen and nutrient supply compared to fully 
encapsulated islets. 
To reduce hypoxia in islets a dynamic culture was combined with CAF-coating in tissue 
culture wells to detect if hypoxia was minimizing the beneficial effects of ECM presence 
(5.3.2). With the rotation platform hypoxia was reduced in pseudoislets, but expression 
of insulin genes Ins 1 and Ins 2 as well as metabolic function was not positively impacted 
(Figure 5.8, Figure 5.9). This might be caused by the higher passages (p24-p29) of 
pseudoislets which can impact on their function (Persaud et al., 2010). Furthermore, the 
rotation speed for CAF-coated wells needs optimisation which was indicated by the 
clumping of some of the pseudoislets (Figure 5.3). The clumping may impact negatively 
on the function due to increasing hypoxia (O'Sullivan et al., 2011). Another possibility 
might be that the presence of ECM components is not sufficient, but that islets need the 
contact via integrins to trigger intracellular pathways (Krishnamurthy et al., 2011, 
Stendahl et al., 2009).  
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To improve revascularisation of islets the interaction of electrospun nanofibers was 
investigated (5.3.3). Due to the attachment of islets and outgrowth of single insulin 
positive cells the integrity and possibly the differentiation status were impacted (Russ et 
al., 2008). The possibility that islets can incorporate nanofibers seems unlikely as Buitinga 
could not observe that after seven days’ culture on electrospun scaffolds (Buitinga et al., 
2013).   
To improve oxygen and nutrient supply in culture a perifusion system for encapsulated 
islets was developed (5.3.4). Encapsulation of pseudoislets further improved the integrity 
score compared to other culture conditions (Figure 5.4). Jung showed that the contact 
with ECM-producing mesenchymal stem cells leads to significant improvement of rat islet 
morphology compared to co-culture through an insert (Jung et al., 2011). However, 
hypoxia in encapsulated islets in static culture was increased (Figure 5.17) which might 
explain why the beneficial effect of the gel was not evident through improved viability 
(Figure 5.16) or insulin protein expression (Figure 5.18). Insulin gene expression was not 
highly impacted through hypoxia or reduction of hypoxia in dynamic culture of 
encapsulated islets. But the reduction of hypoxia exposure might not have been sufficient 
for a beneficial effect. Towards a better oxygen supply for the islets the perifusion system 
was developed with the goal of combining the positive effects of ECM contact with 
hypoxia minimisation for improved islet health. This may also provide a tool for 
continuous long term monitoring of encapsulated islets and impact of changes in glucose 
levels on islet function, similar to existing perifusion systems (Lacy et al., 1976, Bentsi-
Barnes et al., 2011). Preliminary tests with CAF hydrogel showed promising stability for 
around 7 h.   
Overall it was shown that presence of ECM components even with reduced hypoxia 
through dynamic culture is not sufficient for improving islet viability, morphology and 
function during culture (5.3.2). This leads to the assumption that direct contact of β-cells 
with ECM components is necessary. However, increasing hypoxia in encapsulated systems 
needs to be addressed. In this thesis it was hypothesised that a media flow alongside the 
hydrogel may decrease hypoxia and at the same time provide necessary ECM contact. 
Therefore, a perifusion system was developed and preliminary experiments with CAF 
hydrogel alone showed promising stability for future experiments.  
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6.2 Future experiments 
For a better understanding of impact of CIT on acinar and endocrine cells, the NEMIS could 
be applied to higher quality images for additional pancreata. In addition, pancreata with 
low CIT will be sampled over various time points of increasing CIT to investigate whether 
the score increases with extended storage time. It would also be interesting to combine 
these findings with the analysis of stress markers such cytokines or cell death with protein 
analysis or IF staining of the corresponding pancreata for greater mechanistic 
understanding. The impact of islet isolation should be investigated further with the 
extended NEMIS on more isolated islet preparations. If a biopsy sample prior to the 
isolation process is available, impact of the isolation process on endocrine cells could be 
analysed through comparison of islet in situ and following isolation. In addition, fresh islet 
samples and tissue sections could be interrogated for stress markers. 
For a better understanding of islet function glucose stimulated insulin secretion could be 
measured in parallel to Seahorse flux analysis. It would also be interesting to investigate 
islet function in situ which may be possible through precision cut tissue slicing. Expression 
of proteins participating in glycolysis and oxidative phosphorylation could be analysed via 
western blot or staining in pancreas sections, isolated islets and islets after different 
culture conditions to investigate changes in metabolic pathways. 
As a next step in the ECM replacement strategy, the combination of encapsulation and 
perifusion will be investigated. Therefore, the perifusion system requires further 
optimisation to reduce the flow rate as well as provide sterile conditions for cell 
experiments. After an extended culture, encapsulated pseudoislets will be analysed for 
viability, morphology, protein expression and function. If possible, human isolated islets 
will be used to investigate impact of encapsulation and decreased hypoxia in primary cells. 
In a final step the CAF hydrogel should be tested in an in vivo model for biocompatibility, 
but predominantly to assess potential for improve function of transplanted islets 
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